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 Development of chronic inflammation or autoimmunity may be related 
to deregulated mechanisms orchestrating successful resolution of inflammation, 
especially apoptosis of inflammatory cells and their subsequent clearance by 
macrophages (Mφ). Chronically inflamed sites are characterised by an excess of 
the key pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) and 
importantly, TNF-α inhibitors, widely used in the clinical setting for the treatment 
of rheumatoid arthritis (RA), inflammatory bowel disease and psoriasis, 
significantly delay disease progression. TNF-α therefore may affect processes 
implicated in resolution of inflammation. Although TNF-α and pro-inflammatory 
bacterial products such as lipopolysaccharide (LPS) influence rates of 
inflammatory cell apoptosis, little is known about their effects on Mφ 
phagocytosis of apoptotic cells (efferocytosis). In this PhD thesis, the effects of 
several pro-inflammatory agents (i.e., LPS, lipoteichoic acid (LTA), 
peptidoglycan (PGN) and TNF-α) on efferocytosis by human blood monocyte-
derived Mφ (MDMφ) have been investigated. LPS, LTA and PGN all inhibited 
MDMφ efferocytosis in a concentration- and time-dependent manner; however, 
LPS did not inhibit the uptake of immunoglobulin-G (IgG)-opsonized 
erythrocytes. Moreover, although TNF-α did inhibit efferocytosis, phagocytosis 
of IgG-opsonized erythrocytes was not inhibited. Furthermore, the LPS effect 
was attenuated by dimeric soluble human recombinant TNF receptor-1 (sTNF-
R1/Fc), indicating a critical role of TNF-α. Concomitant treatments with 
monomeric soluble human recombinant TNF receptor-1 (sTNF-R1) or the TNF-α 
Converting Enzyme (TACE) inhibitor, TOPI-0, only partially reversed the 
inhibitory effect of LPS.  
 Even though TNF-α release takes place within the first few hours 
following LPS stimulation, the LPS-induced inhibitory effect occurred only if 
treatment was performed for 96 hours or longer. Analysis of supernatants 
obtained from LPS-treated MDMφ revealed that there appears to be interplay 
between concentrations of TNF-α and interleukin-10 (IL-10) and that these 
cytokines exert opposing actions on efferocytosis. IL-10 per se increased MDMφ 
efferocytosis and addition of exogenous IL-10 to LPS-treated samples rescued 
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phagocytosis. The latter effect was associated with the IL-10-induced, 
concentration-dependent inhibition of TNF-α release. Interestingly, when IL-10 
was added to TNF-α-treated MDMφ, only slight augmentation of phagocytosis 
was observed. Furthermore, when IL-10-mediated effects were blocked by 
concomitant treatment with anti-human IL-10 receptor 1 antibody (anti-IL-10-
R1Ab), the LPS inhibitory effect on phagocytosis was much greater and occurred 
at 24 hours after treatment. The role of IL-10 on efferocytosis was also 
investigated using IL-10 deficient murine bone marrow-derived Mφ (BMDMφ). 
IL-10 deficient BMDMφ, when compared to wild-type, were characterised by a 
much lower ability to phagocytose apoptotic neutrophils and this effect was 
independent of culture conditions (control samples and LPS or TNF-α 
treatments). Finally, effects of the synthetic steroid (dexamethasone) and non-
steroidal anti-inflammatory drugs (NSAID) on MDMφ phagocytosis were 
examined. Dexamethasone, like IL-10, augmented MDMφ efferocytosis, reversed 
the inhibitory effects of both LPS and TNF-α, and suppressed LPS-induced 
production of TNF-α. In contrast NSAID did not increase MDMφ efferocytosis 
per se. However, preliminary data suggest that aspirin blocks the inhibitory effect 
of TNF-α on phagocytosis. 
 In summary, it has been determined that prolonged treatment with pro-
inflammatory agents such as LPS, LTA and PGN inhibits MDMφ efferocytosis 
which may potentially postpone the resolution of inflammation in vivo. I have 
shown that TNF-α is a key mediator in this process and that IL-10 exerts an 
important regulatory effect on TNF-α production and consequently on 
efferocytosis. Furthermore, several approaches have been unveiled to 
successfully reverse LPS-mediated inhibition of efferocytosis by decreasing 
either TNF-α production or its inhibitory effect with sTNF-RI/Fc, exogenous IL-
10 or dexamethasone. These findings indicate that TNF-α and other agents which 
influence efferocytosis may have significance in the resolution phase of 
inflammation. In addition, presented findings provide important mechanistic 
information into the potential mode of action of anti-TNF-α agents and steroids 
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1.1 INFLAMMATION  
 Inflammation is a defensive response of an organism that is induced in 
response to any trauma, i.e., infectious, post-ischaemic, toxic or autoimmune injury. 
An inflammatory response is characterised by highly complex interactions between 
the inflammatory cells (leukocytes) and other cells as well as soluble pro- and anti-
inflammatory mediators. As long as it is controlled, inflammation is beneficial and 
leads to recovery from an injury and to healing. For instance, it has been shown that 
genetic deficiencies in principal components of the inflammatory process, e.g., type I, 
II or III leukocyte adhesion deficiency are associated with increased risk of grave 
infections (Etzioni, 2007). Furthermore, people unable to produce the complement 
components properdin and factors D, C5, C6, C7, C8 or C9 are predisposed to 
meningococcal infection (Biesma et al., 2001). However, if inflammation does not 
progress to its resolving phase and occurs in an exaggerated manner, it leads to 
development of various pathological states, such as granulomas (aggregates of Mφ 
and often other inflammatory cells), fibrosis (development of a tissue with excess of 
collagen) or carcinogenesis (DNA oxidation) (Nathan, 2002).     
 Inflamed tissues are usually characterised by redness (erythema), swelling, 
heat, pain and often loss of function, resulting from concerted action of a number of 
processes. For instance, augmented blood flow to the inflamed tissues leads to their 
redness and increased warmth, whereas changes into vascular permeability are 
associated with swelling or oedema. At the basic level, inflammatory response 
involves the recruitment of inflammatory cells (leukocytes) from blood vessel to the 
site of infection or injury (extravasation) (Medzhitov, 2008). A number of 
chemoattractants (platelet-activating factor (PAF), leukotriene B4, various 
chemokines) is involved which play a crucial role in inducing leukocyte adherence on 
endothelial cells and stimulating leukocyte chemotaxis (Witko-Sarsat et al., 
2000;Kim, 2004). Recruitment of leukocytes involves several steps. First of all, 
inflammatory cells begin to adhere loosely (tethering and rolling) to the postcapillary 
endothelial cells. This process is primarily mediated by selectins (E- , L- and P-
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selectins) and their respective ligands (Phillips et al., 1995). Subsequently, 
inflammatory cells flatten and undergo firm adhesion to the endothelial cells due to 
the adhesive functions of the integrins (i.e., β1 and β2 integrins) and the 
immunoglobulin superfamily (i.e., ICAM-1, ICAM-2, VCAM-1) (Witko-Sarsat et al., 
2000). Eventually, inflammatory cells traverse the blood vessel wall and reach the 
affected area. The type of recruited cells is determined by a number of factors 
including the inflammatory stimuli present, structure and physiology of the 
vasculature, expression of various chemokines (e.g., IL-8 for neutrophils or eotaxin 
for eosinophils) or adhesion molecules (e.g., VLA-4 [α4β1] is highly expressed on 
eosinophils and lymphocytes but not on neutrophils) (Yang & Hagmann, 2003). Once 
leukocytes reach the site of inflammation, they are activated by either direct contact 
with pathogens or through the actions of mediators secreted by tissue-resident cells. 
Induction of the inflammatory response by pathogens and mediators regulating 
inflammatory processes are briefly reviewed in chapter 1.2.  
 Activated leukocytes e.g., neutrophils, at the infected or injured tissue, exert 
multiple functions including phagocytosis, antigen presentation or production of 
immune, potentially toxic mediators such as reactive oxygen species (ROS), reactive 
nitrogen species, antimicrobial peptides (e.g., defensins), proteases (e.g., protease 3, 
cathepsin G, elastase) and matrix metalloproteinases (MMP) (Witko-Sarsat et al., 
2000). Since some of these mediators do not discriminate between microbial and host 
cells, their release is usually associated with the increased risk of host tissue 
breakdown. Consequently, the acute inflammatory response is successful only if it is 
followed by resolution and repair phases (Medzhitov, 2008). The mechanisms 
involved in the resolution phase of inflammation are described in more detail in 
chapter 1.3.  
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1.2. INFLAMMATORY MEDIATORS 
 The inflammatory response is regulated by a number of mediators, including 
many cytokines (a major subject of this thesis). The term ‘cytokine’, derived from 
cyto meaning ‘cell’ and kinin meaning ‘hormones’ was first proposed by Stanley 
Cohen in 1974 (Cohen, 2004). Today, it comprises of a family of proteins such as 
lymphokines, monokines, interleukins, colony stimulating factors (CSFs), tumor 
necrosis factor alpha (TNF-α) and chemokines (Tayal & Kalra, 2008), which are 
produced in response to inducing stimuli mainly by helper T-cells or Mφ but also 
other cell types. All cytokines share some common properties:  
• Pleiotropy of action – cytokines may influence growth and differentiation of 
many different cell types or exert opposing actions within different immune and 
inflammatory pathways. 
• Redundancy – different cytokines may exert the same effect on cells. 
• Multifunctionality – the same cytokine may regulate multiple immune 
functions. 
Cytokines are a fundamental part of the immune system. They generate and control 
its responses and play an important role in communication between cells or cells and 
their environment. Thus, abnormalities in cytokine production, their receptors as well 
as signalling pathways that they initiate are involved in a wide variety of diseases. 
The role of cytokines in pathogenesis of inflammatory diseases is described in section 
1.4.1. 
 5
1.2.1. TUMOR NECROSIS FACTOR – ALPHA 
 Tumor necrosis factor alpha (TNF-α) is one of the most rapidly released 
cytokines after exposure to pro-inflammatory stimuli such as pathogens or injury. It 
was first discovered about 30 years ago as a cytokine that is produced upon activation 
by the immune system and able to cause necrosis in many tumor cell lines in vitro 
and in certain animal models (Sugarman et al., 1985;Old, 1988). Initially, TNF-α was 
believed to directly induce apoptosis of tumor cells and therefore to be a powerful 
tumoricidal agent. However, further studies revealed that this was not the case and 
that the anti-tumoral activity of TNF-α is influenced by a functional immune response 
(Hock et al., 1993). In addition, systemic administration of TNF-α in humans results 
in serious side effects, ranging from influenza-like symptoms to the development of 
shock (Mannel & Echtenacher, 2000). Yet, in conditions that prevent systemic 
administration, such as isolated limb perfusion, TNF-α in combination with 
melphalan (chemotherapeutic) has been shown effective in treatment of soft-tissue 
sarcoma (Eggermont & ten Hagen, 2001). The underlying mechanism involves 
degeneration of the tumor vasculature leading to death of tumor cells (Ruegg et al., 
1998).  
 TNF-α is the prototypical member of the TNF superfamily of cytokines able 
to induce signalling pathways for inflammation, cell proliferation, differentiation, cell 
survival and cell death. Interestingly, TNF-α may exert opposing effects such as 
stimulation of processes of regeneration or destruction, depending on many factors 
such as type of tissue, type of TNF-α receptors (TNF-R) or timing and duration of 
TNF-α action in vivo (Wajant et al., 2003). One example here is the role of TNF-α in 
neurodegeneration. Although in transgenic mice, upregulation of TNF-α in the CNS 
results in demyelination, TNF-α expression is also induced in response to brain 
injury, thus, potentially exerting protective functions (Probert et al., 1995). 
Furthermore, in a murine model of retinal ischaemia, the net effect of TNF-α action 
was dependent upon the type of TNF-R expressed in a tissue. In the presence of TNF-
R1, TNF-α potentiated tissue destruction while in the presence of TNF-R2 it had a 
tissue-protective function (Fontaine et al., 2002). Abnormalities in TNF-α production 
or sustained activation of TNF-α signalling has been associated with numerous 
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pathological conditions including sepsis, cerebral malaria, diabetes, cancer, 
osteoporosis, allograft rejection and autoimmune diseases such as multiple sclerosis, 
rheumatoid arthritis and inflammatory bowel disease (IBD) (Chen & Goeddel, 
2002;Feldmann et al., 2005).  
 To exert its biological functions TNF-α interacts with its cognate membrane 
receptors – TNF-R superfamily, whose members include TNF-R1 (CD120a, p55/60), 
TNF-R2 (CD120b, p75/80), Fas antigen, CD27, CD30, CD40 and several other 
receptors (Smith et al., 1994). All of them are characterised by some sequence 
similarities in their extracellular domain (one to six cysteine-rich repeats) and usually 
no similarities in their intracellular domain (Naismith & Sprang, 1998). However, 
both TNF-R1 and Fas can induce apoptosis and share 28% identity of their 
intracellular ‘death domains’ (Tartaglia et al., 1993). Two receptors TNF-R1 and 
TNF-R2 were found to interact with TNF-α. The membrane-bound TNF-α (mTNF-α) 
activates both receptors and its soluble form (sTNF-α) mainly stimulates TNF-R1. 
TNF-R1 is constitutively expressed in most tissues, while expression of TNF-R2 is 
highly regulated and takes place only in immune cells. The proteolytical cleavage of 
extracellular domains of both receptors results in formation of soluble receptors 
fragments. Such soluble receptors (sTNF-R) have been demonstrated to be able to 
neutralise the activity of TNF-α (Wallach et al., 1991). For instance, sTNF-R1 has 
been reported to play a crucial role in the regulation of TNF-α functions in vivo and 
cleavage-resistant TNF-R1 mutations are linked with dominantly inherited 
autoinflammatory syndromes (TNF-R1 associated periodic syndromes; TRAPS) 
(McDermott et al., 1999).    
 Furthermore, binding of TNF-α to TNF-R1 triggers activation of two 
important transcription factors: nuclear factor kappa B (NF-κB) and activator protein 
1 (AP-1). These transcription factors regulate expression of genes important for the 
majority of biological functions of TNF-α (Wajant et al., 2003). In addition, TNF-α 
has the potential to induce apoptosis via the cytoplasmic death domain of TNF-R1. 
The latter phenomenon has been observed in a variety of cell lines and in vivo models 
but, interestingly, this effect of TNF-α is masked by simultaneous activation of NF-
κB pathway (Chen & Goeddel, 2002). 
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1.2.2 TNF-α PRODUCTION 
 TNF-α is primarily produced by monocytes and Mφ as a transmembrane 
protein (mTNF-α) that forms stable homotrimers (51 kDa). The TNF-α protomers (17 
kDa; 157 amino acid) are built up of two antiparallel β-pleated sheets with 
antiparallel β-strands forming a β-structure named ‘jelly roll’ (Bazan, 1993). As 
shown in Figure 1.1, sTNF-α is released after proteolytic cleavage by TNF-α 
converting enzyme (TACE) (Black et al., 1997). Pro-inflammatory mediators 
stimulate production of sTNF-α whereas anti-inflammatory mediators usually exert 











FIGURE 1.1 Schematic representation of mTNF-α processing by TACE. A 
soluble form of TNF-α (sTNF-α) is produced from its transmembrane precursor 
(mTNF-α) by proteolytic cleavage catalysed by transmembrane TNF-α converting 
enzyme (TACE). sTNF-α exerts its biological responses via two transmembrane 
TNF-α receptors, namely TNF-R1 and TNF-R2 or alternatively is deactivated after 
binding to their soluble forms (e.g. sTNF-R1).  
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1.2.2.1 TLR AGONISTS ARE POSITIVE REGULATORS OF 
TNF-α PRODUCTION 
 The human innate immune system provides a first line of defence against 
pathogens. Bacteria stimulate an inflammatory response via highly conserved 
pathogen–associated molecular patterns (PAMP) interacting with Toll–like receptor 
family (TLR) and scavenger receptors (Kopp & Medzhitov, 2003). PAMP motifs are 
carried by bacterial lipopolysaccharide (LPS), lipopeptides, DNA, dsRNA (double-
stranded ribonucleic acid) or ssRNA (single-stranded ribonucleic acid). Ten members 
of the TLR family have been identified so far in humans (Means et al., 2000). 
Initially, TLR receptors have been demonstrated to be implicated in control of 
embryonic development (Hashimoto et al., 1988). However, further studies revealed 
that TLR intracellular carboxyl terminal domain (Toll/IL-1-R (TIR)) shares great 
similarity with that of the vertebrate interleukin-1 receptor (IL-1-R). Activation of IL-
1-R is correlated with acute phase response to bacterial or fungal infections 
(Hashimoto et al., 1988).   
 LPS is a core element of the outer membrane of Gram-negative bacteria cells. 
It is composed of three distinct domains, namely lipid A, a short core of 
oligosaccharide and O–antigen polysaccharide. Lipid A domain carries PAMP motifs 
which are recognised by TLR4 (Chow et al., 1999). However, before LPS is able to 
interact with TLR4, LPS aggregates have to be disrupted by binding to LPS-binding 
protein (LBP) (O'Neill & Bowie, 2007). LPS-LBP complex is then presented to 
TLR4 by another adaptor protein-a monocyte/Mφ receptor molecule (CD14) (Wright 
et al., 1990) resulting in TLR4 homodimerisation and binding of myeloid 
differentiation 2 receptor (MD–2) (Shimazu et al., 1999). Finally, an intracellular TIR 
domain is assembled into the complex, which as demonstrated in Figure 1.2, recruits 
several adaptor proteins that trigger a signalling cascade regulating gene expression 
(Jerala, 2007). Several adaptor proteins have been so far identified including myeloid 
differentiation primary–response gene 88 adaptor like protein (TIRAP/MAL) which 
acts as a bridging adaptor to recruit the myeloid differentiation primary–response 
gene 88 (MyD88). The recruitment of MyD88 induces activation of IL-1-R 
associated kinase 4 (IRAK4) and IRAK1 and subsequently TNF-R–associated factor 
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6 (TRAF6). The latter results in activating of transcription factors NF-κB and AP-1 as 
well as p38 and JNK/MAPK kinases (Doyle & O'Neill, 2006). In the second 
signalling pathway, triggered by the TLR complex, TRIF related adaptor molecule 
(TRAM) recruits TIR–domain–containing adaptor protein inducing interferon β 
(TRIF), which, in turn, activates several signalling pathways leading from either 
TBK1 to IRF3 or TRAF6 to NF-κB as well as from receptor interacting protein 1 
(RIP1) to apoptosis (Jiang et al., 2005).   
 The process of TNF-α production is highly controlled by multiple and 
complex mechanisms. TNF-α gene transcription involves a number of transcription 
factors, namely CREB, LITAF, ATF-2, c-jun, Egr-1, NFAT, Ets, Elk-1, Sp1 or NF-
κB (Skinner et al., 2008). Some of them, e.g., NF-κB are activated upon stimulation 
of cells with LPS. Furthermore, LPS has been demonstrated to upregulate TNF-α 
production on post-transcriptional levels by increasing the stability and translation of 
TNF-α mRNA. LPS stimulation activates several MAP Kinases (MAPK), which 
were originally described as LPS–activated kinases (Han et al., 1994). Their 
relevance to TNF-α production has been established with the use of MAPK 
inhibitors. For instance, blockade of p38 MAPK activation with piridinyl imidazole-
based inhibitor SB203580 substantially reduced translation of TNF-α mRNA 
(Campbell et al., 2004). Similarly, mice that do not express MAPK–activated protein 
kinase–2 (MK2), show a profound defect in translation of TNF-α mRNA. MK2 is an 
immediate substrate of p38 MAPK. It has been proposed that p38 MAPK may control 
stability of TNF-α mRNA or activity of NF–κB (Kotlyarov et al., 1999). Moreover, 
Tpl2/ERK signalling pathway has been reported to be implicated in nuclear export of 
TNF-α mRNA to the cytoplasm. In resting cells Tpl2 is bound to NF-κB p105. 
However, when cells are stimulated with either TLR ligands (e.g., LPS) or pro-
inflammatory cytokines, Tpl2 separates and activates ERK pathway which is critical 
for nuclear transport of TNF-α (Dumitru et al., 2000). Post-transcriptional regulation 
of TNF-α was demonstrated to operate mainly through AU rich elements (ARE) in 
the 3’–UTR of TNF-α mRNA. In unstimulated cells, ARE may exert a destabilising 
effect on TNF-α mRNA and contribute significantly to the permanent silencing of 
TNF-α mRNA. Yet, in activated cells, ARE increase both stability and translation of 
TNF-α mRNA by playing an important role in its nuclear transport.  
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ARE serve as binding sites for certain proteins (i.e. HuR) and their functional state is 
regulated by JNK/SAPK and p38 MAPK–mediated signals, which may be induced by 
LPS stimulation (Kontoyiannis et al., 1999). Consequently, ARE are critical for 
restoration of homeostasis in TNF-α biosynthesis by mediating destabilization of 
TNF-α mRNA and translational silencing after the induction phase of the 







Figure 1.2 Schematic representation of TLR-4 signal transduction pathway. 
Following TLR-4 homodimerisation several adaptor proteins are assembled into 
TLR-4 complex. Two of them, MyD88 and TRIF, activate downstream kinases e.g., 
IRAK1/4 and TBK1 and subsequently a few transcription factors i.e., NF-κB, AP1 
and IRF. In addition, assembly of RIP leads to execution of apoptosis. Key adaptor 
proteins and enzymes involved in TLR-4 mediated signalling are described in more 
depth in chapter 1.2.2.1.  
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1.2.2.2 IL-10 IS A NEGATIVE REGULATOR OF TNF-α 
PRODUCTION 
 IL-10 is an anti-inflammatory cytokine, first described as a soluble factor that 
is able to inhibit production of cytokines e.g., IL-2 and interferon-γ (IFN-γ) by Th1-
type T cells (Fiorentino et al., 1989). This phenomenon is a consequence of the 
inhibitory effect of IL-10 on antigen-presenting cells (APC), namely monocytes, Mφ 
and dendritic cells (Kaur et al., 2008). IL-10 is encoded by a single gene that is 
highly homologous to an open reading frame of Epstein-Barr virus genome (Moore et 
al., 1990). In its bioactive form, IL-10 is a homodimer composed of two 18 kDa 
subunits that interacts with a single class of cell surface receptors (IL-10-R). These 
receptors are mostly expressed by B cells, T cells, NK cells, monocytes and Mφ. The 
functional IL-10-R is a dimer of heterodimers of IL-10-R1 and IL-10-R2. IL-10-R1 
serves as a ligand-binding subunit and recruits JAK1 kinase into IL-10-R. In contrast, 
IL-10-R2 recruits Tyk2 and plays a role in signal transduction (Mosser & Zhang, 
2008). Presence of IL-10 induces bridging of two IL-10-R1 molecules and their 
paired association with two IL-10-R2 molecules. Formation of IL-10-R activates 
Tyk2 kinase which subsequently trans-phosphorylates IL-10-R1 and JAK1. The latter 
is essential for activation and nuclear translocation of a transcription factor STAT3, 
which drives transcription of various IL-10–responsive genes (Donnelly et al., 1999). 
One is a suppressor of cytokine signalling–3 (SOCS-3) that has been demonstrated to 
feedback inhibit a JAK/STAT pathway - a common signalling pathway for cytokines 
(see Figure 1.3). Importantly, IL-10-R does not have SOCS-3 binding sites and 
therefore is not regulated by this factor per se (Murray, 2007). The mechanism by 
which SOCS proteins inhibit the JAK/STAT signalling is thought to involve binding 
of the appropriate substrate by a SOCS Src homology 2 (SH2) domain followed by 
formation an E3 ubiquitin ligase by a second domain (SOCS box). The formation of 
the E3 ubiquitin ligase involves interactions of SOCS box with several proteins i.e., 
elongins B and C, a cullin and Rbx2 and mediates proteasome degradation of the 
substrate (O'Shea & Murray, 2008).    
 IL-10 is produced by a number of cell types (T cells, B cells, monocytes, Mφ, 
dendritic cells) in response to a number of stimuli, e.g., Gram-positive or Gram-
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negative bacteria, purified endotoxin, bacterial exotoxin or certain viruses. Following 
LPS stimulation, production of IL-10 is delayed in comparison to other cytokines 
(e.g., TNF-α, IL-1, IL-6, IL-8, IL-12) (de Waal et al., 1991). Furthermore, its 
appearance is associated with downregulation of other cytokines such as TNF-α. 
Thus, it has been suggested that IL-10 is a negative regulator of continued cytokine 
production (Donnelly et al., 1995). This hypothesis has been further supported by the 
observation that in LPS-stimulated monocytes, neutralisation of IL-10 activity with 
anti-IL-10 antibodies prolongs TNF-α expression and increases ‘net’ TNF-α 
production (Berg et al., 1995). However, the exact molecular mechanism underlying 
IL-10 inhibition of LPS-inducible gene expression is yet to be identified. Initially, it 
has been suggested that IL-10 blocks activation of NF-κB or MAPK by LPS but no 
consensus has been reached with this regard (Donnelly et al., 1999). Interestingly, it 
has been demonstrated in monocytes that IL-10 induces de novo synthesis of SOCS-3 
and that this correlates with inhibited expression of LPS - inducible cytokines, such 
as TNF-α or IL-1 (Donnelly et al., 1999). Moreover, phenotypic analysis of JAK1 
deficient mice (Rodig et al., 1998) and targeted deletion of STAT3 in neutrophils and 
Mφ (Takeda et al., 1999) revealed that both JAK1 and STAT3 are critical for IL-10 
inhibition of LPS – induced cytokine production. Therefore it is possible that IL-10-














FIGURE 1.3 Schematic representation of the IL-10 signal transduction pathway. 
Transduction of IL-10 signalling is initiated by formation of the IL-10-R complex 
that is composed of IL-10 homodimer and two IL-10-R1/IL-10-R2 heterodimers. The 
formation of IL-10-R complex activates tyrosine kinases Jak1 and Tyk2 and 
subsequent phosphorylation of intracellular domains of IL-10-R1. The latter results in 
activation and homodimerisation of a transcription factor STAT3, which translocates 
to the nucleus and drives transcription of IL-10-induced genes, such as SOCS-3. IL-
10 signal transduction pathway and key proteins are described in more depth in 
section 1.2.2.2. 
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1.2.3 TNF-α SIGNALLING 
 TNF-α signalling is initiated by binding of a TNF-α trimer to the extracellular 
domain of TNF-R1. This event causes a release of the inhibitory protein named 
silencer of death domain (SODD) from the intracellular domain TNF-R1 (Jiang et al., 
1999). Following SODD liberation, intracellular TNF-R1 domain is recognised by an 
adaptor protein called TNF receptor-associated death domain (TRADD). As indicated 
in Figure 1.4, TRADD serves as an assembly platform for recruitment of additional 
adaptor proteins: receptor-interacting protein (RIP), TNF-R-associated factor 2 
(TRAF2) and Fas-associated death domain (FADD) (Hsu et al., 1996), which initiate 
distinct signalling pathways (Wajant et al., 2003).  
 
1.2.3.1 NF-κB ACTIVATION via RIP SIGNALLING 
 Following TNF-α stimulation, the signalling pathway for NF-κB activation is 
initiated by association of TRADD and subsequent assembly of TRAF2 and RIP into 
the TNF-R1 complex (Chen & Goeddel, 2002). Both TRAF2 and RIP play an 
important role in the degradation of inhibitor κB (I-κB) via activating a 
multicomponent I-κB kinase (IKK) complex (Ghosh & Karin, 2002). It has been 
shown that TRAF2 is responsible for recruitment and RIP for activation (possibly by 
interacting with mitogen-activated kinase kinase kinase (MEKK3)) of IKK kinases 
within TNF-R1 signalling complex (Devin et al., 2000).   
 The NF-κB/Rel family of transcription factors consists of 5 members (dimers) 
in mammalian cells: p105 (constitutively processed to NF-κB1/p50), p100 (processed 
to NF-κB2/p52 in certain circumstances), c-Rel, RelA/p65 and RelB (Verma et al., 
1995). These factors, in response to some cytokines (i.e., TNF-α and IL-1), bacterial 
products (i.e., LPS) or physical stress (e.g., UV radiation or ROS) activate 
transcription of numerous inflammatory-related genes (Baud & Karin, 2001). Two 
different signalling pathways are involved in activation of NF-κB (Simmonds & 
Foxwell, 2008). One of them, namely ‘classical’ or ‘canonical’, involves 
phosphorylation-dependent ubiquitination and degradation of IκB proteins. IκB 
proteins are normally responsible for retention of NF-κB within the cytoplasm of 
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unstimulated cells. In the ‘alternative’ or ‘non-canonical’ pathway, the p100 itself 
(not I-κB) inhibits and retains RelB in the cytosol. Detailed description of both 








FIGURE 1.4 Schematic representation of TNF-α signal transduction pathway. 
Engagement of TNF-α with TNF-R1 results in assembly of several adaptor proteins, 
namely TRADD, FADD, TRAF2 and RIP, followed by recruitment of additional key 
enzymes (e.g. caspases-8, IKK2) that initiate downstream processes leading to 
apoptosis, cell survival or activation of transcription factors such as NF-κB or AP1. 
Detailed description of TNF-α signal transduction pathway and key adaptor proteins 
and enzymes is presented in section 1.2.3. 
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1.2.3.1.1 THE CANONICAL PATHWAY OF NF-κB ACTIVATION 
 All NF-κB/Rel proteins possess a highly conserved Rel homology domain 
(RHD), which facilitates dimerisation, DNA binding, nuclear localization and 
interaction with the members of inhibitory I-κB protein family. However, only three 
NF-κB/Rel proteins (p65, RelB, c-Rel) contain transactivation domains (TADs) 
enabling their interaction with general transcription factors and consequently 
induction of gene expression. The presence of TADs determines whether specific NF-
κB/Rel protein acts as an activator or a repressor of transcription. For instance, 
common heterodimer p50/p65 acts as an activator of gene transcription due to the 
presence of a TAD in p65 subunit. On the contrary, the p50 subunit does not have the 
TAD domain and therefore acts as a repressor of transcription by competing for 
p50/p65 binding to the NF-κB consensus sequence (Simmonds & Foxwell, 2008).  
 In unstimulated cells, the activity of NF-κB is blocked by I-κB proteins i.e., I-
κBα, I-κBβ, I-κBγ, I-κBε, Bcl-3 or p105 and p100 (the precursors of NF-κB1 and 
NF-κB2 respectively). I-κB proteins mask the nuclear localization sequences in NF-
κB dimers and therefore they stay in the cytoplasm (Wajant et al., 2003). Upon cell 
activation, e.g., with LPS, TNF-α or IL-1, IκB is degraded by the proteasome and 
NF-κB is liberated. Further modifications (phosphorylation or acetylation of subunits) 
result in NF-κB translocation into nucleus (Perkins, 2000). Several kinases have been 
reported to take part in this secondary process i.e. mitogen activated protein kinases 
(MAPK) and protein kinase C (PKC) (Wajant et al., 2003).  
 It has been demonstrated that I-κB degradation is facilitated by a 
multicomponent protein kinase complex, I-κB kinase complex (IKK)  (Simmonds & 
Foxwell, 2008). Various cellular stimuli, e.g., LPS or TNF-α induce signalling 
pathways that converge in the formation of IKK. This complex is composed of a 
number of proteins including two related I-κB kinases, IKK1 and IKK2 (IKKα and 
IKKβ), regulatory protein NEMO (Fip3, IKKγ, IKKAP), a heat shock protein – 90 
(Hsp90) and Hsp90 – associated cdc37 protein (Chen & Goeddel, 2002). The 
activated IKK facilitates phosphorylation of the regulatory domain of I-κB giving a 
signal for its recognition by an SKP1-Cullin-Fbox-type E3 ubiquitin-protein ligase 
complex (Wajant et al., 2003). 
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 One interesting feature of the canonical NF-κB pathway is its rapid but short 
activation. It prevents a persistent response that can potentially result in pathological 
changes in affected cells. Indeed, it has been demonstrated that a promoter of the I-κB 
gene is highly responsive to NF-κB activation and contains 11 consensus sequences 
recognisable by this transcription factor. Consequently, whenever NF-κB triggers 
gene expression, I-κB is also produced and, in turn, binds NF-κB dimers reducing 
their activity (Covert et al., 2005). 
 
1.2.3.1.2 THE NON-CANONICAL PATHWAY OF NF-κB ACTIVATION 
 The non-canonical (alternative) pathway of NF-κB activation is specific for B 
cells. In unstimulated cells, p100 acts as an inhibitory factor responsible for retention 
of RelB in the cytosol. However, when B cells are stimulated, p100 is processed by 
IKK1 complexed with NF-κB inducing kinase NIK and then proteolytically cleaved 
by the proteosome. This leads to liberation of the p52 subunit and formation of 
transcriptionally active p52/RelB heterodimers (Xiao et al., 2006). It is thought now 
that p100 is a new member of the I-κB family, designated I-κBδ (Basak et al., 2007). 
 
1.2.3.2 THE ANTI-APOPTOTIC ACTION AND MAPKKK 
ACTIVATION via TRAF2 SIGNALLING 
 Following TNF-α stimulation, anti-apoptotic signalling begins with 
recruitment of an adaptor protein TRAF2 into TNF-R1 signalling complex (see 
Figure 1.4). It has been demonstrated that TRAF2 depletion sensitises cells for the 
pro-apoptotic action of TNF-α (Li et al., 2002;Fotin-Mleczek et al., 2002;Brown et 
al., 2002a). This observation can be explained by the fact that TRAF2 mediates 
recruitment of the inhibitor of apoptosis proteins (IAP), namely cIAP1 and cIAP2 
into the TNF-R1 complex (Shu et al., 1996). Both cIAP1 and cIAP2 inhibit activity 
of caspase-3 and caspase-7 via binding to their amino-terminal BIR (baculovirus IAP 
repeat) domains (Roy et al., 1997). Furthermore, the carboxy-terminal RING domain 
of cIAP1 and cIAP2 proteins act as E3 ubiquitin ligase involved in proteosomal 
degradation of caspase-3 and -7 (Yang et al., 2000). A more detailed description of 
the IAP family of proteins and their role in regulation of apoptosis is presented in 
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chapter 1.3.1. On the contrary, stimulation of TNF-R2 and assembly of TRAF2 into 
the TNF-R2 complex augments TNF-R1-induced cell death possibly due to 
competition of TNF-R1 and TNF-R2 for binding of TRAF2 and associated cIAP1 
and cIAP2 proteins (Fotin-Mleczek et al., 2002).  
 TRAF2 is also thought to activate a mitogen-activated protein kinase kinase 
kinase (MAPKKK) such as extracellular signal-regulated kinase kinase kinase 1 
(MEKK1) or apoptosis-stimulated kinase 1 (ASK1), which, in turn, activate a cascade 
of kinases regulating activation of c-Jun NH2 -terminal kinase (JNK). The latter 
kinase phosphorylates c-Jun enhancing its transcriptional activity (Chen & Goeddel, 
2002). c-Jun belongs to a family of AP-1 transcription factors, which play an 
important role in a variety of cellular processes such as proliferation, differentiation 
or prevention of apoptosis.   
 
1.2.3.3 THE PRO-APOPTOTIC PATHWAY via FADD 
SIGNALLING 
 Following TNF-α stimulation, signalling for apoptosis begins with association 
of an adaptor molecule FADD to TNF-R1 signalling complex via the bridging 
molecule TRADD. As indicated in Figures 1.4 and 1.5, subsequent interaction of 
receptor-bound FADD with inactive caspase-8/10 via their death effector domains 
leads to their autoproteolytic cleavage and initiation of the apoptosis process (Chen & 
Goeddel, 2002). After activation of caspase-8, downstream signalling for apoptosis 
occurs in principle through the same pathways for all death receptors, i.e., Fas, 
TRAIL-R1/2 or TNF-R1 and depends on the type of cell involved. As shown in 
Figure 1.5, in type 1 cells, activated caspase-8 per se is sufficient to process robustly 
pro-caspase-3 into caspase-3 and induce the execution phase of apoptosis. The 
activated caspase-3 cleaves inhibitors of caspase–activated DNase resulting in 
degradation of DNA in the nucleus. In type 2 cells, processing of pro-caspase-3 by 
caspase-8 alone is not sufficient for triggering apoptosis. Thus, efficient activation of 
pro-caspase-3 in this model depends on release of cytochrome c from mitochondria 
and formation of the caspase–3-inducing apoptosome complex. Activated caspase–3 
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is also able to further activate pro-caspase-8 creating a positive feedback loop (Li et 
al., 1998).  
 Interestingly, as shown in Figure 1.4, the pro-apoptotic effect of TNF-α is 
masked in vivo by simultaneous activation of NF-κB (TNF-R1 is mainly an NF- κB 
inducing receptor). In contrast, the other death receptors such as Fas or TRAIL-R1/2 
show significant pro-apoptotic functions in vivo and Fas- or TRAIL-R1/2 – induced 
NF- κB activation occurs only when the pro-apoptotic pathway is blocked (Wajant et 
al., 2000). The above phenomenon could be explained, at least in part, by various 
abilities of death receptors to assemble a death-inducing signalling complex (DISC). 
While formation of DISC has been proven for Fas and TRAIL receptors, 
demonstration of a TNF-R1–DISC complex has not been successful (Wajant et al., 
2003). Possibly, in the case of TNF-R1, DISC complexes are characterised by much 
lower stability or additional regulatory mechanisms exist that selectively affect 
formation or activity of DISC. For example, several research groups have observed 
that TRAF2 depletion (adaptor protein specific for TNF-R1 but not Fas or TRAIL 
signalling complex) sensitises cells for TNF-α–induced apoptosis (Li et al., 2002). 
The anti-apoptotic role of TRAF2 signalling is described in more detail in section 
1.2.2.2. 
 Furthermore, it has been demonstrated that exclusive activation of TNF-R2 
with agonistic TNF-R2–specific antibodies also induces cell apoptosis. The 
underlying mechanism involves induction of endogenous mTNF-α by activated TNF-
R2. Subsequently, mTNF-α triggers TNF-R1 signalling (Grell et al., 1999). 
Furthermore, the co-existing stimulation of TNF-R2 greatly augments the pro-
apoptotic signalling from TNF-R1 by recruitment of TRAF2 and TRAF2–associated 
anti-apoptotic factors into TNF-R2 signalling complex. Similarly, apoptosis may be 
induced by other members of the TNF receptor family which do not have intracellular 























FIGURE 1.5 Schematic representation of death signalling pathways in 
granulocytes. Binding of TNF-α to its receptor (TNF-R1) activates procaspase-8 via 
death receptor associated proteins (TRADD, FAD). Caspase-8-directed pathways 
lead to apoptosis through caspase cascade or mitochondrial pathway associated with 
cleavage of Bid, release of cytochrome c from mitochondria and formation of the 
apoptosome. Both pathways finally activate pro-caspase-3 resulting in apoptosis. The 
death signalling pathways in granulocytes are described in more detail in section 
1.2.3.3.  
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1.3 RESOLUTION OF INFLAMMATION 
 Currently, two key mechanisms are postulated to play a crucial role in 
successful resolution of the inflammatory response, namely apoptosis of 
inflammatory cells and their clearance by phagocytes. Apoptosis is a mode of cell 
death that, in contrast to necrosis (cell disintegration), does not seem to trigger pro-
inflammatory responses and plays an essential role in almost all physiological 
processes (Haslett, 1999;Wyllie et al., 1980). Apoptotic cells are characterised by 
several common features such as rapid shrinkage of the cytoplasm, nuclear 
coalescence, membrane budding and finally formation of one or more apoptotic 
bodies. More importantly, during apoptosis membrane integrity is maintained and 
potentially toxic intracellular contents are not liberated into surrounding tissue. This, 
in turn, prevents tissue damage and consequential propagation and exaggeration of 
inflammatory processes. Yet, effective apoptosis of activated granulocytes is not the 
only mechanism determining successful resolution of inflammatory responses. 
Apoptotic cells must be subsequently removed by neighbour cells or in higher 
organisms by professional phagocytes to avoid cell disintegration (secondary 
necrosis) and the release of histotoxic intracellular material leading to harmful 
chronic inflammatory effects. In mammals, apoptotic granulocytes are thought to 
undergo non-inflammatory phagocytosis by Mφ or dendritic cells but in certain 
circumstances other cell types such as endothelial cells (Dini et al., 1995), vascular 
smooth muscle cells (Bennett et al., 1995) and fibroblasts may also remove apoptotic 
cells (Hall et al., 1994). Moreover, it has been shown that Mφ clearance of apoptotic 
cells (efferocytosis) induces anti-inflammatory responses in phagocytes such us 
secretion of anti-inflammatory cytokines, e.g., TGF-β, IL-10 and IL-13 (Huynh et al., 
2002;Hoffmann et al., 2005). In contrast, uptake of necrotic cells including 
secondarily necrotic cells derived from nonengulfed apoptotic cells, stimulates 
release of pro-inflammatory mediators i.e. TNF-α, IL-1β, NO (Fadok et al., 
1998;Voll et al., 1997;Fadok et al., 2001). It is now accepted that failure of sufficient 
clearance of apoptotic cells and subsequent secondary necrosis induces pro-
inflammatory responses and may lead to the development of autoimmune diseases 
such as systemic lupus erythematosus (SLE) (Ren et al., 2003), cystic fibrosis 
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(Vandivier et al., 2002a) or chronic obstructive pulmonary disease (COPD) (Hodge et 
al., 2003). 
 
1.3.1 APOPTOSIS OF INFLAMMATORY CELLS  
 Apoptosis is a highly conserved process that engages similar pathways and 
enzymes in almost all living organisms (Hengartner, 2000). One of the examples here 
is a family of caspases (proteases dependent on a cysteine nucleophile), which cleave 
motifs possessing aspartic acid. Caspases are produced as inactive pro-enzymes, 
composed of a large and a small subunit preceded by an N–terminal pro-domain. 
When pro-caspase undergoes activation, two Asp sites are cleaved sequentially and 
the large and the small subunits associate to provide the active site of the enzyme. In 
fact, the active caspase is a tetramer of two heterodimers and contains two active 
sites. Upstream caspases (initiators) can activate themselves in an autocatalytic way 
while downstream caspases (effectors) require initiator caspases for their activation 
via transprocessing. The examples of effector caspases implicated in an execution 
phase of apoptosis are caspase–3 and caspase–7 (Danial & Korsmeyer, 2004). 
Activation of caspases leads to morphological changes associated with apoptosis, 
namely DNA degradation, chromatin condensation and membrane blebbing (Fulda & 
Debatin, 2006). In order to protect cells from unwanted execution of apoptosis a 
family of proteins (IAP) has evolved. IAP were first identified as baculovirus proteins 
that block apoptosis of infected cells via direct or indirect inhibition of caspases 
(Clem et al., 1991). These proteins are characterised by one to three zinc-binding 
motifs whose role is to bind activated caspases. These motifs are termed baculovirus 
IAP repeat (BIR) (Salvesen & Duckett, 2002). Some of the IAP contain also an 
additional, highly conserved, carboxy-terminal RING domain, which plays an 
important role in targeted degradation of proteins by ubiquitinylation (Roy et al., 
1997). In humans, there are eight distinct IAP able to block the cytokine cascade and 
promote cell survival, namely cIAP-1, cIAP-2, XIAP, ILP-2, NAIP, ML-IAP, apollon 
and survivin (Danial & Korsmeyer, 2004). Their activity is, in turn, controlled by a 
number of other proteins, e.g., SMAC, which possess IAP binding motifs (IBM). 
IBM recognise and bind IAP via their BIR domains and consequently, active 
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caspases which execute the apoptosis process (Chai et al., 2000). However, some 
IAP, e.g., survivin, interact directly with SMAC and inhibit its activity (Song et al., 
2003). Interestingly, survivin has been demonstrated to be expressed mainly by 
transformed cell lines and malignancies but not in normal adult tissues. Furthermore, 
cells expressing survivin, such as cancer cells, are resisitant to various pro-apoptotic 
stimuli including a wide range of anti-cancer agents (Zangemeister-Wittke & Simon, 
2004). In addition, survivin forms complexes with hepatitis BX–interacting protein 
(HBXIP) or XIAP and interferes with activation of caspase 9 in this way (Marusawa 
et al., 2003). The role of cIAP-1 and cIAP-2 in TNF-α signalling is described in 
section 1.2.3.2. 
 Three different pathways are involved in the activation of effector caspases 
and subsequent execution of the apoptosis process: the extrinsic death receptor 
pathway (type I cells), the intrinsic (mitochondrial) pathway (type II cells) and the 
endoplasmic reticulum (ER) or stress–induced pathway (Fulda & Debatin, 2006). The 
extrinsic death receptor pathway, induced by ligands of TNF superfamily membrane 
receptors and associated with formation of DISC has been briefly described in 
chapter 1.2.3.3. The ER/stress induced pathway has not been characterised well yet 
but involves activation of caspase 12 by Ca2+ and oxidant stress (Kadowaki et al., 
2004). The mitochondrial pathway can be initiated by the absence of growth factors, 
e.g., IL-2, IL-4 or granulocyte Mφ-colony stimulating factor (GM-CSF) as well as a 
presence of numerous mediators such as IL-1, IL-6, steroids, ROS, peroxynitrite and 
NO which, in turn, activate pro- or anti–apoptotic members of BCL–2 family (Fulda 
& Debatin, 2006). The BCL-2 family of proteins can be divided into three subclasses 
based on the sequence similarities within four BCL-2 homology (BH) 1-4 domains. 
BAK, BAX and BID are the pro-apoptotic members of the BCL-2 family and possess 
either three BH1-3 domains (BAK or BAX) or one BH3 domain (BID). In contrast, 
anti-apoptotic members of the BCL-2 family (BCL-2, BCL-XL, MCL-1, A1 and 
BCL-W) are highly homologous within all four BH1-4 domains. The balance 
between anti- and pro–apoptotic BCL–2 mediators decides if cells enter the intrinsic 
pathway of apoptosis (Danial & Korsmeyer, 2004).  
 In viable cells BAK and BAX exist as monomers. However, when cells 
receive pro-apoptotic stimulation, BAK and BAX form oligomers that cause 
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permeabilisation of the mitochondrial outer membrane (MOM) and liberation of 
intermembrane space (IMS) proteins such as cytochrome c, SMAC/DIABLO and 
apoptotic protease activating factor 1 (Apaf-1) (Danial & Korsmeyer, 2004). The 
‘BH-3 only’ members of BCL-2 family, e.g., BID, are important proteins regulating 
BAK and BAX activation. It has been also shown that BID requires BAK and BAX 
for execution of cell apoptosis (Desagher et al., 1999). In contrast, the anti-apoptotic 
members of the BCL-2 family bind and sequester ‘BH-3 only’ molecules and 
interfere with BAK and BAX activation in this way (Cheng et al., 2001). Following 
cytochrome c liberation from IMS of the mitochondrion, it forms a complex 
(apoptosome) with Apaf-1, which subsequently, in the presence of ATP/dATP, 
recruits pro-caspase–9 into the complex. These events enable self–processing of pro-
caspase 9 into an initiator caspases 9, followed by activation of caspases 3 and 
initiation of apoptosis (Danial & Korsmeyer, 2004). 
 
1.3.2 RECOGNITION OF APOPTOTIC CELLS BY 
PHAGOCYTES  
 Removal of apoptotic cells by professional phagocytes (efferocytosis) in a 
non-phlogistic manner, according to the recent concept, consists of three central 
elements: 1) attraction of phagocytes via soluble “find me” signals; 2) recognition 
and engulfment via displayed “eat me” and lacking “don’t eat me” signals; and 3) 
production of anti-inflammatory cytokines such as IL-10 or TGF-β by phagocytes 
that have ingested apoptotic cells (Lauber et al., 2004). All of these elements are 
discussed in more detail in the following sections. 
1.3.2.1 ATTRACTION OF PHAGOCYTES BY APOPTOTIC 
CELLS 
 In higher organisms apoptotic cells are not usually located in close proximity 
to phagocytic populations therefore secretion of specialised chemotactic signals by 
apoptotic prey appears to be an important factor determining their sufficient clearance 
by phagocytes. Although “find me” signals are so far poorly characterised, recent 
studies demonstrated that apoptotic bodies secrete the phospholipid 
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lysophosphatidylcholine (LPC), which attracts phagocytic cells. LPC is generated by 
the calcium-independent phospholipase-A2 which is activated in presence of caspase-
3 during apoptosis (Lauber et al., 2003). LPC is not the only chemotactic signal 
reported so far. Other examples include S19 (ribosomal protein dimmer) (Horino et 
al., 1998), split human tyrosyl-tRNA synthetase (Wakasugi & Schimmel, 1999) and 
thrombospondin-1 (Moodley et al., 2003).  
 Mφ receptors recognising soluble ‘find me’ signals and the mechanisms by 
which ‘find me’ signals phagocyte chemotaxis are yet poorly identified. Quite 
recently, Peter et al have demonstrated (using RNA interference and expression 
studies) that the G-protein coupled receptor (G2A) on monocytic cells is able to bind 
LPC and induce migration of monocytes towards apoptotic cell culture supernatants 
(Peter et al., 2008). Another study by Truman and colleagues has demonstrated that 
lymphocytes undergoing apoptosis release a chemokine and intracellular adhesion 
molecule named CX3CL1/fractalkine, which is then recognised by fractalkine 
receptor, CX3CR1, on the surface of Mφ and stimulates their chemotaxis towards 
apoptotic cells (Truman et al., 2008).  
 Another intriguing hypothesis that explains migration of phagocytes towards 
apoptotic cells is the generation of electric fields by cells undergoing apoptosis. 
Apoptotic cells lose membrane asymmetry and, consequently, negative charge 
appears on their surfaces which can potentially attract phagocytes (Erwig & Henson, 
2008). Electric fields have been demonstrated to stimulate migration of endothelial 
cells and neutrophils in the direction of a wound centre (Zhao et al., 2006) as well as 
budding of endothelial cell toward the dying cells (Weihua et al., 2005).   
1.3.2.2 PHAGOCYTE RECOGNITION OF APOPTOTIC CELLS  
 Recognition and engulfment of apoptotic particles is a very complex process 
involving multiple ligand-receptor interactions. The contact point between apoptotic 
prey and phagocyte, especially in a view of its resemblances to the neuronal synapse, 
has been termed an engulfment “synapse”. Numerous molecules are involved in the 
formation of the engulfment “synapse”, namely “eat me” signals (molecules enabling 
recognition of apoptotic cells by phagocytes), bridge molecules and phagocytic 
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receptors. All of them are presented in Table 1.1 and briefly reviewed in separate 
sections below.  
 
TABLE 1.1 Efficient phagocytosis of apoptotic cells is dependent upon 
expression of numerous ‘eat me’ signals that interact with phagocytic receptors 
in a direct or an indirect (via bridging molecules) manner. 
‘Eat me’ signals  Bridging molecules  Phagocytic receptors 
• Phosphatidylserine (PS)
• Calreticulin (CRT) 
• TSP binding sites  
• Collectin binding sites  
• Lectin binding sites  
• C1q or C3b binding sites
• Sites resembling  




• Annexin 1 (Anx1) 
• Milk fat-globule-EGF-factor 8 
(MFG-E8) 
• Growth-arrest-specific 6  
(GAS6) 
• β2-glycoprotein-I (β2-GPI) 
• Protein S 
• Thrombospondin-1 (TSP-1) 
• Mannose binding lectin 
 (MBL) 
• Lung surfactant proteins 
 A and D (SP-A, SP-D) 
• First component of the  
classical complement cascade  
(C1q)  
 
• T-cell immunoglobulin  
(Tim4) 
• Brain specific angiogenesis
inhibitor (BAI1) 
• Stabilin2 
• Β2-GPI receptor  
• Receptor-tyrosine kinase  
MER 
• CD91 (LRP1 or α2 
macroglobulin) 
• Vitronectin receptor (αγβ3-
integrin) 
• Receptor-tyrosine kinase  
MER 
• Class A Mφ scavenger 
 receptor (SR-A) 
• Lectin-like  
oxLDL-receptor 1 (LOX-1) 
• CD68 and CD36 
• Formylpeptide receptor 
(FPR2/ALX) for lipoxinA4 




1.3.2.2.1 “EAT ME” and “DON’T EAT ME” SIGNALS 
 The translocation of phosphatidylserine (PS) to the outer leaflet of the plasma 
membrane during apoptosis is one of the most extensively studied “eat me” signals 
(Fadok et al., 1992). Although detail of the mechanism underlying exposure of PS 
remains unclear, a few processes are thought to be engaged. One of them is the 
inhibition of the flippase that normally transfers PS to the inner leaflet of the cell 
membrane. The second one is the activation of a bidirectional non-specific 
phospholipid scramblase (Williamson & Schlegel, 2002). Finally, the potential role of 
the ATP binding cassette transporter (ABC1) in the redistribution of phospholipids 
has also been postulated (Luciani & Chimini, 1996). Even though externalisation of 
PS to the outer leaflet of the cell membrane is clearly associated with apoptosis; its 
role in apoptotic cell recognition and engulfment by phagocytes remains to be 
established. It has been demonstrated that the presence of annexin V that masks 
external PS on apoptotic cell surface, blocks phagocytosis (Krahling et al., 1999). In 
contrast, extensive studies show that some living cells expose PS on the outer leaflet 
of the cell membrane, e.g., activated B cells (Dillon et al., 2001), neutrophils in Barth 
syndrome (Kuijpers et al., 2004) or T lymphocytes characterised by low levels of the 
transmembrane tyrosine phosphatase CD45RB (Elliott et al., 2005). Interestingly, 
these cells are not ingested by phagocytes.  
 During apoptosis, in addition to PS, other molecules, which are normally 
present on the intracellular side of the membrane, appear on the cell surface. These 
include, colocalising with PS, annexin I and the endoplasmic reticulum protein 
calreticulin (CRT) (Erwig & Henson, 2008). CRT is expressed by most cell types and 
its surface levels increases during apoptosis and in response to any cellular stress 
(Heal & McGivan, 1998). Several lines of evidence indicate that CRT plays a 
significant role in clearance of apoptotic cells. First of all, cells deficient in this 
protein undergo apoptosis but their removal by Mφ is impaired (Mesaeli et al., 1999). 
Furthermore, addition of soluble CRT to apoptotic cells not expressing their own 
CRT rescue their clearance by phagocytes (Gardai et al., 2005). In addition, 
interaction of CRT with CD91 has been shown to be essential for efficient removal of 
apoptotic cells. CD91 is also known as a low-density lipoprotein (LDL) receptor-
related protein (LRP1) or α2 macroglobulin receptor and has been shown to be a 
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highly effective internalisation receptor on phagocytes (Orr et al., 2003). Since CRT 
is expressed on the surface of either apoptotic cells or phagocytes, it may activate 
CD91 in either trans or cis fashion. In cis mode, apoptotic cells activate CRT 
localised on the surface of phagocytes whereas in trans mode CRT is attached to the 
apoptotic cell surface and directly interacts with CD91 on phagocytes (Gardai et al., 
2006).  
 During apoptosis, surface proteins undergo various, yet, so far poorly 
described, modifications, e.g., oxidation (i.e. phospholipids), alteration of sugar 
chains or surface charge. Consequently, the surface of apoptotic cells is characterised 
by the presence of specific sites, i.e., thrombospondin (TSP) binding sites, various 
collectin-binding sites, sites capable of binding lectins or the complement proteins 
C1q and C3b as well as sites that resemble oxidised lipoprotein particles (Erwig & 
Henson, 2008). They can interact directly with the receptors on the Mφ surface or 
bind serum proteins that serve as links (bridge molecules) between the phagocytes 
and their apoptotic meal. The bridge molecules are described in more detail in the 
next section. 
 Several studies have demonstrated that “eat me” signals like PS or CRT may 
be expressed by viable cells (Gardai et al., 2006). These findings suggest that living 
cells may express on their surface some kind of inhibitory (“don’t eat me”) signals 
that block phagocytosis of viable “self” cells. Similar mechanisms regulate 
elimination of target cells by NK cells. NK cells express on their surfaces activating 
receptors, which bind certain ligands presented by other cells. This interaction 
enables NK cell activation. However, NK cells also express inhibitory receptors 
(killer cell Ig-like receptor (KIR)) which bind ‘self’ major histocompatibility complex 
(MHC) class 1 molecules. This interaction suppresses activation of NK cells. It has 
been postulated that recruitment of src-homology 2–containing protein tyrosine 
phosphatase–1(SHP-1) and SHP-2 to two immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs) may be involved (Yusa et al., 2004). It is believed that phagocytosis 
of viable cells may be prevented in a similar manner by presentation of markers of 
“self” on the surface of viable cells. These markers would recognise Mφ inhibitory 
receptors such as signal regulatory protein α (SIRPα) (Kharitonenkov et al., 1997).  
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 Interestingly, some “don’t eat me” signals have been identified and shown to 
inhibit uptake of viable cells. One of them, platelet–endothelial cell adhesion 
molecule-1 (PECAM-1), also known as CD31, has been demonstrated to facilitate 
both detachment of viable cells and attachment of apoptotic cells to either human 
recombinant CD31 coated non-adhesive coverslips or Mφ (Brown et al., 2002b). 
Therefore, CD31 seems to be essential for prevention of engulfment of viable “self” 
cells but also for sufficient uptake of cells undergoing apoptosis. Preincubation of 
CD31 positive apoptotic cells with blocking antibody reduced their clearance by Mφ. 
CD47, also known as integrin-associated protein, is another surface molecule which 
is believed to suppress removal of “self” viable cells following its interaction with 
extracellular domain of SIRPα on Mφ (Oldenborg et al., 2001). For instance, 
erythrocytes express CD47 on their surface and thus are not eaten by phagocytes 
(Oldenborg et al., 2000). However, this molecule is also highly expressed on the 
surface of some cancer cells (ovarian cancer cells) and by viruses such as smallpox 
and vaccinia viruses. That impairs their clearance by phagocytes and it is not 
beneficial for host organism (Campbell et al., 1992). 
  
1.3.2.2.2 INTERACTIONS OF APOPTOTIC CELLS WITH PHAGOCYTES 
via BRIDGE MOLECULES 
 Bridge molecules (opsonins) enable indirect recognition of the apoptotic cells 
by phagocytes and therefore enable more efficient phagocytosis. The examples of 
bridge molecules for PS include annexin I (Anx I) (Arur et al., 2003), milk-fat-
globule-EGF-factor 8 (MFG-E8), growth-arrest-specific factor 6 (Gas 6), β2-
glycoprotein-I (β2-GPI) (Lauber et al., 2004) and serum protein S (Anderson et al., 
2003).  
 Other bridge molecules recognise altered sugars and/or lipids on the apoptotic 
cell surface and include thrombospondin-1 (TSP-1) (Stern et al., 1996) and the 
members of the collectin family of molecules: mannose binding lectin (MBL), lung 
surfactant proteins A and D (SP-A, SP-D) (Vandivier et al., 2002b) and the collectin-
like first component of the classical complement cascade C1q (Takizawa et al., 
1996).  
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1.3.2.2.3 PHAGOCYTIC RECEPTORS 
 Given the prominence of PS in the alterations of membrane composition 
during apoptosis and the ability of exogenous PS or PS-binding proteins to block 
phagocytosis it seems to be likely that PS receptors (PSR) on the phagocyte surface 
exist and play an important role in phagocytosis. However, adequate identification of 
this receptor took a lot of time and effort of many research groups. Their effort is 
briefly summarised below.     
 One approach aiming at identification of a phagocyte PSR receptor involved 
the phage display technique. In this approach a range of antibodies was generated 
against human Mφ and one of them, monoclonal antibody 217 (mAb 217), able to 
recognise PS liposomes and was then selected for further studies. Interestingly, 
addition of mAb217 to Mφ inhibited engulfment of apoptotic cells. Subsequently, the 
antigen recognised by mAb217 was cloned and identified in the GenBank database as 
a KIAA 0585 protein (47-48 kDa) of unknown function. Interestingly, transfection of 
two cell lines (class II negative B cell line M12.C3 and Jurkat T cells), which did not 
have the ability to express PSR and phagocytose apoptotic targets, with psr gene 
resulted in proper binding and engulfment of apoptotic cells. Therefore, authors drew 
a final conclusion that the antigen for mAb217 is a PSR (Fadok et al., 2000). Further 
studies have showed that interaction of PS and this putative PSR promotes 
engulfment but not binding of apoptotic targets by phagocytes. Addition of mAb217 
to Mφ induced uptake of previously bound cells but if added prior to apoptotic cells it 
inhibited their uptake (Hoffmann et al., 2001). Furthermore, several studies have been 
performed with PSR deficient animals, which showed tendency to accumulate 
apoptotic cells. However, these studies did not compare expression of the antigen 
recognised by mAb217 in wild-type and knockout animals (Williamson & Schlegel, 
2004). In contrast, a study published by Bose and colleagues with PSR knockout 
mice has showed that the ablation of psr function resulted in the abnormal 
development of mouse embryos but Mφ mantained normal ability to remove 
apoptotic cells. Interestingly, in this study the expression of the antigen recognisable 
by mAb217 in knockout mice was comparable with that of wild-type animals. 
However, when a commercially-generated antibody against PSR has been used, 
authors showed that this protein did disappear from knockout mice (Bose et al., 
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2004). Furthermore, some data demonstrated that the protein cloned by Fadok et al is 
indeed a nuclear protein carrying five nuclear localisation signals (NLS) (Cui et al., 
2004) and that this protein did not contain a consensus sequence for PS-binding motif 
(FxFxLKxxxKxR), which is common in such enzymes as PKC, PLC or PS 
decarboxylase. Consequently, the antibody mAb217 appeared to be the only 
experimental link between PSR and presumptive psr gene, which is now thought to 
encode a nuclear protein playing a role in the development and differentiation and 
perhaps belonging to iron-oxidase family (Cikala et al., 2004).  
 Quite recently, three new PSR have been found simultaneously by three 
separate research teams. One of them is T-cell immunoglobulin and mucin-domain-
containing molecule (Tim4 or Timd4), which was identified with the use of a library 
of hamster monoclonal antibodies recognising mouse peritoneal Mφ (Miyanishi et al., 
2007). Tim4 interacted with PS via its immunoglobulin domain and mAb Kat5-18 
against Tim4 blocked PS-dependent phagocytosis of apoptotic cells. Furthermore, 
when Tim4 was expressed in fibroblasts, these cells gained ability to phagocytose 
apoptotic cells. Interestingly, Tim4 has been proposed to be a tethering receptor for 
PS since its augmentation of apoptotic cell clearance does not seem to involve the 
two known signalling pathways for phagocytosis (Park et al., 2009). Signalling 
pathways for phagocytosis are described in more detail in chapter 1.3.2.3. From other 
members of Tim family proteins, Tim1, but not Tim2 and Tim3, seems to have 
similar ability to stimulate phagocytosis in a PS-dependent manner (Miyanishi et al., 
2007).  
 The second PSR has been identified by Park and colleagues by means of the 
yeast two-hybride system (Park et al., 2007). This protein is a brain specific 
angiogenesis inhibitor 1 (BAI1) that belongs to the adhesion-type-G-protein coupled 
receptor (GPCR) family. Significantly, it contains thrombospondin type 1 repeats 
(TSR) similar to that of thrombospondin 1, which was earlier characterised as a 
bridge molecule mediating interaction between PS and phagocytic receptors (Stern et 
al., 1996). Importantly, BAI1 is also an upstream mediator for ELMO/Dock180/Rac 
and its activation directly triggers signalling pathways for phagocytosis. Similarly to 
Tim4, BAI1 expression in fibroblast results in these cells gaining ability to ingest 
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apoptotic cells. On the contrary, abolished expression or function of BAI1 blocked 
uptake of apoptotic particles in both in vitro and in vivo settings.  
 Finally, the third recently characterised PSR is stabilin-2, previously 
described as hepatic hyaluronan (HA)-binding protein, responsible for the removal of 
excess HA from blood (McCourt et al., 1999). Interestingly, in a recent study by Park 
et al., it has been shown that stabilin-2 recognises and binds PS exposed on the 
surface of aging erythrocytes or apoptotic cells and that this interaction is pivotal for 
their subsequent clearance by Mφ (Park et al., 2008). Furthermore, intereference with 
stabilin-2 expression or function significantly abolished both binding and engulfment 
of both phagocytic preys by Mφ.  
 There are also a number of phagocyte receptors that recognise PS via bridge 
molecules. These receptors include vitronectin receptor (αvβ3-integrin), the receptor-
tyrosine kinase Mer, and the β2-glycoprotein-I (β2-GPI) receptor (Lauber et al., 
2004). Several phagocyte receptors interact also with oxidized low-density 
lipoproteins (oxLDL), namely SR-A (class A Mφ scavenger receptor) (Platt et al., 
1996), LOX-1 (lectin-like oxLDL-receptor1) (Oka et al., 1998), CD-68 (Erdosova et 
al., 2002) and CD36 (Ren et al., 1995). Furthermore, TSP binding sites bind to a 
receptor complex on the phagocyte that comprises of the integrin αvβ3 and the 
scavenger receptor CD36. In addition, formylpeptide receptor FPR2/ALX have been 
demonstrated to play an important role in lipoxin A4 and annexin-derived peptide 
(Ac2-26) – stimulated phagocytosis (Maderna et al., 2010).   
 Recognition and engulfment of apoptotic cells by phagocytes is a complex 
process characterised by multiple interactions between surface molecules presented 
by both phagocytes and apoptotic cells. However, some of the phagocyte surface 
proteins (i.e. CD44) do not directly recognise apoptotic corpses but rather exert 
indirect effects. CD44 is a well known cell surface receptor for HA, fibronectin, 
collagen and fibrin. It plays an important role in a number of processes, e.g., adhesion 
and proliferation of lymphocytes, killing of target cells by NK cells and tumor 
metastasis (Henke et al., 1996). Interestingly, our group has shown that binding of 
bivalent monoclonal anti-CD44 antibody (CD44mAb) to human monocyte-derived 
Mφ in vitro enhances uptake of apoptotic neutrophils. Consequently, in in vivo 
settings CD44 may also induce clearance of apoptotic neutrophils and mediate 
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resolution of inflammation (Hart et al., 1997). The latter suggestion has been 
supported by studies on CD44 deficient mice characterised by bleomycin-induced 
inflammation of alveolar interstitium (Teder et al., 2002). These animals accumulated 
apoptotic material in lungs to a much greater extend than wild-type controls. Impaired 
phagocytosis was also associated with prolonged inflammation and development of 
lung injury. 
 In addition, phagocytosis can be regulated pharmacologically by numerous 
compounds, e.g., glucocorticoids, lipoxins, prostaglandins or statins, which are 
briefly characterised in separate sections of chapter 1.5. 
   
1.3.2.2.4 DIFFERENCES IN RECOGNITION OF APOPTOTIC AND 
NECROTIC CELLS  
 The clearance of apoptotic and necrotic cells including secondary necrotic 
cells is thought to elicit different anti-inflammatory or pro-inflammatory responses 
from phagocytes. Thus, these processes seem to engage specific receptors or adaptor 
molecules. For instance, uptake of apoptotic cells triggers strong anti-inflammatory 
responses from both monocytes and Mφ, such as decreased production of TNF-α, IL-
1β, IL-12 and up-regulation of IL-10 or TGF-β (Voll et al., 1997;Fadok et al., 1998). 
Furthermore, complement components C1q, C3 and C4 interact selectively with 
primary or secondary necrotic cells and serve as an opsonin for apoptotic cells, which 
were not phagocytosed by regular scavenger mechanisms (Gaipl et al., 2001). C1q, 
together with serum DNase 1, is implicated in the degradation of chromatin from 
necrotic cells and subsequent uptake of chromatin fragments by monocyte-derived 
phagocytes (Gaipl et al., 2004). Similarly, C-reactive protein (CRP) does not 
recognise early apoptotic neutrophils but binds intracellularly to late apoptotic, 
membrane-permeable cells (Hart et al., 2005). On the contrary several receptors 
systems such as thrombospondin-CD36-αvβ3 complex, CD14 and surface receptor 
recognised by mAB217G8E9 are involved in uptake of both apoptotic and necrotic 
cells (Bottcher et al., 2006). The role of PS and its receptors in phagocytosis remains 
controversial, however, PS is exposed on the outer leaflet of apoptotic as well as 
necrotic cells and therefore may play a role in both processes (Brouckaert et al., 
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2004). Some data indicate, however, that the presence of PS on the apoptotic cell 
surface may induce their engulfment by phagocytes and subsequent production of 
anti-inflammatory mediators, e.g., TGF-β (Park et al., 2008). The role of TGF-β in 
resolution of inflammation is described in more detail in chapter 1.3.2.4.       
 
1.3.3 ENGULFMENT OF APOPTOTIC CELLS BY MΦ 
 Engulfment is a very complex process and depends on numerous factors such 
as the type of ingested particles (apoptotic or necrotic) or the type of receptors 
involved. However, a few common principles have been established with regard to 
this process. Following recognition of a target particle by phagocytes, actin 
polymerisation occurs at the site of uptake and the particle is ingested via an actin-
dependent mechanism. After internalisation, the phagosome undergoes complex 
changes leading to the creation of a mature phagolysosome. In the mature 
phagolysosome ingested particles are trafficked into a series of increasingly acidified 
membrane-bound structures, where they subsequently undergo degradation (Erwig & 
Henson, 2008). The process of internalisation per se seems to depend on the type of 
receptors involved. For instance, phagocytosis mediated by Fcγ receptors relies on 
their sequential interactions with IgG-opsonised particles. Following recognition by 
Fcγ receptors, IgG-opsonised particles are phagocytosed by tight pseudopod 
extensions, which are formed on the surface of phagocytes (‘zipper’ mechanism) 
(Griffin, Jr. et al., 1976). In contrast, the uptake of apoptotic cells involves formation 
of the spacious phagosomes, which are accompanied by ruffling of the cell membrane 
and uptake of the surrounding fluid (deCathelineau & Henson, 2003).  
 Furthermore, elegant studies in such model organisms as nematode 
Caenorhabditis elegans, fruit fly Drosophila melanogaster and mammalian cells 
revealed that the engulfment machinery involves very conserved signalling pathways 
(Reddien & Horvitz, 2000;Gumienny & Hengartner, 2001). Two signalling pathways 
have been identified so far, which regulate activity of Rho family GTPases (Gardai et 
al., 2006). Rho family GTPases includes such enzymes as RhoA and Rac-1, which 
exert opposite effects on phagocytosis of apoptotic cells - RhoA inhibits this process 
while Rac-1 is essential for proper engulfment (Morimoto et al., 2006). Therefore, the 
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‘net’ capacity of phagocytes for uptake of target particles depends on the activation of 
RhoA and Rac-1 and the RhoA/Rac-1 balance on the surface of phagocytes. As 
demonstrated in Figure 1.6, signalling pathways for phagocytosis converge in a 
trimolecular complex ELMO/CrkII/DOCK180 in mammals (known respectively as 
CED-12, CED-2 and CED-5 in the C.elegans) (Henson, 2005). It has been shown that 
assembly of this complex activates the guanine nucleotide exchange activity of 
DOCK180 for Rac-1 (CED-10 in the C.elegans), which in turn promotes 
reorganisation of cytoskeletal elements and enables uptake of target particles (Krysko 
et al., 2006). The important role of Rho-GTPases in engulfment of apoptotic cells is 
further supported by a number of studies. For instance, the study by Gumienny and 
colleagues demonstrated that Rac activation was critical for phagocytes to ingest 
apoptotic cells in vitro, whereas activation of RhoA inhibited this process (Gumienny 
et al., 2001). Interestingly, activation of Rac was quite rapidly followed by activation 
of RhoA. This observation may explain, at least in part, the fact that uptake of 
apoptotic cells by Mφ reduces their ability to engulf a second apoptotic meal (Erwig 
et al., 1999).  
 As mentioned above, the activation of signalling pathways for phagocytosis 
leads to assembly of a trimolecular complex ELMO/CrkII/DOCK180 in mammals or 
analogical CED-12/CED-2/CED-5 in the C.elegans. It is known that one signalling 
pathway is composed of recently identified in both, mammalian cells and worms, 
RhoG/MIG-2 and its activator TRIO/UNC-73 (guanine exchange factor (GEF) for 
RhoG) (deBakker et al., 2004). However, the cell surface receptor for this pathway is 
still unknown. A second signalling pathway in mammalian cells is formed of the two 
cell surface receptors ABC1 (CED-7 in C.elegans) and CD-91/LRP (CED1 in 
C.elegans) and its adaptor protein GULP (CED-6 in C.elegans). ABC1 downstream 
ligands have not been identified yet (Zhou et al., 2001). Quite recently, another cell 
surface receptor, named BAI1, has been postulated to signal through 
ELMO/Dock180/Rac-1. This molecule is a surface receptor for PS and its role in the 
























FIGURE 1.6 Schematic representation of the signal transduction pathway for 
Mφ engulfment of apoptotic cells. Phosphatidylserine (PS) and possibly other ‘eat 
me’ signals on the surface of apoptotic cells are recognised by phagocytic receptors 
such as BAI1 and possibly other unidentified yet receptors resulting in formation of 
CRKII/ELMO/DOCK180 complex. The latter enables activation of Rac-1, which in 




1.3.4 IMMUNOLOGICAL CONSEQUENCES OF 
APOPTOTIC CELL CLEARANCE 
 Clearance of apoptotic cells, in contrast to the uptake of necrotic cells, is 
assumed not to induce pro-inflammatory responses in Mφ (Meagher et al., 1992). 
Importantly, it has been demonstrated that engulfment of apoptotic cells stimulates 
Mφ production of anti-inflammatory mediators such as transforming growth factor β 
(TGF-β), prostaglandin E2 or platelet-activating factor (PAF) (Fadok et al., 
1998;Huynh et al., 2002). TGF-β is implicated in inhibition of pro-inflammatory 
cytokine production via inhibition of NF-κB activation and phosphorylation of p38 
MAPK kinase (Xiao et al., 2002). However, the production of TGF-β by Mφ as well 
as its anti-inflammatory effects appear only after a longer (> 18 hours) interaction of 
Mφ with apoptotic targets (Fadok et al., 1998;Huynh et al., 2002). Currently, it is 
believed that apoptotic cells exert their anti-inflammatory effect much earlier, just 
upon binding to the Mφ. The contact of activated Mφ with apoptotic cells has been 
reported to change their functional state from pro- to anti-inflammatory (Cvetanovic 
& Ucker, 2004) and inhibit IL-12 production by activated Mφ (Kim et al., 2004). In 
addition, apoptotic cells per se are able to release anti-inflammatory mediators, e.g., 
IL-10 or TGF-β and manipulate the Mφ activation in this way (Gao et al., 1998;Chen 
et al., 2001). The role of IL-10 in regulation of pro-inflammatory cytokine production 
and signalling is discussed in more detail in chapter 1.2.2.2. 
 Even though Mφ uptake of apoptotic cells is usually seen as favourable in 
terms of the resolution of inflammation, there are a few scenarios in which this 
process triggers pro-inflammatory consequences. For example, it has been reported 
that bacterially–triggered apoptotic neutrophils upregulate the production of the pro-
inflammatory cytokine TNF-α in human Mφ (Zheng et al., 2004). Furthermore, 
apoptotic cells, opsonised with IgG antibody, are consequently recognised via Fc 
receptors and trigger pro-inflammatory response in phagocytes (Hart et al., 
2004a;Gregory & Devitt, 2004). 
 The immunological consequences of phagocytosis are even more complicated 
when late apoptotic cells (also called secondary necrotic cells) are considered. 
Secondary necrotic cells, similarly to primary necrotic cells, do not mantain 
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membrane integrity and thus, the intracellular contents escape into surrounding tissue. 
For a long time it has been assumed that these cells induce pro-inflammatory 
responses in Mφ. However, it has been demonstrated that clearance of secondary 
necrotic neutrophils by Mφ did not induce production of pro-inflammatory mediators, 
i.e., IL-8 or TNF-α (Ren et al., 2001). Furthermore, uptake of secondary necrotic cells 
by LPS-activated J774A.1 Mφ blocked production of pro-inflammatory cytokines, 
i.e., TNF-α and IL-6 in these cells (Cocco & Ucker, 2001). In contrast, it is widely 
appreciated that uptake of primary necrotic (lysed) neutrophils usually induce 
production of macrophage - inflammatory protein 2 (MIP-2), IL-8, TNF-α and IL-10 
(Fadok et al., 2001;Li et al., 2009). These observations led to a conclusion that the 
onset of secondary necrosis does not always trigger inflammatory consequences and 
that the secondary necrotic cells can not be simply compared with the primary 
necrotic cells. First of all, during apoptosis the contents of secondary necrotic cells is 
exposed to the activated caspases, which take apart crucial cellular components, 
processes or enzymes. In contrast, lysed (primary necrotic) neutrophils release 
numerous proteases and other mediators into the tissue, which further exaggerate the 
inflammatory response. One of the examples here is a high mobility group box 1 
protein (HMGB-1). This protein leaks from primary necrotic cells and activates Mφ, 
similarly to LPS, via interaction with TLR2 and TLR4. However, HMGB-1 remains 
bound in secondary necrotic cells (Scaffidi et al., 2002). Similarly, heat-shock 
proteins and uric acid are released from primary necrotic cells but remain within the 
secondary necrotic cells (Krysko et al., 2006). Significantly, it has been reported that 
primary necrotic cells are characterised by activated transcription factor NF-κB, 
phosphorylated p38 MAPK and are capable of producing certain pro-inflammatory 
proteins (e.g., IL-6) (Vanden et al., 2006).  
 Taken together, the immunological consequences of phagocytosis of 
apoptotic, secondary necrotic or primary necrotic cells seem to be quite complex. 
Furthermore, functional responses of Mφ to phagocytosis are also influenced by 
multiple factors such as the activation state of Mφ, source of target cells, stimuli that 


















FIGURE 1.7 Immunological consequences of phagocytosis. A. In general the Mφ 
uptake of apoptotic cells is believed to be anti-inflammatory. Apoptotic cells produce 
anti-inflammatory mediators such as IL-10 or TGF-β and following phagocytosis 
induce their release by phagocytes. In addition, the uptake of apoptotic cells by 
phagocytes inhibits the release of pro-inflammatory mediators (i.e., TNF-α).  B. In 
general, the Mφ uptake of primary necrotic cells is believed to be pro-inflammatory. 
Primary necrotic cells release pro-inflammatory mediators i.e., cytokines (TNF-α, IL-
6) or proteins such as HMGB-1. HMGB-1, similarly to bacterial products, induces 
pro-inflammatory activation of phagocytes via TLR2 or TLR4. Following 
phagocytosis, primary necrotic cells induce the release of pro-inflammatory 
mediators such as TNF-α, MIP2 or IL-8 from phagocytes. As described in chapter 
1.3.4 many additional factors may change immunological consequences of 
phagocytosis and therefore presented diagram is not always applicable.  
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1.4 CHRONIC INFLAMMATORY CONDITIONS 
 
1.4.1 THE ROLE OF CYTOKINES IN CHRONIC 
INFLAMMATION 
 Cytokines are a large family of low-molecular weight proteins that enable 
communication between cells and coordinate almost all biological processes, e.g., cell 
proliferation, migration, inflammation, immunity, fibrosis, repair and angiogenesis. 
Consequently, abnormalities in cytokine levels or their receptors and signalling 
pathways play an essential role in the pathogenesis of chronic inflammatory 
conditions. The first observations supporting this hypothesis came from various 
parallel studies of thyroiditis, diabetes and rheumatoid arthritis (RA) in the early 
1980s and were then followed by studies performed by Feldmann’s group showing 
that synovial cells chronically express IL-1 (Feldmann & Maini, 2003). The same 
research group further demonstrated that TNF-α is a ‘master regulator’ of production 
of other equally important pro-inflammatory cytokines and that TNF-α blockade 
reduces production of IL-1, GMC-SF, IL-6 or IL-8, introducing the concept of a 
TNF-α-dependent cytokine cascade (Brennan et al., 1989;Feldmann, 1996). The latter 
finding led to the development of anti-TNF-α therapy, first licensed for treatment of 
RA. Therefore, for historical reasons, RA has been chosen as an example of chronic 
inflammatory conditions, which are associated with abnormalities in cytokine levels 
or functions and as such is briefly described below. 
 The affected joints in RA are characterised by several common features, 
namely pain, stiffness and inflamed synovial membranes (synovitis). Chronic 
inflammation of synovium leads to joint destruction, limited functionality and 
significant comorbidity in functional systems of the body, e.g., cardiovascular, 
neurologic and metabolic systems. Another characteristic of RA is a huge number of 
immune cells recruited into the synovium, namely activated neutrophils, Mφ, B and T 
cells, mast cells or plasma cells. In addition, other cells such as activated synovial 
fibroblasts, chondrocytes and osteoclasts contribute substantially to the processes of 
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cartilage and bone destruction and further promote inflammatory responses (Brennan 
& McInnes, 2008).  
 A number of studies have demonstrated an essential role for cytokines in 
orchestrating the inflammatory processes in RA. First of all, synovial fluid has been 
shown to contain numerous pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-18), 
chemokines (IL-8, IP-10, MCP-1, MIP-1 and RANTES), MMPs (MMP-1, -3, -9, -13) 
or enzymes (COX-1, COX-2 and iNOS) (Simmonds & Foxwell, 2008). The complex 
interactions between them prolong and exaggerate pro-inflammatory signals resulting 
in a chronic and persistent inflammation. As it has been mentioned above, the 
production of pro-inflammatory mediators seems to be highly regulated by TNF-α 
and TNF-α blockade reduces synthesis of all the other pro-inflammatory cytokines in 
joints (Feldmann et al., 2005). Moreover, TNF-α per se is able to induce degradation 
of cartilage (Dayer et al., 1985) and bone (Bertolini et al., 1986) in vitro. It has been 
appreciated that TNF-α mediates a number of processes relevant to the pathogenesis 
of RA (Brennan & McInnes, 2008) including:  
 the release of pro-inflammatory cytokines including IL-1, IL-6, IL-23, 
GM-CSF, 
 the release of hepcidin, an endogenous antimicrobial peptide, that 
induces the acute phase response, 
 the release of chemokines including IL-8, MCP-1, RANTES and SDF-1 
leading to leukocyte accumulation, 
 the production of PGE2, 
 the activation of osteoclasts resulting in bone resorption 
 the activation of chondrocytes resulting in cartilage destruction 
 the activation of endothelial cells and up-regulation of E-selectin and 
VCAM-1 resulting in leukocyte accumulation,  
 the processes of angiogenesis. 
 In addition to TNF-α, other members of the TNF superfamily, namely 
lymphotoxin-β, B lymphocyte regulator (BLyS), proliferation-inducing ligand 
(APRIL), are also implicated in development of RA. They regulate maturation, 
differentiation and activation of B cells, formation of higher lymphoid organisations, 
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as well as production of autoantibodies (i.e., rheumatoid factor) (Brennan & McInnes, 
2008).  
 Furthermore, several members of the IL-1 superfamily play important roles in 
the pathogenesis of RA. The synovial membrane in arthritic joints has been 
demonstrated to be characterised by high levels of IL-1α and IL-1β as well as the 
natural IL-1 receptor antagonist (IL-1ra). The latter limits the pro-inflammatory 
stimulation of cells by IL-1α and IL-1β (Dayer, 2003). Interestingly, IL-1ra-deficient 
mice developed spontaneous arthritis, in which Th-17 cells seemed to mediate most 
of the observed pro-inflammatory effects (Nakae et al., 2003). Furthermore, IL-1α 
and IL-1β have been shown to be directly implicated in several pathological 
processes in RA, such as production of pro-inflammatory cytokines by synovial 
mononuclear cells or chondrocytes, the release of MMPs and prostanoids by 
fibroblasts, and osteoclast-mediated bone erosion (Dayer, 2003).  
 Another important cytokine implicated in the pathogenesis of RA is IL-6. It 
controls maturation and activation of a number of cells that mediate pathological 
changes in RA, e.g., B and T cells, Mφ, osteoclasts, chondrocytes and endothelial 
cells. It also exerts a broad effect on haematopoiesis in the bone marrow (Kishimoto, 
2005). IL-6 is also likely to trigger the hepatic acute phase response in RA and induce 
synthesis of hepcidin that is directly implicated in the development of anaemia of 
chronic disease (anaemia caused by chronic infection, inflammation, renal failure or 
cancer) (Brennan & McInnes, 2008). Described in more detail TNF-α, IL-1 and IL-6 
are only a few of the cytokines, which are expressed in inflamed synovium. The other 
examples include IL-23, IL-12, IL-17, IL-22, IL-15 or IL-7 and their role in RA is 
still under investigation.  
 Summing up, abnormal levels of cytokines may significantly contribute to the 
development of chronic inflammatory and autoimmune disorders, e.g., RA, 
ankylosing spondylitis, psoriasis, asthma, chronic obstructive pulmonary disease 
(COPD), IBD, multiple sclerosis (MS) or Alzheimer’s disease (AD). The inflamed 
synovium in RA or similarly sputum in individuals with asthma or COPD (Barnes, 
2008) and many other chronically inflamed tissues are characterised by 
overexpression of these mediators. Consequently, there is a growing interest in 
cytokines as therapeutic targets and a number of cytokine inhibitors (anti-cytokines) 
 43
have been developed and evaluated during clinical trials for their inflammation 
resolving properties. Some of them are currently licensed for treatment of RA, 
psoriasis or IBD, as described in more detail in chapter 1.5.3.  
 
1.4.2 CLEARANCE DEFICIENCY AND AUTOIMMUNITY 
 Clearance of apoptotic cells is a fundamental mechanism of resolution of 
inflammation. It is believed that if this process is impaired, apoptotic cells undergo 
secondary necrosis, exacerbating inflammatory processes and leading to tissue injury. 
In addition, it has been demonstrated that uptake of apoptotic targets actively triggers 
production of anti-inflammatory cytokines (e.g., IL-10 or TGF-β) by phagocytes 
helping to maintain an anti-inflammatory milieu (Voll et al., 1997;Fadok et al., 
1998). Furthermore elegant studies by Xu and colleagues have shown that the 
increase in Mφ production of IL-10 is positively correlated with augmentation of Mφ 
uptake of early apoptotic cells (Xu et al., 2006). Mounting evidence implicates 
defects in clearance of apoptotic cells in pathogenesis of human autoimmune diseases 
such as systemic lupus erythematosus (SLE), COPD or cystic fibrosis (Krysko et al., 
2006). It has been reported that in SLE patients Mφ uptake of various phagocytic 
targets, e.g., yeast and bacteria, is impaired (Hurst et al., 1984;Salmon et al., 1984). 
In addition, Herrmann and colleagues demonstrated that Mφ isolated from SLE 
patients are characterised by reduced ability to ingest apoptotic cells. Similarly, in 
SLE patients phagocytosis by tingible body Mφ that usually phagocytose apoptotic 
cells in lymph nodes is impaired (Baumann et al., 2002;Herrmann et al., 1998).  
 It is believed, that there is a strong link between cell apoptosis and 
autoimmunity. As mentioned above, deficient clearance of apoptotic cells results in 
these cells undergoing secondary necrosis, which are a source of harmful, cytotoxic 
and pro-inflammatory agents. In addition, secondary necrotic cells contain potentially 
immunogenic autoantigens. As demonstrated in Figure 1.8, in higher organisms 
formation of autoantigens may have detrimental consequences as their innate immune 
system presents autoantigens to the adaptive immune system and triggers production 
of autoantibodies (Mahoney & Rosen, 2005). The most typical class of autoantigens 
produced in autoimmune disorders are nucleosomal proteins, which are generated by 
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internucleosomal cleavage of DNA during apoptosis (Baumann et al., 2002). 
Consequently, the rise in antibodies against nucleosomes is a common characteristic 
of SLE and other autoimmune diseases. Additionally, if uptake of apoptotic cells is 
delayed, specific enzymes such as caspases generate neoantigens that induce the loss 
of tolerance by B cells and formation of immune complexes (Casiano et al., 1996). 
Importantly, autoantibodies have the ability to opsonise apoptotic particles and 
influence phagocytosis in this manner. For instance, anti-phospholipid antibodies 
recognise externalised PS on apoptotic cell surfaces and change the outcome of the 
uptake of apoptotic cells by Mφ. The opsonised cells are recognised by Mφ Fc 
receptors and, consequently, their uptake by Mφ triggers pro-inflammatory responses 
(Price et al., 1996).  
 In addition to Mφ, apoptotic and necrotic cells may be phagocytosed by 
dendritic cells (DCs), also known as antigen presenting cells. It is believed that 
phagocytosis by tissue or follicular DCs takes place whenever removal of apoptotic 
cells by Mφ is impaired. Phagocytosis by DCs may induce various immunoresponses 
(i.e. tolerance or immune activation), which are determined by the levels of DCs 
maturation. Only mature DCs are able to cross-present self or foreign antigens to 
CD8+ cytotoxic T lymphocytes (CTL) and stimulate production of antibodies by B 
cells (Savill et al., 2002). DCs maturation is, in turn, regulated in a positive or a 
negative manner by multiple environmental factors. For instance, uptake of necrotic 
cells and the presence of pro-inflammatory signals (e.g., LPS, TNF-α, IL-1β or IFN-
α, viral or bacterial proteins or high antigen load) are very powerful inductors of DCs 
maturation and activate immune responses (Manderson et al., 2004). In contrast, 
uptake of apoptotic cells and the presence of anti-inflammatory cytokines such as 
TGF-β or IL-10 strongly inhibit maturation of DCs and promote peripheral tolerance 
(Manderson et al., 2004). It has been shown that engulfment of apoptotic material by 
DCs may inhibit even strong pro-maturation signals such as LPS, indirectly reducing 
capacity of DCs to stimulate T cells (Chen et al., 2001). Furthermore, uptake of 
purely apoptotic cells by DCs does not induce antigen presentation and some authors 
hypothesise that this effect is related to interaction of PS, present on the surface of 
apoptotic cells, with PSR and stimulation of anti-inflammatory cytokine production. 
On the contrary, uptake of necrotic cells induce opposite effects promoting DC 
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maturation as well as a break in peripheral tolerance (Sato et al., 2002;Sauter et al., 
2000). 
 Little is known about the exact processes reducing Mφ capacity for clearance 
of apoptotic cells. It has been postulated that downregulation of certain “find me” or 
“eat me” signals as well as phagocytic receptors may contribute to defects in removal 
of apoptotic cells and development of autoimmunity. Mounting evidence suggests 
that homozygous deficiency of any of the early components of classical complement 
activation pathways (C1q, C1r, C1s, C4 and C2) may be associated with the 
development of SLE (Manderson et al., 2004). This is a direct consequence of 
accumulation of apoptotic material and upregulation of self-antigens and immune 
complexes which induce tissue inflammation, DC maturation and production of 
autoantibodies. Reduced levels of complement fragments are also associated with 
decreased threshold activation of T and B cells due to lack of regulatory signals that 
maintain peripheral tolerance to self-antigens (Manderson et al., 2004;Manderson et 
al., 2004;Munoz et al., 2005). In addition, it has been postulated that impaired 
clearance of apoptotic cells significantly contributes to pathogenesis of cystic fibrosis 
(CF). This autoimmune condition is characterised by massive recruitment of 
inflammatory cells and release of intracellular proteases in lungs. Apoptotic cells are 
accumulated in the airways of CF patients and it has been suggested initially that their 
reduced uptake is caused by elastase-mediated cleavage of PSR from surface of 
phagocytes (Vandivier et al., 2002a). However, as described in a section 1.3.2.2.3 the 
identification of a putative PSR has been quite troublesome and three new PSRs have 
been recently identified. Thus, further work is required in order to fully determine the 
role of PSR in CF. 
 In summary, based on current knowledge, it is widely appreciated that 
deficient clearance of apoptotic cells is crucial for development of autoimmunity and 
is strongly related to production of autoantigens and creation of a pro-inflammatory 
environment. However, the exact mechanisms underlying the actual defects in 





FIGURE 1.8 Diagram illustrating the cascade of events resulting from efficient 
(A) or impaired (B) clearance of apoptotic cells (next pages). Efficient clearance 
of apoptotic cells prevents cell necrosis and stimulates production of anti-
inflammatory mediators by phagocytes. In an anti-inflammatory environment 
maturation of antigen presenting cells (i.e. dendritic cells) and immune responses are 
inhibited. On the contrary, when clearance of apoptotic cells is affected, accumulated 
apoptotic cells undergo secondary necrosis resulting in production of autoantigens 
and pro-inflammatory mediators. In the presence of pro-inflammatory mediators 
maturation of dendritic cells is induced. Mature dendritic cells, after gaining access to 
autoantigens, present them to T helper cells followed by subsequent B cell production 








































1.5 ANTI-INFLAMMATORY THERAPEUTICS 
AND RESOLUTION OF INFLAMMATION 
 Our group and others have shown that pharmacological or immunological 
intervention may drastically modulate Mφ ability to phagocytose apoptotic cells. In 
sections below there is a short description of glucocorticoids, NSAID and cytokine 
inhibitors, which are widely used as anti-inflammatory therapeutics. Some of them 
have been demonstrated to influence the rate of Mφ clearance of apoptotic cells and 
consequently to play a role in the resolution of inflammation. These data are briefly 
presented below.   
 
1.5.1 GLUCOCORTICOIDS 
 Glucocorticoids are hormones that play an important role in the control of 
inflammation. Normally, inflammation triggers a negative feedback loop to the 
hypothalamic – pituitary – adrenal (HPA) axis, which stimulates release of 
glucocorticoids (e.g. cortisol) by the adrenal cortex (Johnson & Rn, 2006). 
Glucocorticoid stimulation triggers a number of signalling pathways and eventually 
opposes the inflammatory response. A number of synthetic glucocorticoids (e.g., 
hydrocortisone, fludrocortisone, prednisolone, dexamethasone, betamethasone, 
triamcinolon) have been introduced into the clinic and are widely used as the most 
potent and cost-effective anti-inflammatory and immunosuppressive drugs. However, 
in addition to their beneficial effects, treatment with glucocorticoids is inevitably 
associated with precipitation of adverse drug reactions (ADR) outweighing, in some 
cases, the benefit of the treatment. These include: diabetes, osteoporosis, proximal 
myopathy, Cushing’s syndrome (acne, moon face, striae) and many others. 
Glucocorticoids act through the intracellular glucocorticoid receptor (GR), mainly its 
isoform alpha (GRα), that belongs to the nuclear receptor superfamily (Gronemeyer 
et al., 2004). GR, in its inactive state, resides in the cytoplasm, where it forms a 
complex with a number of proteins i.e. heat shock proteins (hsp90, hsp70) co-
chaperones and immunofillins. Following association of a ligand, GR undergoes a 
series of conformational changes leading to exposure of nuclear localisation signal 
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and rapid translocation to the nucleus (Defranco, 1999). In the nucleus, GR either 
activates or suppresses transcription of certain genes via interaction with 
glucocorticoid response elements (GRE) (Yamamoto et al., 1998). Interestingly, 
some GRE do not directly recognise GR but initially interact with other transcription 
factors and then recruit GR via protein:protein interaction (tethering) (Reichardt et 
al., 2001). Several transcription factors have been reported to provide tether for GR, 
namely AP-1, NF-κB, STAT3 or STAT5 (Chinenov & Rogatsky, 2007).  
 As demonstrated in Figure 1.9, glucocorticoids exert their anti-inflammatory 
effects via a number of distinct mechanisms. One of them is inhibition of AP-1 and 
NF-κB activation, especially important in downregulation of TLR-mediated 
inflammation. AP-1 and NF-κB are transcription factors that induce transcription of 
many pro-inflammatory mediators in immune cells, especially Mφ, monocytes, 
neutrophils and dendritic cells as well as in epithelial and endothelial cell types (Oda 
& Kitano, 2006). Glucocorticoids induce also expression of certain proteins, such as 
IκB and glucocorticoid-inducible leucine zipper (GILZ), which interfere with AP-1 
and NF-κB binding of DNA and inhibit their transcriptional activity (Chinenov & 
Rogatsky, 2007). Interestingly, recent evidence suggests that glucocorticoids may act 
in a more complex manner and target pathways upstream of, or unrelated to, AP-1 
and NF-κB. For instance, GR inhibit several protein kinases including JNK and p38 
without inhibiting their transcription (Caelles et al., 1997;Hirasawa et al., 1998). This 
observation can be explained, at least in part, by glucocorticoid augmentation of 
transcription of an inhibitory MAPK phosphatase 1 (MKP1) (Kassel et al., 
2001;Furst et al., 2007). In fact, in MKP1-/- mouse Mφ, glucocorticoid treatment does 
not inhibit activation of JNK and p38 by LPS and the consequential production of 
inflammatory mediators such as TNF-α or IL-1β (Abraham & Clark, 2006). 
Furthermore, GR interferes with activation of transcription factors belonging to IRF 
family. They are activated by the majority of TLRs via both MyD88-dependent and 
independent pathways and induce transcription of a number of genes e.g. interferon β, 
IP10 and RANTES. For instance, it has been demonstrated that activation of IRF3 
requires binding of additional protein named GRIP1. Importantly, GRIP1 is also a 
cofactor of an active GR complex. In the presence of glucocorticoids, activated GR 
competes with IRF3 for GRIP1 and consequently transcription of IRF3-inducible 
 50
genes is decreased (Chinenov & Rogatsky, 2007). Glucocorticoids have been also 
reported to interfere with pro-inflammatory cytokine signalling via upregulation of 
transcription of SOCS1. Expression of SOCS protein is induced by TLR signalling 
and provides a negative feedback loop that limits an inflammatory response (the 
detailed mechanism is described in chapter 1.2.2.2). Indeed, mice deficient in SOCS1 
are characterised by upregulated production of cytokines in response to LPS and are 
more sensitive to septic shock (Nakagawa et al., 2002). Importantly, data from in 
vitro and in vivo studies clearly indicate that glucocorticoids have the ability to induce 
transcription of SOCS1 (Chinenov & Rogatsky, 2007).    
 The effects of glucocorticoids on apoptosis of inflammatory cells and their 
subsequent clearance by phagocytes have been evaluated. For instance, it has been 
demonstrated that glucocorticoids dramatically delay neutrophil but promote 
eosinophil and lymphocyte apoptosis (Meagher et al., 1996). The latter may be of 
particular importance for treatment of asthma, which is characterised by an 
eosinophilic inflammation of airways (Walsh et al., 2003). Treatment of 
exacerbations of asthma with steroids results in the resolution of the eosinophilic 
inflammation, possibly by inducing apoptosis in lung eosinophils. Glucocorticoid-
induced apoptotic eosinophils are subsequently recognised and phagocytosed by 
alveolar Mφ (Woolley et al., 1996). Furthermore, severity of asthma, as assessed by 
symptom scores and airflow obstruction, has been positively correlated with 
reduction of eosinophil apoptosis (Duncan et al., 2003). In addition to regulation of 
cell apoptosis, glucocorticoids significantly augment, in a concentration- and time- 
dependent manner, the ability of Mφ to phagocytose apoptotic cells (Liu et al., 1999). 
Our group has demonstrated that monocytes treated with dexamethasone for the first 
24 hours of 5 day culture displayed significantly increased phagocytic capacity. This 
effect was mediated via the GR and blocked by GR antagonist RU38486 (Liu et al., 
1999). Furthermore, monocytes treated with dexamethasone for a duration of 5 days 
and longer were characterised by “reprogrammed” differentiation associated with 
high phagocytic capability, altered morphology and reorganisation of cytoskeletal 
elements. This phenotype of Mφ also displayed high levels of active Rac and, when 
compared with untreated cells, high cytoskeletal activity (formation of cellular 
extensions and lamellipodia). The latter observation may significantly contribute to 
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glucocorticoid-induced increase in clearance of apoptotic neutrophils. Furthermore, 
these cells were distinctively round, smaller and demonstrated decreased adhesion as 
a consequence of decreased activation of paxillin and pyk2 (important proteins 
involved in adhesion contacts) as well as downregulated expression of p130Cas 
(mediator of adhesion signalling). In addition, the cell membrane was characterised 
by increased activity, which was likely to result from both increased cytoskeletal 
elements remodelling and decreased cell adhesion (Giles et al., 2001). Mφ are 
thought to be one of the most important cells involved in removal of apoptotic cells. 
However, non-professional phagocytes such as DC, hepatocytes, fibroblasts and 
epithelial cells may also be involved in this process. For instance, small airway 
epithelial cells are capable of ingesting apoptotic eosinophils and, importantly, this 
process is significantly augmented by dexamethasone treatment. The latter 
observation adds another important fact to the role of glucocorticoids in therapy of 
































FIGURE 1.9 GR exerts its anti-inflammatory effects by interfering with pro-
inflammatory signalling at multiple levels and via various mechanisms. For 
illustrative purposes TLR-mediated pro-inflammatory pathways are depicted. GR 
induces expression of numerous genes e.g. IκB, GILZ or MKP1 that inhibit activation 
or action of transcription factors NF-κB and AP1 (1,2,3). In addition GR inhibits 
activity of IRF transcription factors. The exact mechanism is not fully understood but 
it is possible that GR competes with IRF3 for GRIP1 binding (4). More detailed 
description of GR interference with pro-inflammatory signalling is presented in 
chapter 1.5.1. TLR-mediated signal transduction and key adaptor proteins and 
enzymes are described in more depth in section 1.2.2.1. GR – glucocorticoid 
receptor. 
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1.5.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS  
 The term non-steroidal anti-inflammatory drugs (NSAID) covers a group of 
various therapeutics characterised by anti-inflammatory, anti-analgesic and anti-
pyretic properties. The examples include aspirin, ibuprofen, ketoprofen, flurbiprofen, 
indomethacin, etodolac meloxicam, diclofenac. They all demonstrate ability to inhibit 
activity of the enzyme called cyclooxygenase (COX). Aspirin is one of the most 
commonly used NSAID and, as so, it is used in the majority of studies investigating 
mechanism of action as well as the role of NSAID in resolution of inflammation, 
inflammatory cell apoptosis and their clearance by Mφ.  
 Eicosanoids are a group of signalling molecules, which are generated in the 
process of oxygenation of twenty-carbon essential fatty acids (EFAs), such as 
arachidonic acid (AA). Eicosanoids are further divided into several groups depending 
on the enzymes involved in their biosynthesis. One of them, prostanoids, is composed 
of the products of AA metabolism by COX, i.e., prostaglandins (PG) prostacyclins 
(PGI2) and thromboxanes (TX). The second group includes leukotrienes (LT) – 
products of AA metabolism by 5-lipoxygenase. There is also a third group of lipoxins 
(LX), which are also AA metabolites playing a crucial role in resolution of 
inflammation as further described below. Prostanoids are important mediators of the 
inflammatory response and control processes of vasodilation (PGI2), vasoconstriction 
(TXA2), platelet aggregation (TXA2, PGI2,) as well as pain and fever (PGE2). LT 
such as LTB4 stimulate chemotaxis and adhesion of leukocytes as well as release of 
ROS and enzymes from neutrophils (LTB4). Furthermore, cysteinyl LT (i.e., LTC4, 
LTD4, and LTE4) were reported to be the slow reacting substance of anaphylaxis. 
They are potent inducers of bronchoconstriction, vasodilatation of most vessels and 
coronary vasoconstriction. They also increase vascular permeability and stimulate 
mucus secretion. They play a crucial role in development of such pathophysiological 
conditions as asthma, allergic rhinitis as well as gastrointestinal diseases and 
atherosclerosis (Capra, 2004). Therefore, cysteinyl LT inhibitors have been 
introduced to clinic for treatment of asthma and allergic rhinitis. The example is 
leukotriene receptor antagonists, namely montelukast and zafirlukast.  
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 NSAID exert their therapeutic effects via blocking the activity of the above-
mentioned COX enzyme. COX metabolises the first step of a conversion of AA into 
PGG2 and H2. PGG2 and PGH2 are, in turn, metabolised into individual prostanoids 
(PGD2, PGE2, PGJ2, PGI2, PGF2α and TXA2) (Gilroy, 2005). There are at least two 
isoforms of COX. COX1 is expressed constitutively whereas COX2 is expressed in 
response to variety of stimuli and is responsible for PG biosynthesis in inflamed 
tissue (Amann & Peskar, 2002). However, it has been demonstrated that COX2 is 
constitutively expressed in some tissues, e.g., in the central nervous system and 
kidney (Harris et al., 1994;Yamagata et al., 1993). NSAID differ in their potency to 
block COX1 and COX2 and aspirin is regarded as non-selective COX inhibitor 
whereas ibuprofen and indomethacin show greater selectivity towards COX2. 
Blockade of COX by aspirin prevents formation of prostanoids, but, at the same time, 
allows formation of 15(R) –hydroxyeicosatetraenoic acid (15(R) – HETE), which can 
be further metabolised by lipoxygenase (LOX) isoenzymes into LX i.e., 15-epi-
lipoxin A4 and 15-epi-lipoxin B4 (LXA4 and LXB4 respectively). Formation of LX is 
an exclusive characteristic of aspirin, not shared with other NSAID (Claria & Serhan, 
1995). LXs exert a number of anti-inflammatory effects, e.g., inhibition of 
granulocyte recruitment but they stimulate monocyte chemotaxis and adherence. The 
anti-inflammatory as well as vasorelaxing properties of both LXA4 and LXB4 can be 
explained, at least in part, by their ability to stimulate the synthesis of PGI2 and nitric 
oxide (NO) in endothelial cells (Gilroy, 2005). There are several reports in the 
literature demonstrating the ability of aspirin to inhibit activation of pro-inflammatory 
transcription factors NF-κB and AP-1. (Amann & Peskar, 2002). However, the extent 
to which these effects contribute to the anti-inflammatory properties of aspirin 
remains to be established. Importantly, in mice deficient in p105 (the precursor of the 
p50 component of NF-κB) aspirin maintained its anti-inflammatory properties, while 
the anti-inflammatory effect of dexamethasone was abolished (Cronstein et al., 1999).  
 Several lines of evidence indicate that eicosanoids may play an important role 
in the resolution of inflammation via regulation of Mφ efferocytosis. For instance, 
PGs were demonstrated to reduce Mφ capacity for clearance of apoptotic neutrophils. 
This effect was correlated with the increases in cellular cAMP levels. Pretreatment of 
Mφ with PGE2, PGD2 or cAMP stable analogues such as 8-bromo-cAMP and 
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dibutyryl-cAMP changed Mφ adhesion, reduced membrane activity and cell 
locomotion as well as significantly decreased in the proportion of Mφ that 
phagocytosed apoptotic cells (Rossi et al., 1998b). In addition, it has been reported 
that other pro-inflammatory mediators, which stimulate activity of adenylate cyclase 
and protein kinase A (PKA) are likely to inhibit clearance of apoptotic cells 
(Oropeza-Rendon et al., 1979). In cytotoxic T cells, PKA is able to phosphorylate 
Rho, which is a key negative regulator of cytoskeletal organisation. These data 
further support the pivotal role of cAMP in regulation of the phagocytosis process 
(Lang et al., 1996). The activation of the Rho family GTPases requires prenylation 
(covalent attachment of lipid adducts) and subsequent membrane insertion. 
Interestingly, statins have been demonstrated to reduce cellular levels of prenylation 
substrates via inhibition of HMG-CoA reductase. For instance, lovastatin suppresses 
prenylation and membrane localization of RhoA to a greater extent than Rac-1 thus 
altering RhoA–Rac-1 membrane balance towards Rac-1. Since Rac-1 is a positive 
regulator of phagocytosis, lovastatin is able to increase Mφ ability to phagocytose 
apoptotic cells (Morimoto et al., 2006).  
 In addition, it has been demonstrated that LX promote the resolution phase of 
inflammation by inhibiting neutrophil chemotaxis and adhesion (Serhan, 1997). For 
instance, findings presented by Godson and colleagues clearly show that LXA4 and 
its stable synthetic analogues augment phagocytosis in a concentration-dependent 
manner (Godson et al., 2000). Interestingly, stable cAMP analogue 8-bromo-cAMP 
attenuated while PKA inhibitor–Rp-cAMP mimicked LXA4 effects on phagocytosis. 
The effects of Rp-cAMP and LXA4 were not additive suggesting that the same 
mechanism is involved, possibly, inhibition of PKA. The latter has been further 
supported by the fact that upon cell stimulation with PGE2, LXA4 did indeed inhibit 
PKA activity. These findings clearly point out the critical role of PKA in regulation 
of phagocytosis. One of PKA’s cellular substrates is scavenger receptor CD36 (Hatmi 
et al., 1996) and loss of CD36 phosphorylation in platelets results in increased 
cytoadhesion (Asch et al., 1993). Monoclonal antibodies against CD36 blocked pro-
phagocytic properties of LXA4 indicating that LXA4 may induce dephosphorylation 
of CD36 and promote recognition of apoptotic cells by phagocytes (Godson et al., 
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2000). A new phagocytic receptor FPR2/ALX has been demonstrated to play an 
important role in LXA4 – stimulated phagocytosis (Maderna et al., 2010).  
1.5.3 CYTOKINE INHIBITORS 
 Cytokines are very important inflammatory mediators, which are produced by 
immune cells and orchestrate immune and inflammatory responses. However, if their 
levels are abnormal, cytokines significantly contribute to the pathogenesis of chronic 
inflammatory conditions, as described in more detail in section 1.4. Cytokines and 
their receptors are either cell surface molecules or found as soluble forms that have 
been released to the extracellular environment. Consequently, their action can be 
blocked by protein-based biologics such as monoclonal antibodies and soluble 
receptor-IgG fusion proteins. Research is progressing rapidly in the field of cytokine 
inhibitors and they seem to be a very promising, new class of anti-inflammatory 
therapeutics. Currently, a few of them are licensed for the treatment of certain chronic 
inflammatory conditions i.e., RA, psoriasis or Crohn’s disease.  
 The first cytokine inhibitors introduced to the clinic were TNF-α inhibitors. 
This was based on the observation that TNF-α participates in the pathogenesis of 
numerous diseases such as RA, diabetes, septic shock or congestive heart failure. 
Some of these conditions have been demonstrated to have autoimmune or chronic 
inflammatory component (Tayal & Kalra, 2008). So far, two strategies have been 
developed to block the action of circulating TNF-α, namely monoclonal anti-TNF-α 
antibodies (used under generic names infliximab and adalimumab) and the dimeric 
soluble TNF-R2 Fc fusion protein (used under generic name etanercept). Initially, 
infliximab was approved to be used with the disease modifying anti-rheumatic drug 
methotrexate (MTX) for RA patients with an inadequate response to sole MTX 
therapy. This was then expanded to include psoriasis, ulcerative colitis, psoriatic 
arthritis, Crohn’s disease and ankylosis spondolitis and is further progressing to 
include such conditions as diabetes, stroke, asthma and malignancy (Williams et al., 
2007).  
 The TNF-α blocking agents are thought to exert their anti-inflammatory effect 
by a number of mechanisms (Williams et al., 2007). They decrease expression of the 
pro-inflammatory cytokines, reduce recruitment of leukocytes into the joints, reduce 
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angiogenesis, increase activity of the regulatory T cells, normalise T cell 
hyporesponsiveness and prevent joint erosion. However, a few concerns are 
associated with the use of anti - TNF-α agents. First of all, their efficacy is quite 
variable but can be improved by combined treatment with MTX (Maini et al., 1998). 
It has been demonstrated that combination of TNF-α inhibitors with MTX augments 
joint protection (Lipsky et al., 2000) and probably induces joint repair (Klareskog et 
al., 2004). Another problem is the risk of infection, especially tuberculosis (TB) and 
sepsis. TNF-α is the main mediator of host defence and its inhibition has been 
reported to augment the risk of recrudescence of TB (Keane et al., 2001). Therefore, 
it is recommended that all the patients should be evaluated for TB before starting 
TNF-α inhibitors.  
 Interleukin–1 (IL-1) is another cytokine that has been shown to play an 
important role in the pathogenesis of RA. Similarly to TNF-α inhibitors, several 
approaches have been used to block interaction between IL-1 and IL-1 type I receptor 
(IL-1-R1). One of them is a recombinant form of human IL-1 receptor antagonist 
(used under generic name anakinra), which has been licensed for treatment of RA in 
combination with MTX, following successful clinical trials (Bresnihan et al., 1998). 
An alternative approach includes fully human anti-IL-1 mAb and soluble IL-1-R1 Fc 
fusion protein which are still under investigation (Williams et al., 2007). 
Interestingly, and in contrast to animal studies, IL-1 blockers are less effective in 
human RA than TNF-α blockers (Williams et al., 2000). The examples of other 
cytokines that have been targeted in RA include IL-2 (a humanised antibody against 
the α-chain of the IL-2 receptor used under generic name daclizumab) and IL-6 (a 
humanised anti-IL-6 receptor antibody used under generic name tocilizumab) 
(Williams et al., 2007).   
 Summing up, if mechanisms implicated in disease pathogenesis are relatively 
simple and involve abnormalities in cytokine levels or signalling, cytokine therapy 
seems to be a very promising approach. Therefore, a number of other cytokine (IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-18, IL-21 etc.) inhibitors have been 
used experimentally in animals and are being tested in patients for various conditions 
(Tayal & Kalra, 2008). However, given the pleiotropic and redundant functions of 
cytokines, there is a great chance that a particular cytokine may play opposing roles 
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in immune and inflammatory pathways. For instance, IFNγ-mediated activation of 
myeloid cells significantly contributes to inflammation. However, this cytokine also 
helps to limit autoimmune responses by reducing proliferation of lymphoid cells. 
Consequently, the ‘net’ effect of IFNγ blockade is detrimental in some animal models 
(Williams et al., 1993;Vermeire et al., 1997). Similarly, the effect of TNF-α 
inhibition is beneficial in a number of diseases. Yet, in patients with MS it was found 
to worsen the disease, augmenting disease progression (1999). This phenomenon can 
be explained, at least in part, by neuroprotective effects of TNF-α. Therefore, the 
successful identification of suitable cytokine targets in chronic inflammatory or 
autoimmune conditions requires fine characterisation of the underlying biology. 
Nevertheless, research is continuing in the field of cytokine inhibitors aiming at 
development of new therapies, improvement of those already in use and increase of 
clinical benefit by establishing the safest and the most effective dosage levels.   
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1.6 HYPOTHESES AND AIMS 
 Inflammation, as long as it is controlled, is a crucial mechanism defending 
organisms in case of infection or tissue injury. Inflammatory processes are regulated 
in a very complex manner by numerous mediators, e.g., cytokines. Furthermore, 
abnormalities in cytokine levels have been demonstrated to play a fundamental role in 
development of chronic inflammation and autoimmunity. Overexpression of TNF-α 
seems to be of particular importance and inhibition of TNF-α with TNF-α blocking 
agents has been shown to be a relatively successful approach for treatment of RA, 
psoriasis and Crohn’s disease. 
 Currently, it is postulated that at least two key mechanisms are involved in 
resolution of inflammatory responses, namely apoptosis of inflammatory cells and 
their subsequent clearance by phagocytes. Accumulation of apoptotic cells, usually 
associated with impaired clearance, results in secondary necrosis, further tissue 
damage and exacerbation of inflammation.  
  
Based on the above observations the main hypotheses addressed in this PhD 
thesis are as follows:  
1) Given that sites of chronic inflammation are characterised by an 
overexpression of TNF-α and that TNF-α inhibitors enhance resolution of 
inflammation, agents that induce TNF-α production or TNF-α per se interfere 
with processes involved in the resolution of inflammation. This hypothesis is 
further supported by observations by Ward and colleagues that TNF-α, depending on 
time of treatment, may either induce or inhibit apoptosis of inflammatory cells (Ward 
et al., 1999). Yet, data regarding TNF-α effects on Mφ clearance of apoptotic cells 
are not conclusive. For instance, a report by Savill and colleagues demonstrates that 
TNF-α may augment clearance of apoptotic cells by immature Mφ (Ren & Savill, 
1995). In contrast, findings by McPhillips and colleagues regarding mature Mφ 
demonstrate otherwise (McPhillips et al., 2007).  
2) Anti-inflammatory agents (e.g., IL-10 or glucocorticoids) oppose TNF-α 
effects on Mφ clearance of apoptotic cells and consequently promote resolution 
of inflammation. IL-10 and glucocorticoids have been previously shown to augment 
Mφ clearance of apoptotic cells (Liu et al., 1999;Xu et al., 2006). Yet, there is not 
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much known about these agents exerting similar effects in pro-inflammatory 
conditions (e.g., overexpression of TNF-α). It seems to be likely that pro- and anti-
inflammatory mediators exert opposite effects on certain processes (e.g., Mφ 
phagocytosis of apoptotic neutrophils) and therefore the ‘net’ effect depends on the 
balance between them.  
 
Therefore the aims of this PhD thesis were to:  
1) Characterise the effects of the pro-inflammatory cytokine TNF-α on Mφ 
efferocytosis of apoptotic neutrophils. A number of pro-inflammatory mediators, i.e., 
LPS, lipoteichoic acid (LTA), peptidoglican (PGN) have been used to induce Mφ 
production of TNF-α. Their effects on Mφ phagocytosis were compared with those of 
exogenous human recombinant TNF-α.  
2) Examine, if the LPS, LTA or PGN effects on phagocytosis are mediated by 
stimulation of Mφ production of TNF-α. We compared the efficacy of several TNF-α 
inhibitors, i.e., dimeric soluble human recombinant TNF-R1/Fc chimera (sTNF-
R1/Fc), monomeric soluble human recombinant TNF-R1 (sTNF-R1) and TACE 
inhibitor to reduce bioactivity of TNF-α released into culture medium.  
3) Evaluate the role of IL-10 in regulation of Mφ ability to phagocytose apoptotic 
neutrophils in the absence or presence of pro-inflammatory mediators (LPS or TNF-
α). The effect of IL-10 on production of TNF-α by Mφ stimulated with pro-
inflammatory agents has also been investigated. 
4) Examine the effects of anti-inflammatory drugs such as glucocorticoids and NSAID 
(i.e., aspirin, ibuprofen, and indomethacin) on Mφ phagocytosis of apoptotic 
neutrophils. Selective COX1 and COX2 inhibitors (SC-650 and NS-398) as well as 
paracetamol (limited effect on COX1 and COX2) have been included as additional 
controls. Their effects have also been assessed in the presence of pro-inflammatory 


















2 MATERIALS AND METHODS 
 
2.1 REAGENTS  
 All reagents were obtained from Sigma-Aldrich Co. (Poole, UK) unless 
otherwise stated. 
 
2.1.1 TISSUE CULTURE SOLUTIONS  
 Tissue culture Iscove's modified dulbecco's medium (IMDM) was obtained 
from PAA Laboratories (Pasching, Austria) and Dulbecco's Modified Eagle Medium 
(DMEM) was obtained from Gibco Lige Technologies (Paisley, UK) and they were 
supplied sterile, endotoxin free, at pH 7.  
 Hank's Buffered Salt Solution (HBSS), phosphate buffered saline (PBS) (1x 
and 10x) both with or without Ca2+ and Mg2+, penicillin/streptomycin (100 U/ml) 
solution and Trypsin (0.25%), ethylenediaminetetraacetic acid (EDTA) solution (all 
sterile, endotoxin free) were from PAA Laboratories (Pasching, Austria). 
 Foetal bovine serum and foetal calf serum were heat inactivated (50°C, 1 h) 
before addition to media. 
 All tissue culture solutions were stored at 4°C and pre-warmed to 37°C in a 
water bath prior to use. 
 
2.1.2 PLASTIC WARE 
 Tissue culture 50 ml flasks were from Becton Dickinson Labware (Oxford, 
UK) and 75 ml flasks were from Corning Incorporated (Corning, NY). 
 Tissue culture plates (48-well, 6-well, 96-well EIA/RIA high binding) were 
from Corning Incorporated (Corning, NY) and flexible 96-well plates were from 
Becton Dickinson Labware (Oxford, UK). 




2.1.3 REAGENTS FOR ISOLATION OF HUMAN BLOOD 
CELLS 
 Dextran T500 from Amersham Pharmacia Biotech (Buckingham UK) was 
prepared as a 6% solution in 0.9% NaCl, aliquoted and stored at 4°C. Sodium 
chloride solution 0.9% from Baxter (Glasgow, UK) was stored at RT, sodium citrate 
solution 3.8% and 1M calcium chloride solution from Sigma (St.Louis MO, USA) 
were aliquoted and stored at 4°C, Percoll™ from GE Healthcare Bio-Sciences AB 
(Uppsala, Sweden) 100% solution was aliquoted (27 ml) and stored at 4°C.  
 
2.1.4 BACTERIAL WALL COMPONENTS 
 Lipopolysaccharide (LPS) from E.coli, serotype 0127:B8, was purchased 
from Sigma-Chemicals Co. (St.Louis MO, USA) and stock solutions (1mg/ml in 
sterile PBS without Ca2+ and Mg2+) were aliquoted and stored at -20°C.  
 Peptidoglycan (PGN) and lipoteichoic acid (LTA) from S.aureus were 
purchased from Fluka (Buchs, Switzerland) and stock solutions (10 mg/ml in sterile 
PBS without Ca2+ and Mg2+) were aliquoted and stored at -20°C.  
 
2.1.5 RECOMBINANT PROTEINS 
 Recombinant human (rh) TNF-α, recombinant mouse (rm) TNF-α, rh IL-6, rh 
IL-10 were from R&D Systems (Minneapolis, LA, USA) and rh IL-1β was from 
Merck Chemicals (Nottingham, UK). Stock solutions of the recombinant proteins (10 
µg/ml in sterile PBS without Ca2+ and Mg2+) were aliquoted and stored at -20°C. 
 Soluble (s)rh TNF receptor 1/ Fc Chimera (sTNF-R1/Fc) and monomeric srh 
TNF-R1 (sTNF-R1) were from R&D Systems (Minneapolis, LA, USA) and stock 
solutions (50 µg/ml in sterile PBS without Ca2+ and Mg2+) were aliquoted and stored 
at -20°C. 
 Recombinant human Annexin-V fluorescein isothiocyanate (FITC) conjugate 
was purchased from Roche (Hertfordshire, UK) and used in a 1:500 dilution, whereas 
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Annexin-V APC conjugate was purchased from Invitrogen (Paisley, UK) and used in 
a 1:50 dilution. 
  
2.1.6 CELL TRACKER™ PROBES  
 Cell Tracker™ Green CMFDA and Cell Tracker™ Far Red DDAO-SE were 
purchased from Invitrogen (Paisley, UK). Stock solutions (in sterile PBS without 
Ca2+ and Mg2+) were aliquoted and used in a 1:1000 dilution and stored at -20°C. 
  
2.1.7 CYTOKINE MEASUREMENT 
 BDTM - Cytometric Bead Array (CBA) Human Inflammation Kit was from 
BD Biosciences Pharmingen (San Diego, CA, USA). DuoSet® ELISA 
(human/mouse TNF-α, human/mouse IL-10) was from R&D Systems (Minneapolis, 
LA, USA).  
 
2.1.8 ANTIBODIES 
 Monoclonal anti-human IL-10 receptor 1 antibody (anti-IL-10-R1Ab) was 
from R&D Systems (Minneapolis, LA, USA) and stock solution (1 mg/ml in sterile 
PBS without Ca2+ and Mg2+) was further diluted to 1 µg/ml and stored at -20°C.  
F(ab’)2 anti-human IgG FITC conjugated antibody from goat was from CALTAG 
laboratories (Buckingham, UK) and used in 1:50 dilution of a stock solution 
(1mg/ml).   
 Antibodies used for western blotting were obtained from Cell Signalling 
(Herts, UK) and diluted according to manufacturer’s instructions. These include:  
1) Primary antibodies (from rabbit): 
• phospho-p44/42 MAP Kinase (Thr202/Tyr204) and p44/42 Kinase antibodies,  
• phospho-SAPK/JNK (Thr183/Tyr185) and SAPK/JNK antibodies, 
• PhosphoPlus® p38 MAP Kinase (Thr180/Tyr182) and p38 MAP Kinase 
antibodies, kits were from Cell Signalling and diluted according to manufacturer’s 
instructions. 
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2) Secondary anti–rabbit, HRP-linked antibody 
3) anti-biotin, HRP – linked antibody. 
 
2.1.9 OTHER REAGENTS 
 R-roscovitine was purchased from Merck Chemicals LTD (Nottingham, UK). 
Dexamethasone was purchased from Organon (Cambridge, UK). SC-650 and NS-398 
inhibitors as well as TNF-α Convertase (TACE) Inhibitor (TAPI-1) were from Merck 
Chemicals (Nottingham, UK). Bio-Rad Dc Protein Assay Reagent A and Reagent B 
were obtained from Bio-Rad Laboratories (Hercules, CA).   
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2.2 CELL ISOLATION AND CULTURE 
2.2.1 HUMAN PERIPHERAL BLOOD CELLS  
2.2.1.1 CELL ISOLATION FROM HUMAN PERIPHERAL BLOOD 
 Human mononuclear cells, neutrophils and erythrocytes were isolated from 
peripheral blood of healthy volunteers (Haslett et al., 1985;Rossi et al., 1998a). As 
demonstrated in Figure 2.1 the main steps of the isolation process are:  
1) 40 ml of blood was drawn from the antecubial fossa through a 19-gauge (19 
G) needle into 50 ml BD Falcon® tubes that contained 4 ml of citrate (0.38 % final 
concentration) and mixed by gentle inversion of tube,  
2) platelet rich plasma (PRP) was separated from whole blood by 
centrifugation (350 g, 20 min), 
3) PRP was aspirated from the erythrocyte/leukocyte rich layer and was then 
used to prepare autologous serum by incubating (37°C, 30-60 min) with addition of 
calcium chloride (220µl of 1M CaCl2 per 10 ml of PRP),  
4) erythrocytes were separated from leukocytes by dextran sedimentation: 6 ml 
of pre-warmed (37°C) 6 % dextran was added into each tube, topped up to 50 ml with 
pre-warmed (37°C) saline solution (0.9 % NaCl), gently mixed and allowed to 
sediment for not longer than 30 min at RT,  
5) leukocyte-rich upper layer was gently aspirated and washed with saline 
solution, followed by centrifugation (350 g, 6 min) to obtain a leukocyte-rich pellet, 
6) isotonic 90 % Percoll solution was prepared by adding 3 ml of 10 x PBS 
without Ca2+ and Mg2+ into 27 ml of 100 % Percoll™ (9:1 ratio); obtained solution 
was further diluted into 55 %, 68 % and 81 % isotonic Percoll™ solutions in 1x PBS 
without Ca2+ and Mg2+; discontinuous gradients were prepared by layering 3 ml of 68 
% Percoll solution (middle layer) onto 3 ml of 81 % Percoll™ solution (lower layer) 
in 15 ml polypropylene tubes,  
7) leukocyte pellet was re-suspended in 3 ml of 55 % Percoll solution and 
layered on the top of 68 % Percoll solution to form the upper layer of the gradient, 
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8) sub-populations of leukocytes were separated by centrifugation (720 g, 20 
min, acceleration 0, break 0) of gradients,  
9) mononuclear cells and granulocytes were next harvested (55:68 % and 
68:81 % interface respectively) into separate 50 ml polypropylene tubes and washed 
twice in 1x PBS without Ca2+ and Mg2+ (220 g, 6 min). Erythrocytes may also be 
harvested at this point and stored at 4°C.  
 Yields of isolated cells were assessed with the use of a bright line 
haemocytometer. For this purpose 10 µl of cell suspension was placed under a cover 
slip on the haemocytometer, the number of cells in the central 25 squares counted by 
light microscopy (x10 magnification) and the cell yield calculated according to the 
following equations:  
 
Cell Number in central 
25 squares of 
 a hemocytometer 
X 10 000 =
 
Cell Number in 1 ml
of a cell suspension 
Cell  Number in 1 ml 
of a cell suspension X Total volume of a cell suspension = Total cell yield  
 
After cell number had been assessed the cells were centrifuged (220 g, 6 min) and re-
suspended at the appropriate concentration in pre–warmed (37°C) IMDM 
supplemented with penicillin/streptomycin. The typical yield from 160 ml of whole 
blood was 100 x 106 for mononuclear cells and 250 x 106 for granulocytes, however, 
considerable variation between donors was observed. Typical photomicrographs of 

































FIGURE 2.1. Schematic diagram demonstrating isolation of cells from human 
peripheral blood. All steps of the isolation of human blood cells are described in 




















FIGURE 2.2. Typical photomicrographs of freshly isolated human blood 
neutrophils (A) and monocytes (B). Human blood cells have been isolated 
following the protocol described in sectin 2.2.1.1. Following isolation, 100 µl of cell 
suspension have been used to prepare slides, which were then stained using Diff-
Quik™ physiological stain. Images were obtained using an Axiovert S100 inverted 
microscope (Carl Zeiss), RS Photometrix camera and analysed with Open lab 
software, 3.1.5 version. Magnification 1000x. 
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2.2.1.2 CULTURE OF HUMAN MONOCYTE-DERIVED MΦ 
(MDMΦ) 
 Mononuclear cells isolated by Percoll™ gradient centrifugation were re-
suspended in IMDM at the concentration 4 x 106 cells/ml (monocyte/lymphocyte ratio 
was assessed by flow cytometry), plated at 0.5 ml/well in 48-well plates and 
incubated for 1 hour (37°C, 5 % CO2) to allow monocyte adhesion to the plate. 
Following 1 hour incubation, tissue culture medium was aspirated and non-adherent 
cells including contaminating lymphocytes were removed by washing twice with 
HBSS with Ca2+ and Mg2+. Monocytes were then cultured in IMDM supplemented 
with penicillin/streptomycin and 10 % (v/v) autologous serum +/- treatment for 6 
days at 37°C and 5 % CO2 atmosphere to allow their maturation into Mφ.  
 
2.2.1.3 CULTURE OF HUMAN NEUTROPHILS 
 Following isolation by Percoll™ gradient centrifugation neutrophils (on 
average >98% pure as assessed by morphology or flow cytometry) were cultured at 
37°C and 5% CO2 atmosphere at a concentration of 5x106/ml in IMDM supplemented 
with penicillin/streptomycin and 10% autologous serum either for 20-24 hours to 
undergo constitutive apoptosis or alternatively for 8 hours, when apoptosis (>90% on 
average) was induced with 20 µM R-roscovitine (Rossi et al., 2006).  
 If apoptotic neutrophils were used as phagocytic targets to assess Mφ 
phagocytosis by flow cytometry, neutrophils immediately after isolation were re-
suspended in IMDM supplemented with penicillin/streptomycin at the concentration 
of 20 x 106 cells/ml and incubated for 15 minutes (37°C, 5% CO2) with Cell 
Tracker™ Green CMFDA at a final concentration of 2 µg/ml (1 µl of 1 mg/ml stock 
solution per 1x106 of neutrophils). Following centrifugation (220 g, 6 minutes) 
neutrophils were re-suspended 5x106/ml in IMDM supplemented with 
penicillin/streptomycin and 10% autologous serum and cultured as described above 
(in majority the of experiments we used neutrophils that had undergone constitutive 
apoptosis).   
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 Apoptosis of neutrophils was assessed by oil-immersion light comparative 
microscopy of DiffQuik™ stained cyto-centrifuge preparations or alternatively by an 
annexin-V binding assay (Rossi et al., 2006), which are described in more detail in 
section 2.3. Only neutrophil samples with less than 5 % necrosis (assessed by 
propidium iodide uptake) were used.  
 
2.2.2 MURINE BONE MARROW DERIVED MΦ (BMDMΦ) 
 Bone marrow was obtained from femurs prepared from IL-10-/- and wild type 
(wt) mice (Kuhn et al., 1993). To obtain bone marrow, both femurs were removed 
and placed in HBSS and kept at 4°C. BMDMφ growth/conditioned medium was used 
throughout for isolating bone marrow cells and during the culture (Dulbecco’s 
modified eagle medium (DMEM) F-12 GlutMAX supplemented with 10 % FBS 
(v/v), 1 % penicillin/streptomycin cocktail (v/v) and 10 % L929 conditioned 
medium). To obtain bone marrow the following procedure was applied: 
1) Femurs were placed on the bottom of Petri dish in a hood and one by one surface 
sterilized by wiping with bacteriological wipes and dipping into ethanol. From this 
point onward sterile techniques were adopted.  
2) Sterilized femurs were placed on the lid of Petri dish containing a small amount of 
BMDM growth/conditioned medium to prevent bones from drying up (due to ethanol 
dip).  
3) Using a 19-gauge (19G) needle 10 ml of BMDMφ medium were aspirated into a 
10 ml syringe and the 19G needle was replaced with a 25G needle. 
4) The scalpel and forceps were sterilized in 70 % ethanol and used to firmly hold 
and sever the femur at its both ends to expose the cavity of the bone marrow (red 
circular dot in cross-section). 
5) The femur was then picked up with sterile forceps, the 25G needle inserted into 
marrow cavity and bone marrow flushed out into the Falcon® tube. Next, the femur 
was inverted, the 25G needle inserted into its second end and marrow flushed out 
again until the cavity looked white. 
6) The 25G needle was replaced with a 19G needle and the content of the Falcon® 
tube was aspirated and flushed out to break up any clumps and form a single cell 
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suspension which was next transferred into a Teflon pot and topped up with 30 ml of 
BMDMφ growth/conditioned medium to a final volume of 40 ml. 
7) Teflon pots were placed into an incubator (37ºC, 5 % CO2) and 10 ml of BMDM 
growth/conditioned medium was replaced every other day.  
 On day 4 of culture, cells were harvested and yield assessed by use of a bright 
line haemocytometer (see section 2.2.1.1 for isolation of cells from human peripheral 
blood). Next, cells were re-suspended at the concentration 2x106 cells/ml in BMDMφ 
growth/conditioned medium, plated at 0.5 ml/well on 48-well plates and cultured for 
4 days at 37ºC and 5 % CO2. Medium was changed every 48 hours and appropriate 
treatment was applied. Typical photomicrographs of BMDMφ cultured for 4 days in 

















FIGURE 2.3. Typical photomicrographs showing wt (A) and IL-10-/- (B) 
BMDMφ cultured for 4 days in BMDMφ growth/conditioned medium. BMDMφ 
have been isolated and cultured for 4 days following the protocol described in section 
2.2.2. On day 4, 100 µl of cell suspension has been used to prepare slides, which were 
then stained using Diff-Quik™ physiological stain. Images were obtained using an 
Axiovert S100 inverted microscope (Carl Zeiss), RS Photometrix camera and 
analysed with Open lab software, 3.1.5 version. Magnification 1000x. 
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2.3 ASSESSMENT OF CELL VIABILITY  
 
2.3.1 CELL MORPHOLOGY 
 Morphology of cells was assessed following cyto-centrifugation (300 rpm, 3 
min). Obtained slides were fixed in methanol (100 %, 1 minute) and then stained 
using Diff-Quik™ physiological stain before they were analysed by light microscopy 
(x 400-1000 magnification) (Rossi et al., 2006). Apoptotic cells were characterised 
by condensed, pyknotic nucleus or alternatively lack of nucleus (so called ghost cells) 
while membrane integrity was maintained. In contrast, necrotic cells were defined as 
those with disrupted membrane. To assess cell morphology at least 500 cells per slide 










FIGURE 2.4. Typical photomicrographs of apoptotic neutrophils (next page). 
Human blood neutrophils have been cultured for either 8 hours in culture medium (A) 
or for 8 hours in the presence of 20 µM R-roscovitine (B) or for 24 hours in culture 
medium (C). Following culture, 100 µl of cell suspension has been used to prepare 
slides, which were then stained using Diff-Quik™ physiological stain. Apoptotic 
cells are characterised by distinct, condensed, pyknotic nucleus or alternatively lack 
of nucleus, whereas non-apoptotic neutrophils have typical multi-lobed nucleus. 
Images were obtained using an Axiovert S100 inverted microscope (Carl Zeiss), RS 
Photometrix camera and analysed with Open lab software, 3.1.5 version. 



















2.3.2 FLOW CYTOMETRY 
 In order to assess apoptosis of neutrophils prior to the phagocytosis assay, 
flow cytometric analysis was used (Rossi et al., 2006). This method allows 
characterisation of individual cells suspended in a focused stream of fluid, which 
passes through different laser beams. Particular cells vary in their ability to fluoresce 
or scatter the laser light and these fluctuations are then recorded by specific detectors. 
The light scatter provides information about the relative size (forward scatter; FS) and 
the relative granularity (side scatter; SS) of a cell. For instance, Mφ are bigger (have 
higher FS) and less granular (have lower SS) than neutrophils. 
 In addition, the flow cytometry technique can be used to detect the presence 
of certain proteins on the cell surface by means of fluorescent-conjugated antibodies 
or reagents. The latter is of particular importance for assessment of cell apoptosis. 
During apoptosis some of the cellular markers disappear from the cell surface 
whereas some are translocated to the outer leaflet of the plasma membrane. PS is an 
example of a marker that externalises during apoptosis (as described in section 1.3.2). 
Importantly, another protein, Annexin-V shows high affinity for PS binding and 
therefore FITC-conjugated Annexin-V (detected by FL-1 channel of the flow 
cytometer) is extensively used to quantify percentage of apoptotic cells within cell 
populations (Vermes et al., 1995). In addition, necrotic or secondary necrotic (late 
apoptotic) cells are characterised by lack of cell membrane integrity. Consequently, 
dyes such as propidium iodide (PI) can freely enter cells and these cells are positive 
for PI staining (detected by the FL-2 channel of the flow cytometer). As demonstrated 
in Figure 2.5, healthy, viable cells are Annexin-V and PI negative (FL-1- and FL-2-), 
early apoptotic cells are Annexin-V positive but PI negative (FL-1+ and FL-2-), 
whereas necrotic cells and late apoptotic/secondary necrotic cells are positive for both 
Annexin-V and PI (FL-1+ and FL-2+).  
 To assess neutrophil viability by the above-described approach Annexin-V 
was diluted (1:500) in binding buffer (500 ml HBSS supplemented with 2.5 ml of 1M 
CaCl2) and aliquoted 280 µl per FACS tube. Next 20 µl aliquots of neutrophil 
suspension (4x106/ml) were added to FACS tubes and incubated for 15 minutes on 
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ice. Finally 1 µl of PI (1 mg/ml) was added to FACS tubes approximately 2 minutes 






















FIGURE 2.5 Representative flow cytometric profiles of freshly isolated (left 
panels) and cultured for 24 hours (right panels) neutrophils. The % of apoptotic 
cells within the cell population can be estimated on the basis of Annexin-V binding 
(higher FL-1 signal), whereas the % of necrotic cells is demonstrated by 
internalisation of PI (higher FL-2 signal). The data can be plotted as two dimensional 
dot plots diagrams (A) or histogram plots of cells detected by FL-1 (B) or 
alternatively FL-2 channels (C). Nφ – neutrophils.  
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2.3.3 ASSESSMENT OF CELL MEMBRANE INTEGRITY 
 Staining of cells with Trypan blue, a derivative of toluidine, allows 
distinguishing between live/apoptotic and necrotic cells. Live/apoptotic cells maintain 
membrane integrity and are selective towards compounds that can enter the 
intracellular compartments. In contrast, necrotic cells have disrupted membranes and 
the above-mentioned selectivity is lost. Thus, upon staining, Trypan blue can freely 
traverse the membrane and stain necrotic cells. Cells are then examined under the 
light microscope, counted and the percentage of necrotic cells can be evaluated.   
 In all experiments, where the viability of Mφ was assessed by this method, 
cells were first trypsinised and harvested to Eppendorf™ tubes. Subsequently, an 
equal volume of 0.4% Trypan blue was added to 150 µl of cell suspension and 
incubated in room temperature for 5–15 minutes. Following incubation, 10 µl of cell 
suspension was placed on the haemocytometer and the number of both stained and 




2.4 ASSESSMENT OF Mφ PHAGOCYTOSIS 
 In this thesis phagocytosis has been assessed for human MDMφ (see section 
2.4.1) and mouse BMDMφ (see section 2.4.2). Information presented in this chapter 
characterise phagocytic targets and methods used for assessment of phagocytosis for 
these two types of cells.  
 
2.4.1 HUMAN MONOCYTE-DERIVED MΦ (MDMφ)  
 MDMφ were cultured for the duration of 6 days in IMDM supplemented with 
penicillin/streptomycin and 10 % autologous serum, follwing which the appropriate 
treatment was applied. For ELISA or CBA assays, culture supernatants were removed 
and stored at -80°C. For the phagocytosis assay, adherent MDMφ were washed with 
HBSS with Ca2+ and Mg2+ and incubated with apoptotic neutrophils (re-suspended in 
serum-free IMDM supplemented with penicillin/streptomycin at 5x106/ml) for 30-60 
minutes at 37°C, providing a phagocyte-to-target ratio of approximately 1:10 (0.5 ml 
of neutrophil suspension was added to each well).  
 
2.4.1.1 PHAGOCYTIC TARGETS  
 In the majority of experiments, apoptotic human neutrophils were used as 
phagocytic targets. These cells were isolated from human blood cells (see section 
2.2.1.1 for isolation protocol) and cultured for 20 hours to obtain cells undergoing 
constitutive apoptosis (see section 2.2.1.3 for culture conditions). Apoptosis was also 
induced by R-roscovitine (see section 2.2.1.3 for culture conditions). Human 
erythrocytes opsonised with anti–human erythrocyte Ab were used as another 
phagocytic target (see section 2.2.1.1 for isolation protocol and 2.4.1.3 for labelling 
and opsonisation protocols). 
 
2.4.1.2 PHAGOCYTOSIS ASSAY BY FLOW CYTOMETRY 
 For the flow cytometric phagocytosis assay (Jersmann et al., 2003), 
neutrophils were labelled with Cell Tracker™ Green CMFDA (see section 2.2.1.3 for 
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labelling protocol). After incubation of Mφ with apoptotic neutrophils (30-60 
minutes), neutrophils and medium were removed from wells. Remaining cells were 
incubated with trypsin/EDTA for 15 minutes at 37°C followed by 15 minutes on ice 
and transferred to FACS tubes. In order to ensure that all the Mφ were removed from 
wells, plates were examined by light microscopy. Harvested cells were analysed by 
flow cytometry in a FACSCalibur flow cytometer with CellQuest software (Becton-
Dickinson, UK). Neutrophil and Mφ populations were separated by forward and side 
scatter profiles and a minimum of 6000 events within the Mφ gate were acquired (see 
Figure 2.6). The number of FL1+ events in the Mφ gate was divided by the total 
number of Mφ to obtain the % of Mφ that had internalised neutrophils.  
 
2.4.1.3 PHAGOCYTOSIS OF ERYTHROCYTES OPSONISED 
WITH HUMAN IgG ANTIBODIES 
 Following discontinuous Percoll™ density gradient centrifugation, 
erythrocytes were harvested, washed and resuspended at 107/ml in Iscove’s DMEM, 
stained with Cell Tracker™ Green CMFDA for 3 hours and then incubated at 4ºC 
with rabbit polyclonal anti-human erythrocyte Ab (1:1000) for 30 minutes. 
Opsonized erythrocytes were then washed and resuspended at 4x106/ml and 2x106 
erythrocytes were added to each well with adherent Mφ and incubated at 37ºC for 30 
minutes (Hart et al., 1997). The % phagocytosis was assessed by flow cytometry 
following the same protocol as for phagocytosis of apoptotic neutrophils. 
 
2.4.1.4 PHAGOCYTOSIS ASSAY BY MICROSCOPY  
 In order to assess phagocytosis by microscopy (Rossi et al., 1998b), Mφ were 
incubated with unlabelled apoptotic neutrophils as described above (see section 
2.4.1.2). Following the phagocytosis assay, medium was removed from each well and 
wells were washed approximately 4 times with ice-cold PBS without Ca2+ and Mg2+ 
to remove all non-engulfed neutrophils. Next, cells were fixed with 2.5 % 
glutaraldehyde in PBS without Ca2+ and Mg2+ for 10 minutes and stained for 
myeloperoxidase using 0.1 mg/ml dimethoxybenzidine and 0.03 % (v/v) hydrogen 
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peroxide in PBS without Ca2+ and Mg2+(solution was prepared just prior to staining). 
To achieve appropriate staining cells were incubated at 37°C, in 5 % CO2 for 
approximately 10-20 minutes. Finally, uptake of apoptotic neutrophils by Mφ was 
assessed by inverted light microscopy. Typical photomicrograph representing MDMφ 


















FIGURE 2.6. Representative flow cytometric dot-plots demonstrating two 
MDMφ subpopulations: ingesting and non-ingesting apoptotic neutrophils. 
Some treatments may influence levels of phagocytosis and consequently change the 
size of MDMφsubpopulation that performs efferocytosis, e.g., treatment with 
dexamethasone augments efferocytosis but treatment with LPS reduces this process. 








FIGURE 2.7. Typical photomicrograph representing MDMφ uptake of 
apoptotic neutrophils. Unlabelled apoptotic neutrophils (cultured for 20 hours were 
incubated with mature MDMφ (cultured for 6 days in culture medium) for 30-60 
minutes and then cells were fixed and stained as described in section 2.4.1.4 Images 
were obtained using an Axiovert S100 inverted microscope (Carl Zeiss), RS 
Photometrix camera and analysed with Open lab software, 3.1.5 version. 
Magnification 320x. aNφ – apoptotic (20 hours culture) neutrophils. 
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2.4.2 MURINE BONE MARROW-DERIVED MΦ 
(BMDMφ) 
 On the day of the phagocytosis assay BMDMφ culture supernatants were 
removed and Mφ were washed with HBSS with Ca2+ and Mg2+and then labelled with 
Cell Tracker™ Far Red DDAO-SE at the final concentration of 1 µg/ml in HBSS 
with Ca2+ and Mg2+ (150 µl added to each well in 48-well plate) for 30 minutes at 
37°C, 5 % CO2. Subsequently 100 µl of FBS was added to each well to bind excess 
of Cell Tracker™ Far Red DDAO-SE and incubated for 15 minutes at 37°C, 5 % 
CO2. Finally, cells were washed twice with HBSS with Ca2+ and Mg2+ and apoptotic 
neutrophils, labelled with Cell Tracker™ Green CMFDA, added, following the same 
protocol as for phagocytosis by human Mφ. 
 Since populations of murine BMDMφ and human neutrophils overlap with 
human neutrophils when plotted SS against FS two fluorescent labels were used: Cell 
Tracker™ Far Red DDAO-SE (for labelling of BMDMφ, FL-4+) and Cell Tracker™ 
Green CMFDA (for labelling of human neutrophils, FL-1+) allowing gating 
BMDMφas a FL-4+ positive cells and then assessing percentage of FL-1+ 
subpopulation within it. All the BMDMφcells were FL-4+ but only those that had 







2.5 MEASUREMENT OF CYTOKINE 
CONCENTRATIONS 
 
2.5.1 ENZYME-LINKED IMMUNOSORBENT ASSAY 
(ELISA) 
2.5.1.1 PRINCIPLES OF ELISA 
 ELISA is a technique that belongs to the family of enzyme-linked 
immunoassays, developed to measure microamounts of substances in test samples 
(Lequin, 2005). All these techniques are based on interaction between an antigen 
(usually a substance of interest) and a specific antibody and consist of several 
common steps (van Weemen & Schuurs, 1974;Engvall & Perlmann, 1971), namely:  
1) immobilization of antigen on the surface (often a U-bottomed 96 well),  
2) blocking of the surface with non-interacting protein i.e., bovine serum albumin 
(BSA) to avoid non-specific binding of detection antibody to the surface, 
3) interaction between antigen and specific detection antibody which is linked to 
an enzyme, 
4) addition of a substance that is converted by an enzyme to a detectable signal. 
Two antibodies may be used for detection of an antigen; a primary antibody specific 
for antigen and a secondary antibody that is linked to the enzyme that enables 
detection. Secondary antibody is specific for an Fc region of a primary antibody and 
therefore its use is not limited to one particular primary antibody. 
Performance of ELISA may vary and currently the most important methods are (van 
Weemen, 2005):  
1) ‘indirect’ ELISA – where antigen is immobilised on the surface just by non-
specific adsorption and this is a main limitation of this method. 
2) sandwich ELISA – where surface is covered with a specific, capture antibody 
which in turn binds a specific antigen. The main advantage of this method is selective 
binding of antigen of interest to the surface what allows detection even in crude or 
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impure samples. The main principles of sandwich ELISA are demonstrated in Figure 
2.8. 
3) competitive ELISA – where an antibody is added to a sample where it binds an 
antigen present in the sample. Samples are then washed over the surface, previously 
coated with an antigen which recognises an unbound antibody from the sample. 
Hence the antigen from the sample and from the surface competes for the antibody. 
The antibody bound to the surface is next detected by a secondary antibody linked to 
the enzyme. In competitive ELISA the higher the original concentration of an antigen 
in the sample the weaker the final signal.  
 
2.5.1.2 EXPERIMENTAL PROTOCOLS 
In this PhD thesis the sandwich ELISA has been used to assess concentrations of 
TNF-α and IL-10 in MDMφculture supernatants. DuoSet ELISA Development kit has 
been used according to the manufacturer’s instruction. Culture supernatants were 
collected on day 6 of the MDMφ culture, centrifuged (600g; 6 minutes) and stored in 

























FIGURE 2.8. Schematic diagram demonstrating the principles of ‘sandwich’ 
ELISA. The entire procedure is described in more detail in section 2.5.1 and 
important steps indicated in the above figure.  
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2.5.2 CYTOMETRIC BEAD ARRAY (CBD) 
2.5.2.1 PRINCIPLES OF CBA 
 Similar to the ‘sandwich’ ELISA, the CBA is based on antigen–antibody 
interactions, where capture antibody is used to immobilise antigen and detection 
antibody is linked to an enzyme that produces detectable signal. The main difference 
to an ELISA technique is the surface that carries captures antibodies. In ELISA, as 
described in section 2.5.1.1, capture antibodies coat a well of typically 96-well plate. 
In contrast, in CBA, capture antibodies coat a surface of a bead. Interaction between 
an antigen and antibodies and formation of a ‘sandwich’ in CBE approach is 
schematically demonstrated in Figure 2.9. Beads may differ in size, colour or 
intensity of the colour and thus can be analysed separately by different channels of 
the flow cytometer. Consequently, CBA has a number of advantages over ELISA, 
namely:  
• multiple substances are analysed simultaneously  
• volume of a sample is reduced  
• wide dynamic range of fluorescence is used  
• time of an assay is reduced (approximate 4 hours).  
 
2.5.2.2 EXPERIMENTAL PROCEDURES 
In this PhD thesis, CBA (Human Inflammation Kit) has been used that measures 
concentrations of IL-8, IL-1β, IL-6, IL-10, TNF-α and IL-12p70. Cytokine 
concentrations in the MDMφ culture supernatants were determined according to the 
manufacturer’s instructions. Culture supernatants were collected on day 6 of the 
MDMφ culture, centrifuged (600g; 6 minutes) and stored in aliquots at -80ºC until 



















FIGURE 2.9 Formation of a ‘sandwich’ in CBA assay. The above diagram 
demonstrates complex interaction between an antigen and antibodies in CBA 
approach to measure the antigen levels. The principles of this technique are described 
in more detail in section 2.5.2.  
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2.6 sTNF-R1/Fc BINDING ASSAY  
 Neutrophils, isolated from human blood (as described in section 2.2.1), were 
cultured at 37°C and 5 % CO2 atmosphere at a concentration of 4x106/ml in IMDM 
supplemented with penicillin/streptomycin and 10% FBS (human IgG free) for 20 
hours, then washed twice (300g, 5 minutes, 4°C) in PBS without Mg2+/Ca2+, re-
suspended at the concentration of 0.8x106/ml in flow buffer (PBS without Mg2+/Ca2+ 
with 2% FBS) and plated at 100 µl/well in 96-well FlexiPlate. Cells were incubated 
on ice for 20 minutes either in flow buffer alone or in the presence of 500 ng/ml 
sTNF-R1/Fc or 100 µg/ml heat aggregated human recombinant IgG. Next, cells were 
washed twice (300g, 5 minutes, 4°C) in PBS without Mg2+/Ca2+, incubated for 20 
minutes on ice with goat F(ab’)2 anti-human IgG, FITC conjugated antibody (1:50, 
detected by FL-1 channel on flow cytometer) washed twice (300g, 5 minutes, 4°C) in 
PBS without Mg2+/Ca2+, and re-suspended in Annexin-V (1:40, APC conjugate, 
detected as FL-3 on flow cytometer) binding buffer. Assessment of binding was 
performed by flow cytometry analysis (Hart et al., 2004a). The % necrotic cells was 






2.7 WESTERN BLOTTING 
2.7.1 PRINCIPLES OF WESTERN BLOTTING 
 Western blotting is an analytical technique, related to CBA and ELISA which 
are described in section 2.5. It is used for detection of a specific protein in a given 
sample i.e., cell extract. W. Neal Burnette named this method by analogy to Southern 
blotting, which is a DNA detection method, developed earlier by Edwin Southern 
(Burnette, 1981). Detection of RNA is termed northern blotting. Western blotting 
combines several steps which are indicated in Figure 2.10 and reviewed in detail by 
Towbin at al. (Towbin et al., 1979). These steps include:  
1) tissue homogenation and cell lysis,   
2) gel electrophoresis to separate native or denatured proteins by the length of the 
polypeptides (denaturing conditions) or by their 3-D structures (native / non–
denaturing conditions),  
3) transfer of proteins to the membrane (typically nitrocellulose or PVDF),  
4) blocking of the membrane in a dilute solution of protein, typically BSA, to 
prevent interaction between membrane and antibodies used for detection of a target 
protein,  
5) probing with primary antibody specific for protein of interest,  
6) probing with secondary antibody that allows easy detection,  

























FIGURE 2.10 Schematic diagram demonstrating the main steps of protein 
detection by western blotting. The entire procedure is described in more details in 
section 2.7 and important steps are indicated in the above figure.  
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2.7.2 EXPERIMENTAL PROTOCOLS 
2.7.2.1 PREPARATION OF MDMφ LYSATES 
 Mononuclear cells isolated by Percoll™ gradient centrifugation (see section 
2.2) were re-suspended in IMDM at the concentration 4 x 106 cells/ml, plated at 3 
ml/well in 6-well plates (1 hour, 37°C, 5 % CO2). Then non-adherent cells were 
removed by washing twice with HBSS with Ca2+ and Mg2+ and monocytes were 
cultured in IMDM supplemented with penicillin/streptomycin and 10 % (v/v) 
autologous serum +/- treatment (6 days, 37°C, 5 % CO2) to allow their maturation 
into MDMφ. On day 6 MDMφ were washed twice in ice–cold PBS without Ca2+ and 
Mg2+ supplemented with 100 µM Na3VO4 and lysed with 150 µl RIPA lysis buffer 
(30 minutes, 4°C). The composition of RIPA lysis buffer is presented in Table 2.1. In 
order to minimise protein degradation, proteinase inhibitor cocktail has been added to 
RIPA lysis buffer just before the lysis (10 µl for every 1 ml of the buffer). Following 
lysis, cells were scraped, lysates were harvested into Eppendorf™ tubes and 
cytocentrifuged (15 minutes, 13000 rpm, 4 °C). Supernatants were aliquoted and 








TABLE 2.1 Composition of RIPA lysis buffer 
RIPA lysis buffer Stock solutions Volume / 50 ml 
100 µM Na3VO4 1 mM Na3VO4 5 ml 
50 mM NaCl 1 M NaCl 2.5 ml 
50 mM TRIS pH 7.4 1 M TRIS pH 7.4 2.5 ml 
0.5 % deoxycholate 10 % deoxycholate 2.5 ml 
0.1 % SDS 10 % SDS 0.5 ml 
1% NP40 100 % NP40 0.5 ml 
1 mM EGTA 0.5 M EGTA 100 µl 
1 mM NaF 0.5 M NaF 100 µl 
1 mM PMSF 1 M PMSF 50 µl 
 
RIPA lysis buffer was made out of stock solutions on the day of lysis and kept 
on ice. Just prior to lysis proteinase inhibitors were added. Stock solutions may 
be prepared in advance and stored in the laboratory.  
 
2.7.2.2 MEASUREMENT OF PROTEIN CONCENTRATION  
 The concentration of proteins in obtained lysates was measured by Bio-Rad 
Dc Protein Assay following the manufacturer’s instruction. This assay is based on the 
colorimetrical method of Lowry in which copper (II) ion in alkaline solution reacts 
with amino bonds of the protein and is reduced to copper (I) (Lowry et al., 1951). 
Next copper (I) reduces Folin reagent and it turns blue. Intensity of the colour 
(proportional to protein concentration) is measured as a maximum absorbance (Amax) 
at 750 nm with a spectrophotometer or microplate reader. Finally, by a comparison to 
a standard curve, relative concentration of the protein in samples of interest can be 
measured. The standard curve was created by preparing series of dilutions of 1.35 
mg/ml BSA solution.  
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2.7.2.3 SOLUTIONS AND REAGENTS 
• Running Buffer - NuPAGE® 20X MES SDS Running Buffer (Invitrogen™, 
Carlsbad, CA), reconstituted in purified water. 
• Sample Buffer – NuPAGE® 4X LDL Sample Buffer (Invitrogen™, Carlsbad, 
CA). 
• Sample Reducing Agent - NuPAGE® 10X Sample Reducing Agent 
(Invitrogen™, Carlsbad, CA). 
• Molecular weight size marker – biotinylated protein ladder (Cell Signalling, 
Herts, UK) 
• Gels for electrophoresis - NuPAGE® Novex 4-12 % Bis-Tris precast gels 
(Invitrogen™, Carlsbad, CA). 
• Transfer buffer - NuPAGE® 20X Transfer Buffer (Invitrogen™, Carlsbad, 
CA), in 10 % solution of methanol in purified water (i.e., 50 ml of NuPAGE® 20X 
Transfer Buffer, 100 ml of methanol and 850 ml of purified water have been used for 
total volume of 1000 ml).  
• Blocking Buffer – 1X TBS, 0.1 % Tween-20, 5 % w/v nonfat dry milk in 
purified water.  
• 10 X TBS (Tris-buffered saline) – for total volume of 1000 ml: 24.2 g Tris 
base, 80 g NaCl in purified water, pH adjusted to 7.6 with HCl. 
• Wash Buffer TBS/T – 1X TBS, 0.1 % Tween-20 in purified water. 
• Primary Antibody Dilution Buffer – 1X TBS, 0.1 % Tween-20 with 5 % 
BSA in purified water. 
• Detection Reagents - 20X LumiGLO® chemiluminescent reagent and 20X 
peroxide used along with horseradish peroxidise (HRP) tagged detection antibodies 
(Cell Signalling, Herts, UK). In the presence of hydrogen peroxide, HRP converts 
luminol to an excited intermediate dianion. This dianion emits light on return to its 
ground state which is captured by x-ray film. 
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2.7.2.4 PROTEIN ELECTROPHORESIS 
 In general, gel electrophoresis is a method of separation of charged molecules, 
i.e., DNA or proteins, based on their ability to migrate in a gel toward opposite 
charge. In this PhD thesis polyacrylamide (PAGE) gel electrophoresis has been used 
to separate proteins in analysed samples. PAGE gels may be composed of various 
concentrations of acrylamide and cross-linker producing gels that differ in the size of 
pores. The choice of suitable PAGE gel depends on the size of analysed proteins. The 
higher the molecular mass of proteins the lower percentage of PAGE gel is usually 
used. Proteins are separated due to their differences in mass – low molecular mass 
proteins migrate slower than those of higher molecular mass. In this project, the 
gradient 4-12 % PAGE gels have been used. Prior to electrophoresis, proteins were 
resuspended in a sample buffer and treated with sample reducing agent containing 
sodium dodecyl sulphate (SDS), which denatures secondary and non-disulfide-linked 
tertiary structures. In addition, incubation with SDS results in each protein having a 
negative charge proportional to its mass and independent of its primary structure. 
Consequently, migration of proteins in the gel towards the positive pole depends 
mainly on its mass (charge). Finally, the mass of analysed proteins is established by a 
comparison to specific molecular weight size markers. Gels and all the necessary 
reagents and equipment to run electrophoresis were purchased from Invitrogen™ 
(Carlsbad, CA) and are described in section 2.7.2.3. The manufacturer’s instructions 
have been followed.  
2.7.2.5 MEMBRANE TRANSFER OF PROTEINS  
 Following gel electrophoresis, proteins have been transferred from PAGE gel 
on nitrocellulose blotting membrane (Gottingen, Germany). This step allows further 
detection of proteins with the use of specific antibodies. In the presented study, 
proteins were transferred to the membrane in transfer buffer (described in section 
2.7.2.3) by application of electric current. For this purpose, a sheet of nitrocellulose 
membrane has been placed on the top of PAGE gel, covered with a stack of filter 
papers (Whatmann 3mm) and sponges, all soaked in the transfer buffer, and placed 
into transfer apparatus, where proteins move in the direction of anode. The binding of 
proteins to the surface of the membrane is based upon hydrophobic and charged 
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interactions between the membrane and a protein. The manufacturer’s instructions 
have been followed throughout the entire procedure. 
2.7.2.6 ANTIBODIES, INCUBATION CONDITIONS AND 
DETECTION 
 After proteins had been transferred to the membrane, the following steps were 
undertaken in order to detect proteins of interest:  
1) Wash with 25 ml 1 X TBS (5 minutes, room temperature (RT), gentle 
agitation). 
2) Incubation in 25 ml of Blocking Buffer (1 hour, RT, gentle agitation). 
3) Wash 3 times with 15 ml of Wash Buffer (5 minutes each wash, RT, gentle 
agitation). 
4) Incubation in 10 ml of Primary Antibody Dilution Buffer. Primary antibodies 
used in this study are listed in section 2.1.8 and 1:1000 dilution was used (overnight, 
4ºC, gentle agitation).  
5) Wash 3 times with 15 ml of Wash Buffer (5 minutes each wash, RT, gentle 
agitation). 
6) Incubation in 10 ml of Blocking Buffer containing HRP-conjugated secondary 
antibody (1:2000) and HRP–conjugated anti–biotin antibody (1:1000) to detect 
biotinylated protein markers (1 hour, RT, gentle agitation). These antibodies are listed 
in section 2.1.8. 
7)  Wash 3 times with 15 ml of Wash Buffer (5 minutes each wash, RT, gentle 
agitation). 
8) Incubation with 10 ml LumiGLO® (0.5 ml 20 X LumiGLO® , 0.5 ml 20 X 
Peroxide and 9.0 ml Milli – Q water) (1 minute, RT, gentle agitation). 
9) The membrane was drained of excess of developing solution, wrapped in plastic 
wrap and exposed to x-ray film (Kodak BioMax light film) to read results.  
10) X-ray films have been developed in Medical Film Processor (Konica SRX-
101A).  
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2.8 STATISTICAL ANALYSIS 
 Results are expressed as the mean ±SEM of n=number of independent 
experiments using Mφ from different donors. Statistical significance (defined as 
p<0.05) was evaluated by ANOVA (InStat3) with comparisons between groups using 
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3 THE EFFECTS OF PRO-INFLAMMATORY 
STIMULI ON MΦ EFFEROCYTOSIS 
 
3.1 INTRODUCTION 
 The inflammatory response is a physiological way of defending a host 
organism, subjected to tissue injury, infection or other forms of trauma. However, 
inflammation must be appropriately controlled and resolved in order to prevent its 
harmful consequences including progressive tissue damage, which is associated with 
pathological conditions (e.g., RA, Crohn’s disease, asthma etc.) (Savill et al., 1989). 
Sites of chronic inflammation are characterised by overexpression of numerous pro-
inflammatory mediators including TNF-α (Feldmann et al., 1994). Yet, few studies 
describe the effects of pro-inflammatory cytokines on two important mechanisms 
underlying resolution of inflammation: apoptosis of inflammatory cells and their 
subsequent clearance by Mφ. For instance, it has been previously shown that TNF-α, 
depending on duration of treatment, may exert variable effects on apoptosis of 
inflammatory cells (Ward et al., 1999). Acute treatment with TNF-α induces 
neutrophil apoptosis while prolonged exposure results in cell survival. Furthermore, 
the findings regarding the effects of TNF-α on Mφ clearance of apoptotic cells are 
contradictory. In the study published by Savill and colleagues, TNF-α augmented 
clearance of apoptotic cells by immature Mφ (Ren & Savill, 1995). In contrast, some 
studies have recently demonstrated that TNF-α inhibits clearance of apoptotic cells by 
mature Mφ (McPhillips et al., 2007;Borges et al., 2009).  
 One of the objectives of this PhD thesis was a thorough evaluation of the 
effects of TNF-α on MDMφ clearance of apoptotic neutrophils. The production of 
TNF-α in MDMφ has been induced by several agents, i.e., LPS, LTA and PGN. 
These are constituents of bacterial cell walls that are recognised by the TLR family of 
receptors (Draing et al., 2008). LPS is a component of Gram-negative bacterial cell 
walls, which is recognised by TLR4, located on the surface of host cells. Due to its 
powerful pro-inflammatory properties, LPS is commonly used by scientists to induce 
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inflammation in various model systems (Marshall, 2005). LPS, its recognition by host 
cells and pro-inflammatory signalling pathways are described in more detail in 
section 1.2.2.1.  
 LTA and PGN are also components of Gram-positive bacterial cell walls and 
are recognised by the cell surface receptor TLR2. Even though administration of LTA 
in vivo exerts similar effect to LPS (systemic shock), it has been reported that 
signalling pathways triggered by these agents are not identical (Draing et al., 2008). 
For instance, no final consensus has been reached regarding the requirement of CD14 
and LBP in LTA-induced cellular responses (see chapter 1.2.2.1 for more information 
on CD14 and LBP). Furthermore, TLR4 recruits two types of adaptor proteins 
TRIF/TRAM and MyD88/Mal while TLR2 engages only the latter. TLR2 has been 
also demonstrated to act in a complex with other receptors such as TLR1, TLR6 or 
CD36 (Deininger et al., 2008). Activation of either TLR4 or TLR2 leads to 
subsequent activation of pro-inflammatory transcription factors (e.g., NF-κB or AP1) 
and production of certain pro-inflammatory mediators such as TNF-α, as described in 
section 1.2.2.1.  
 In this PhD thesis, in order to establish the effects of TNF-α on phagocytosis, 
monocytes isolated from human blood were differentiated into MDMφ during 6 days 
culture. MDMφ production of TNF-α was induced with LPS, LTA and PGN 
(increasing concentrations and durations of treatment were used). Alternatively, 
MDMφ were cultured for various durations of time with increasing concentrations of 
exogenous human recombinant TNF-α. On day 6, Mφ ability to phagocytose 
apoptotic neutrophils (constitutive or R-roscovitine-induced apoptosis) has been 
assessed by either flow cytometry (majority of experiments) or microscopy, as 
described in section 2.4.1. Furthermore, the effects of TNF-α on various phagocytic 
targets, i.e., apoptotic neutrophils and IgG-opsonised human erythrocytes, have been 
studied. It is recognised that mechanisms involved in the uptake of apoptotic cells are 
different from that involved in engulfment of opsonised particles (Rossi et al., 
1998b). During apoptosis, the cell membrane undergoes thorough remodelling and 
some of these changes may provide binding sites for opsonins such as antibodies and 
complement proteins. Opsonins, in turn, may mediate Mφ phagocytosis by classical 
phagocytic receptors e.g., Fc receptors (Hart et al., 2004b). The latter process is very 
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efficient and may provide an additional mechanism preventing secondary necrosis 
and consequential tissue damage in tissues overload with inflammatory cells during 
inflammation. Thus, in order to investigate the TNF-α regulation of Mφ phagocytosis 
further, human erythrocytes were opsonised with human IgG antibodies and their 





3.2.1 ISOLATION AND CULTURE OF HUMAN BLOOD 
CELLS  
 Human blood cells were isolated by Percoll™ gradient centrifugation, 
following a protocol described in section 2.2.1.1. Subsequently, human monocytes 
were cultured for 6 days in culture medium (see section 2.2.1.3 for culture conditions) 
undergoing differentiation into mature human MDMφ. During this time MDMφ were 
treated with a number of pro- and anti-inflammatory agents. Typical treatments were 
as follows: 1 µM dexamethasone (96-144 hours), 0.1–100 ng/ml TNF-α or LPS (6, 
24, 48, 96 or 144 hours), 0.01–10 ng/ml IL-1β (120 hours), 0.1 – 100 µg/ml LTA or 
PGN (6, 16, 32, 48, 72, 96 hours).  
 On day 6, MDMφ were assessed for their ability to phagocytose different 
targets. In the majority of experiments these targets were human neutrophils that had 
undergone constitutive apoptosis for 20 hours of culture (see section 2.2.1.3 for 
culture conditions). Apoptosis of human neutrophils was also induced by 20 µM R-
roscovitine over 8 hours of culture (see chapter 2.2.1.3 for culture conditions). Other 
phagocytic targets used in this study were opsonised human erythrocytes (see section 
2.2.1.1 for isolation protocol and 2.4.1.3 for labelling and opsonisation protocols). 
 
3.2.2 ASSESSMENT OF APOPTOSIS AND NECROSIS 
 Prior to performing the phagocytosis assay, the percentage of apoptotic cells 
within neutrophil populations was determined by morphology or alternatively by 
Annexin-V binding assessed by flow cytometry (see sections 2.3.1 and 2.3.2 for 
experimental protocol). The percentage of necrotic cells was determined by PI 
staining assessed by flow cytometry. Only neutrophils with less than 5 % of necrosis 
were used in the phagocytosis assay.  
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3.2.3 ASSESSMENT OF PHAGOCYTOSIS BY FLOW 
CYTOMETRY 
 In the majority of experiments described in this chapter efferocytosis was 
assessed by flow cytometric analysis that employs labelling of phagocytic targets 
with FL1+ Cell Tracker™ Green (CMFDA) prior to the phagocytosis assay. 
Following the phagocytosis assay, the % of FL1+ MDMφ (MDMφ that had engulfed 
phagocytic targets) within the entire MDMφ population was assessed by flow 
cytometry as described in section 2.4.1.1.  
 
3.2.4 ASSESSMENT OF PHAGOCYTOSIS BY 
MICROSCOPY 
 To obtain photomicrographs of MDMφ that have been cultured in different 
conditions and have or have not engulfed apoptotic neutrophils, unlabelled apoptotic 
neutrophils were incubated with mature MDMφ and then cells were fixed, stained 
and observed under light microscope. Photomicrographs were taken as described in 
section 2.4.1.2.  
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3.3 RESULTS  
 
3.3.1 LPS INHIBITS MDMΦ EFFEROCYTOSIS IN A 
CONCENTRATION- AND TIME-DEPENDENT MANNER 
 Human blood monocytes were differentiated in vitro for 6 days following a 
well-established protocol for generating Mφ (Rossi et al., 1998b). In order to examine 
effects of LPS on MDMφ efferocytosis of apoptotic cells, monocytes were treated 
with LPS (10 ng/ml) for the duration of 96–144 hours and then co-cultured with 
apoptotic neutrophils to determine efferocytosis. The % of MDMφ ingesting 
apoptotic neutrophils was assessed by flow cytometric analysis. Efferocytosis was 
decreased by LPS treatment from control levels of 39.4 ± 3.4 % to 20.5 ± 3.0 % 
(p<0.001; n = 19; Figure 3.1A). MDMφ cultured in the presence of dexamethasone (1 
µM, 96–144 hours), previously shown to augment efferocytosis of apoptotic 
neutrophils, were characterised by increased uptake of apoptotic neutrophils up to 
64.6 ± 3.4 % (p<0.001; n = 19; Figure 3.1A). Representative flow cytometric dot-
plots demonstrating differences in MDMφ uptake of apoptotic neutrophils upon 
treatments with dexamethasone or LPS are presented in Figure 3.1B. Their 



















FIGURE 3.1 Effects of dexamethasone and LPS on MDMφ efferocytosis of 
neutrophils. A. Human MDMφ cultured in medium (control) for 6 days and treated 
on average for 96-144 hours with either 1µM dexamethasone or 10 ng/ml LPS were 
assessed for their ability to phagocytose apoptotic neutrophils. The % efferocytosis 
assessed on day 6 by flow cytometry is expressed as mean ± SEM for n=19 
experiments. Significant difference for comparison to medium control is represented 
by ***p<0.001. B. Representative flow cytometric dot-plot profiles demonstrating 
changes in efferocytosis for treatments with either 1µM dexamethasone or 10 ng/ml 
LPS for 120 hours in comparison to medium control. aNφ–apoptotic (20 hours 
culture) neutrophils, DX – dexamethasone. 
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 Having found that LPS treatment inhibits efferocytosis, I next sought to 
investigate if this effect was concentration- and time-dependent. For this purpose 
human blood monocytes were cultured for 6 days and treated with increasing 
concentrations of LPS for 120 hours or with 10 ng/ml LPS for 6, 48, 96 and 144 
hours. Efferocytosis was assessed on day 6 by flow cytometry. As demonstrated in 
Figure 3.2A, the LPS inhibitory effect was dependent on its concentration. The first 
significant decrease from 42.9 ± 6.2 % (control levels) to 29.3 ± 3.6 % was observed 
upon treatment with 0.1 ng/ml LPS (p<0.05; n = 4) and this effect further increased in 
parallel with increase in LPS concentration. Efferocytosis levels were 17.7 ± 4.6 % 
for treatment with 1 ng/ml LPS (p<0.01, n = 4), 14.0 ± 4.3 % for treatment with 10 
ng/ml LPS (p<0.001; n = 4) and 13.9 ± 3.9 % for treatment with 100 ng/ml LPS 
(p<0.001; n = 4). The approximate IC50 value for LPS was 0.6 ng/ml. The inhibitory 
effect of LPS was also dependent upon length of treatment. Interestingly, LPS 
required at least 96 hours to induce significant reduction in efferocytosis levels from 
38.7 ± 4.8 % (control) to 21.8 ± 3.3 % (p<0.05; n = 4). Inhibition was even greater 
































FIGURE 3.2 Concentration- and time-dependent effects of LPS on MDMφ 
efferocytosis of neutrophils. Human MDMφ were cultured with either increasing 
concentrations of LPS for 120 hours (A) or with 10 ng/ml LPS for increasing 
durations of time (B) and then assessed for their ability to ingest apoptotic 
neutrophils. The % efferocytosis assessed on day 6 by flow cytometry is expressed as 
mean ± SEM of n=4 separate experiments. Significant differences for comparisons to 
medium control are represented by *p<0.05, **p<0.01 and ***p<0.001.  
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3.3.2 LTA INHIBITS MDMΦ EFFEROCYTOSIS IN A 
CONCENTRATION- AND TIME-DEPENDENT MANNER 
 Having found that the TLR-4 agonist, LPS, reduced MDMφ efferocytosis I 
next sought to investigate whether the TLR-2 agonist, lipoteichoic acid (LTA), would 
exert a similar effect. For this purpose, human blood monocytes were differentiated in 
vitro for 6 days and treated with increasing concentrations of LTA for various 
durations of time. Efferocytosis was measured on day 6 by flow cytometry. As shown 
in Figure 3.3A, after 32 hours of treatment, LTA, at a concentration of 100 µg/ml, 
significantly reduced efferocytosis to 21.3 ± 2.6 % in comparison to control levels 
34.3 ± 3.6 % (p<0.05; n = 5). Next, I examined the time-dependence of the LTA 
effect. Human blood monocytes were differentiated for 6 days into MDMφ and 
treated for increasing durations of time: 6, 16, 32, 48, 72 and 96 hours with 100 µg/ml 
LTA. On day 6, MDMφ phagocytosis was assessed by flow cytometry. Interestingly, 
I was able to detect significant inhibition at early time points. At the 16 hour time 
point, efferocytosis was reduced from 34.9 ± 4.5 % (control) to 24.3 ± 3.9 % (p<0.05; 
n = 4). At 32 hours after treatment the LTA inhibitory effect was even greater (18.5 ± 
3.2 %, p<0.01, n=4 in comparison to control) and was sustained till the 96 hour time 


























FIGURE 3.3 Concentration- and time-dependent effect of LTA on MDMφ 
efferocytosis of neutrophils. Human MDMφ were cultured for 6 days and treated as 
indicated with either increasing concentrations of LTA for 32 hours (A) or with 100 
µg/ml LTA for increasing durations of time (B). On day 6, their ability to ingest 
apoptotic neutrophils was assessed by flow cytometry. Data are expressed as mean ± 
SEM of n=5 (A) or n=4 (B) separate experiments. Significant differences for 
comparisons to medium control are represented by *p<0.05, **p<0.01*** and 
p<0.001.  
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3.3.3 PGN INHIBITS MDMΦ EFFEROCYTOSIS IN A 
CONCENTRATION- AND TIME-DEPENDENT MANNER 
 Since I demonstrated that LTA can block MDMφ uptake of apoptotic 
neutrophils, I then decided to use another TLR-2 agonist, PGN, to examine its effect 
upon efferocytosis. For this purpose human blood monocytes were differentiated in 
vitro for 6 days and cultured for 16 hours with increasing concentrations (0.1, 1, 10, 
100 µg/ml) of PGN. Efferocytosis was measured on day 6 by flow cytometry. As 
shown in Figure 3.4A PGN at concentrations 10 and 100 µg/ml significantly reduced 
efferocytosis from control levels 29.0 ± 5.8 % to 14.6 ± 2.5 % (p<0.05, n = 4) and 7.0 
± 0.9 % (p<0.01, n = 4) respectively. Next, I examined the time-dependence of the 
PGN effect. Human blood monocytes were differentiated for 6 days into MDMφ and 
treated for increasing durations of time: 6, 16, 32, 48, 72 and 96 hours with 10 µg/ml 
PGN. Phagocytosis was measured on day 6 of the culture by flow cytometry. The 
first significant inhibition of efferocytosis was observed at 16 hours; 18.7 ± 1.9 % in 
comparison to control 35.3 ± 4.5 % (p<0.01, n = 4) but this effect disappeared at 32 
and 48 hours after treatment. Intriguingly, at later time points: 72 and 96 hours, 
MDMφ again showed reduced ability for phagocytosis; 21.2 ± 8.3 % (p<0.05, n = 4) 






















FIGURE 3.4 Concentration- and time-dependent effect of PGN on MDMφ 
efferocytosis of neutrophils. Human MDMφ were cultured for 6 days and treated as 
indicated with either increasing concentrations of PGN for 16 hours (A) or with 10 
µg/ml PGN for increasing durations of time (B). On day 6 their ability to ingest 
apoptotic neutrophils was assessed by flow cytometry. Data are expressed as mean ± 
SEM of n=4 separate experiments. Significant differences for comparisons to 
medium control are represented by *p<0.05 and **p<0.01.  
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3.3.4 TNF-α INHIBITS MDMφ EFFEROCYTOSIS IN A 
CONCENTRATION- AND TIME-DEPENDENT MANNER 
 Since LPS, LTA and PGN have been shown to induce Mφ production of 
TNF-α (Fan et al., 2003;Su et al., 2006), I investigated whether Mφ treated with 
TNF-α would have decreased ability to phagocytose apoptotic neutrophils. Thus, 
human blood monocytes were differentiated for 6 days and treated first with 
increasing concentrations (0.1, 1, 10 and 100 ng/ml) of TNF-α for 120 hours. As 
shown in Figure 3.5A, TNF-α inhibited efferocytosis in a concentration-dependent 
fashion. Significant inhibition from control levels 31.9 ± 3.4 % to 24.5 ± 4.4 % 
(p<0.01; n = 13) was observed upon treatment with 1 ng/ml TNF-α. The further 
increase in TNF-α concentration up to 10 ng/ml resulted in augmentation of its 
inhibitory effect and the levels of efferocytosis were 13.4 ± 2.0 % (p<0.001; n = 13). 
Similar levels of efferocytosis (13.5 ± 2.3 %; p<0.001; n = 13) were obtained upon 
treatment with 100 ng/ml TNF-α. The approximate IC50 for TNF-α was 8.3 ng/ml. 
Next, I investigated the time dependence of the TNF-α effect and found that TNF-α 
(10 ng/ml) requires a shorter time than LPS to induce significant inhibition of 
efferocytosis. As indicated in Figure 3.5B, after 6 hours of TNF-α treatment, the 
levels of phagocytosis were reduced from 42.4 ± 5.3 % to 28.0 ± 2.5 % (p<0.05; n = 
6). Longer TNF-α treatments, 48, 96 and 144 hours, further decreased efferocytosis to 
similar levels: 15.3 ± 2.1 %, 14.8 ± 2.6 % and 13.3 ± 6.3 % respectively (p<0.001, n 
= 6). Figure 3.5C compares typical flow cytometric profiles of efferocytosis by 



































FIGURE 3.5 (previous page). Concentration- and time-dependent effect of TNF-
α on MDMφ efferocytosis of neutrophils. A. Human MDMφ for concentration-
response experiments were cultured for 6 days and treated for 120 hours with 
increasing concentrations of TNF-α (A) whereas for time-course experiments MDMφ 
were treated for increasing durations of time with 10 ng/ml TNF-α (B). On day 6, 
MDMφ efferocytosis of neutrophils was assessed by flow cytometry. The % 
efferocytosis is expressed as the mean ± SEM of n=13 (A) or n=6 (B) experiments. 
Significant differences for comparisons to medium control are represented by 
*p<0.05, **p<0.01 and ***p<0.001. C. Representative flow cytometric dot-plot 
profiles demonstrating changes in efferocytosis of neutrophils resulting from 96 hours 
treatment with 10 ng/ml TNF-α in comparison to medium control. aNφ – apoptotic 
(20 hours culture) neutrophils 
 
FIGURE 3.6 (next page). Representative photomicrographs showing MDMφ 
efferocytosis of apoptotic neutrophils. Human MDMφ were cultured for 6 days in 
culture medium (control) or treated for 120 hours with either 1 µM dexamethasone, 
10 ng/ml LPS or 10 ng/ml TNF-α. On day 6, MDMφ efferocytosis of apoptotic 
neutrophils was assessed by microscopy. Images were obtained using an Axiovert 
S100 inverted microscope (Carl Zeiss), RS Photometrix camera and analysed with 
Open lab software, 3.1.5 version. Magnification 320x. aNφ – apoptotic (20 hours 















3.3.5 LPS - AND TNF-α - INDUCED INHIBITION OF 
EFFEROCYTOSIS APPEARS TO BE SPECIFIC FOR 
APOPTOTIC CELLS  
 I next investigated whether the effects of TNF-α and LPS on efferocytosis 
were specific only for neutrophils undergoing constitutive apoptosis. For this purpose 
I induced apoptosis in neutrophils with the cyclin-dependent kinase inhibitor, R-
roscovitine (8 hours treatment), previously shown by our group to augment neutrophil 
apoptosis (Rossi et al., 2006). As shown in Figure 3.7A TNF-α (10 ng/ml) and LPS 
(10 ng/ml) markedly inhibited uptake of R-roscovitine-induced apoptotic neutrophils 
from 40.6 ± 5.2 % to 25.0 ± 5.2 % and 23.5 ± 7.9 % (p<0.05, n = 4) respectively 
whereas dexamethasone increased the uptake up to 70.1 ± 5.5 % (p<0.001, n = 4). On 
the contrary, MDMφ phagocytosis of Ig-G opsonised erythrocytes was not inhibited 
by 10 ng/ml TNF-α (59.2 ± 16.3 %) and 10 ng/ml LPS (50.5 ± 10.8 %) in comparison 
to control (40.5 ± 7.6 %) but here again dexamethasone (1 µM) significantly 


















FIGURE 3.7 LPS and TNF-α inhibit MDMφ uptake of R-roscovitine–induced 
apoptotic neutrophils but not opsonised erythrocytes. MDMφ were cultured for 6 
days and treated for 120 hours with either 1µM dexamethasone, 10 ng/ml TNF-α or 
10 ng/ml LPS. On day 6, MDMφ ability to ingest either apoptotic neutrophils 
(apoptosis was induced by 20 μM R-roscovitine, 8 hours treatment) (A) or human 
IgG opsonized erythrocytes (B) was assessed by laser flow cytometric analysis. Data 
are expressed as mean phagocytosis ± SEM for n=4 experiments. Significant 
differences for comparisons to medium control are represented by *p<0.05 and 
***p<0.001.  
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3.3.6 IL-1β INHIBITS MDMφ CLEARANCE OF 
APOPTOTIC NEUTROPHILS 
 Since TNF-α triggers production of other pro-inflammatory cytokines by Mφ 
(Feldmann et al., 1995) I next investigated whether MDMφ treated with another 
cytokine, i.e., IL-1β, would also display impaired efferocytosis. For this purpose 
human blood monocytes were cultured for 6 days in medium (medium control) or 
treated for 96 hours with either 10 ng/ml TNF-α (TNF-α control) or increasing 
concentrations (0.01, 0.1, 1, 10 ng/ml) of IL-1β. As shown in Figure 3.8, TNF-α 
significantly decreased efferocytosis and the mean levels were 8.6 ± 2.9 % (p<0.001, 
n = 6) in comparison to medium control levels 29.4 ± 5.9 %. Interestingly, MDMφ 
treated with 1 and 10 ng/ml IL-1β were also characterised by decreased ability for 
efferocytosis, 14.0 ± 5.2 % (p<0.01, n=6) and 16.0 ± 6.8 %, (p<0.05, n=6) 
respectively. Similar experiment has also been conducted with IL-6 and obtained data 




FIGURE 3.8 Effects of IL-1β on MDMφ efferocytosis of apoptotic neutrophils. 
Human MDMφ were cultured in medium (control) for 6 days and treated as indicated 
for 96 hours with either 10 ng/ml TNF-α or increasing concentrations of IL-1β. On 
day 6, their ability to ingest apoptotic neutrophils was assessed by flow cytometry. 
The % efferocytosis is expressed as mean ± SEM for n=6 experiments. Significant 
differences for comparisons to medium control are represented by *p<0.05, **p<0.01 
and ***p<0.001.  
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3.3.7 SUMMARY OF THE RESULTS 
 
 Efferocytosis of apoptotic neutrophils is inhibited by bacterial products, i.e., 
LPS, LTA and PGN. These effects are concentration-dependent and the timing of 
response differs between analysed compounds.  
 
 TNF-α inhibits efferocytosis of apoptotic neutrophils in a concentration- and 
time-dependent manner. My preliminary data also suggest that TNF-α-inducible 
cytokine, IL-1β, may exert similar inhibitory effects. 
 
 TNF-α and LPS inhibit the uptake of R-roscovitine-induced apoptotic cells 
but not human IgG-opsonised erythrocytes. On the contrary, dexamethasone 







 The interrelationship between over expression of pro-inflammatory cytokines 
such as TNF-α at inflamed tissues and development of chronic inflammation is not 
fully understood. Since chronic inflammation has been shown to be associated with 
defects in resolution of inflammation (Gilroy et al., 2004;Serhan et al., 2007), I 
hypothesised that the presence of pro-inflammatory mediators may delay the 
resolving phase of inflammation. There are at least two main mechanisms involved in 
resolution of inflammation: inflammatory cell apoptosis and subsequent clearance by 
Mφ (Serhan et al., 2007;Serhan & Savill, 2005;Gilroy et al., 2004). It has been 
previously shown that key pro-inflammatory mediators such as LPS and TNF-α can 
influence the rate of inflammatory cell apoptosis (Lee et al., 1993;Murray et al., 
1997;Ward et al., 1999). The experiments presented in chapter 3 focus on the effects 
of several pro-inflammatory agents, i.e., bacterial products LPS, LTA, PGN (which 
are well-known inducers of TNF-α production) as well as human recombinant TNF-α 
on Mφ clearance of apoptotic neutrophils.  
 Data presented in chapter 3 show for the first time that prolonged treatment 
with LPS decreases the ability of human monocyte derived Mφ to ingest apoptotic 
neutrophils in a concentration- and time-dependent manner. I was particularly 
interested in the effects of prolonged pro-inflammatory challenge that would more 
likely mimic chronic inflammatory conditions. Therefore, I initially, treated human 
monocytes during their differentiation into mature Mφ with LPS for a duration of 96–
144 hours. The inhibition of phagocytosis was observed with concentration of LPS as 
low as 0.1 ng/ml and the effect was positively associated with the increase in LPS 
concentration. Interestingly, when the time-dependence of LPS (10 ng/ml) effects 
was examined, I found that at least 96 hours incubation was required to achieve 
significant reduction in the phagocytosis. This is partially in agreement with the 
observation by McPhillips and colleagues, who demonstrated that treatment of the 
murine Mφ cell line, J774, with 10 ng/ml LPS for 24 hours did not result in decreased 
uptake of apoptotic Jurkat cells (McPhillips et al., 2007). The latter study did not 
examine the effects of LPS treatment for durations longer than 24 hours.  
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 I also used two TLR2 agonists, LTA and PGN, to evaluate their effects on Mφ 
phagocytosis of apoptotic neutrophils. Interestingly, both agents were able to exert 
inhibitory effects, yet, the kinetics of observed inhibition was distinct from that 
induced by LPS. First of all, much higher concentrations of LTA (100 µg/ml) and 
PGN (10 µg/ml) were required to induce significant decreases in phagocytosis levels. 
The minimal time of incubation, which was necessary to observe the inhibitory effect, 
varied between analysed agents. Upon LTA and PGN treatments the inhibition of 
phagocytosis was observed after 16 hours incubation whereas upon LPS treatment 
inhibitory effect occurred only after 96 hours incubation. Interestingly, upon PGN 
treatment, inhibitory effect occurred after 16 hours, then disappeared and occurred 
again after 96 hours.  
 The above-mentioned differences between the inhibitory effects of LPS, LTA 
and PGN may be explained, at least in part, by the fact that LPS is a much more 
powerful activator of immune cells and has a greater efficacy to induce cytokine 
production in Mφ. Several possible mechanisms underlie the lower ability of LTA to 
activate immune cells in experimental settings. First of all, LTA is a major 
immunostimulatory constituent of the Gram-positive bacteria cell wall, which is 
anchored in the bacterial membrane and protrudes through the murein sacculus 
(PGN) (Gutberlet et al., 1997). It has been shown that adhesion of LTA to e.g., a 
polystyrene surface (imitating the physiological situation) drastically increases its 
immunostimulatory potency in comparison to soluble LTA (Deininger et al., 2008). 
The surface presentation of LTA has been associated with 2- to 10-fold enhancement 
of the release of pro-inflammatory cytokines e.g., TNF-α. It has been also reported 
that soluble LTA does not activate JNK, which is crucial for pro-inflammatory 
cytokine production (Draing et al., 2008). In this PhD thesis, the soluble form of LTA 
has been used and this could potentially explain the much lower effect of LTA in 
comparison to LPS. Importantly, the surface presentation of LPS does not further 
increase its immunostimulatory properties (in nature LPS is a constituent of the outer 
bacterial membrane). It has been also suggested that LTA is a major 
immunostimulatory constituent of PGN and, consequently, highly pure (LTA-free) 
PGN does not activate TLR-2 (Travassos et al., 2004). Small amounts of LTA 
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presented in the PGN framework were demonstrated to induce cytokine production, 
probably by reproducing natural conditions (Travassos et al., 2004).  
 There is contradiction in the literature with regard to the role of LBP in LTA-
induced cell activation. While some studies suggest that LBP enhances or has no 
effect on LTA-induced signalling, other studies demonstrate that LBP may actually 
block this process (Schroder et al., 2003;Mueller et al., 2006). This discrepancy may, 
at least in part, result from contamination of commercially available LTA 
preparations with LPS (LBP plays an important role in induction of LPS signalling as 
described in section 1.2.2.1). Importantly, one recent study has demonstrated that the 
activity of pure LTA (no TLR4 activity) is blocked in the presence of soluble LBP 
(Mueller et al., 2006). This is in contrast to LPS, which requires soluble LBP in order 
to be presented to the cell surface receptor TLR4 and exert its pro-inflammatory 
effects. Since in this PhD thesis experiments with LPS, LTA and PGN were 
performed in the serum-supplemented medium (soluble LBP is a serum constituent), 
it is possible that presence of soluble LBP interfered with pro-inflammatory activity 
of LTA in my system.  
 Finally, LPS, LTA and PGN may exert various effects on phagocytosis 
because they stimulate distinct host cell surface receptors (TLR-4 or TLR-2 
respectively). The ‘net’ outcome of TLR-4 and TLR-2 stimulation differ in the 
pattern of released cytokines, e.g., LTA, in contrast to LPS, triggers strong 
chemokine production and almost no IL-12 and IFNγ release (Draing et al., 2008). 
Thus, it is likely that overall differences in the released mediators are responsible for 
the observed various effects of LPS and LTA on phagocytosis. Nevertheless, since 
LPS, LTA and PGN are well-known inducers of TNF-α production I wanted to 
establish the effects of exogenous TNF-α on phagocytosis. Interestingly, in my 
system, TNF-α treatment of monocyte/Mφ resulted in significant reduction of the Mφ 
clearance of apoptotic neutrophils. I also obtained preliminary data demonstrating 
that IL-1β but not IL-6 (TNF-α-inducible cytokines) exerts a similar effect. The TNF-
α-induced inhibitory effects were observed as early as 6 hours after TNF-α treatment 
and were positively associated with the duration of treatment (the maximal inhibition 
was observed after 144 hours treatment). These effects were also concentration-
dependent and 1 ng/ml concentration was sufficient to induce significant inhibition of 
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phagocytosis. Further increase in the TNF-α concentration resulted in additional 
reduction of phagocytosis. This observation is partially consistent with the study by 
McPhillips and colleagues, which demonstrated that short-term treatment (up to 4 
hours) of murine J774 Mφ with TNF-α (1-10 ng/ml) significantly reduced their 
ability to phagocytose apoptotic Jurkat cells (McPhillips et al., 2007). However, in 
the latter study the TNF-α effect disappeared if treatment was performed for longer 
than 4 hours. It is likely that different experimental conditions (possibly the fact that I 
used human cells) contributed, at least partially, to the above-described discrepancy. 
In this PhD thesis, human primary cells have been used (human monocytes and 
neutrophils isolated from peripheral blood), while in the study by McPhillips et al 
experiments were performed with murine J774 Mφ and apoptotic Jurkat cells. 
Furthermore, in this PhD thesis, Mφ were stimulated with human recombinant TNF-α 
and in the study by McPhillips et al with mouse recombinant TNF-α, which could 
potentially affect the kinetics of the response.  
 The study published by McPhillips et al also suggests the possible mechanism 
underlying TNF-α inhibition of phagocytosis. The authors demonstrated that TNF-α 
treatment induced generation of ROS, followed by activation of phospholipase cPLA2 
and upregulation of the active Rho levels. Indeed, the latter effect significantly 
reduces Mφ phagocytosis as described in more detail in section 1.3.3. My data 
complement the observation by McPhillips et al and indicate that TNF-α impairs 
phagocytosis of apoptotic neutrophils. If this is the case in vivo, the presented data 
add more insight into how over expression of TNF-α in inflamed tissue contributes to 
development of chronic inflammatory conditions. Indeed, one recent in vivo study in 
mice has demonstrated that TNF-α inhibits clearance of apoptotic cells by alveolar 
Mφ. This effect was associated with increased lung recruitment of inflammatory 
leukocytes and elevated release of pro-inflammatory cytokines, i.e., IL-6, KC and 
MCP-1 while levels of anti-inflammatory IL-10 and TGF-β remained unaffected 
(Borges et al., 2009).   
 It is also noteworthy that the effect of TNF-α on phagocytosis is suggested to 
be influenced by the degree of Mφ maturation. One study demonstrates that TNF-α 
significantly augments phagocytosis by immature (4 day differentiated) human 
monocyte derived Mφ (Ren & Savill, 1995). This observation has been confirmed by 
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McPhillips et al who demonstrated that TNF-α augmented phagocytosis of apoptotic 
cells by immature Mφ (4 day differentiated) and inhibited phagocytosis by mature 
Mφ (7 day differentiated). Importantly, TNF-α treatment increased the levels of 
active Rho only in mature Mφ while the levels of active Rho in immature Mφ 
remained unaltered. It is therefore possible that, at inflammatory sites, TNF-α can 
inhibit clearance of apoptotic cells by mature Mφ but would not affect phagocytic 
functions of incoming and maturing Mφ. 
 It is intriguing that LPS did not exert inhibitory effects on phagocytosis during 
the first 24 hours of Mφ treatment, particularly since Mφ produce TNF-α as early as 2 
hours after LPS treatment (de Waal et al., 1991). Furthermore, as shown in Figure 
3.5B, TNF-α inhibited Mφ phagocytosis of apoptotic neutrophils after 6 hours 
incubation (shorter durations of time have not been here studied) and according to 
McPhillips et al Mφ treated with TNF-α for 20 minutes had reduced ability to 
phagocytose apoptotic cells. In this PhD study, after 6 hours treatment with LPS, 
minor decreases in the phagocytosis levels have been observed for each individual 
experiment. Yet, statistical analysis demonstrates that these results, when plotted 
together, are not significantly different from controls (Figure 3.2B). The lack of the 
significant inhibitory effect of LPS during the first 24 hours of treatment could be 
explained, at least in part, by findings by Ding and colleagues (Ding et al., 1989). The 
authors demonstrated that during endotoxinaemia Mφ and some other host cells may 
be unresponsive to TNF-α because such cells internalise their TNF-Rs in response to 
LPS prior to TNF-α production. The latter effect was dependent on both the 
concentration of LPS and duration of treatment (1 hour treatment with 10 ng/ml LPS 
resulted in a complete loss of cell surface TNF-α binding sites). Furthermore, authors 
of this study provided several lines of evidence indicating that this effect is mediated 
by LPS per se and that TNF-α, which is released from Mφ in response to LPS, is 
responsible for only a minor portion of TNF-Rs internalisation. Interestingly, in this 
PhD thesis high concentrations of TNF-α were detected at Mφ culture supernatants at 
6 hours after treatment with 10 ng/ml LPS (data presented in Figure 5.1, chapter 5). 
Therefore, one may speculate that Mφ treated with LPS are unresponsive to TNF-α at 
early time points or endogenously produced TNF-α does not mediate inhibitory 
effects of LPS. I performed a number of experiments in order to shed more light into 
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significant delay of LPS-inhibitory effects. They included depletion of endogenously 
produced TNF-α from culture medium, treatment with anti-inflammatory cytokine 
IL-10 or assessment of phagocytosis by IL-10 deficient BMDMφ. The results are 
presented and discussed in the following chapters.  
 It is believed that apoptotic cells are cleared by mechanisms different from 
those that are implicated in the phagocytosis of necrotic or opsonised cells (Hart et 
al., 2004b). Thus, control experiments have been performed, in which I tried to 
establish specificity of TNF-α or LPS effects on phagocytosis. For this purpose, in 
order to obtain negligible levels of necrosis, human neutrophils have been 
synchronised in apoptosis with the use of R-roscovitine (8 hours treatment). The Mφ 
uptake of R-roscovitine-induced apoptotic neutrophils (Rossi et al., 2006) was 
inhibited by both TNF-α and LPS further supporting my findings. Next, I examined 
the effects of TNF-α and LPS on the Mφ uptake of human IgG-opsonised 
erythrocytes. Interestingly, this process was not affected by TNF-α and LPS 
treatments indicating that pro-inflammatory stimuli do not block all phagocytic 
pathways in Mφ. This observation is in agreement with previously published data 
(Rossi et al., 1998b) demonstrating that Mφ phagocytosis of apoptotic neutrophils is 
regulated by mechanisms distinct from those modulating phagocytosis of cells coated 
with IgG and complement (Michlewska et al., 2007;Ravichandran & Lorenz, 2007). 
Interestingly, opsonins such as antibodies or complement have been shown to bind to 
apoptotic cells and enable their clearance via classical phagocytic receptors, such as 
Fc receptors. For instance, patients with antiphospholipid syndrome (APLS) are 
characterised by elevated levels of ‘antiphospholipid antibodies’ including β2-
glycoprotein I (β2-GPI) antibodies, which bind to the surface of apoptotic cells and 
augment their clearance by immature dendritic cells (Rovere et al., 1998). The latter 
observation suggests an important role in antigen presentation and exacerbation of 
autoimmune disease. In addition, C1q deficiency in SLE is associated with reduced 
phagocytosis of apoptotic cells (Michlewska et al., 2007). As discussed in section 
1.3.2.4 the outcome of phagocytosis may differ depending on the type of removed 
particles. In general, phagocytosis of apoptotic cells is thought to be anti-
inflammatory and to actively inhibit release of pro-inflammatory mediators such as 
TNF-α, IL-1β or IL-8 and promote the secretion of anti-inflammatory cytokines 
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including TGF-β, PGE2 or IL-10 (Fadok et al., 1998;Voll et al., 1997). Furthermore, 
in vivo studies showed that in a murine model of LPS-induced endotoxic shock 
administration of apoptotic cells protect mice from LPS-induced death (Ren et al., 
2008). The latter effect was associated with decreased levels of circulating pro-
inflammatory cytokines such as TNF-α, inhibition of neutrophil recruitment and 
reduction in LPS serum levels. On the contrary, phagocytosis of opsonised particles is 
considered to be pro-inflammatory and stimulate release of pro-inflammatory 
cytokines e.g., TNF-α (Fadok et al., 2001). For instance, in Wegener’s 
granulomatosis, opsonisation of apoptotic neutrophils with anti-neutrophil 
cytoplasmic antibodies (ANCA) has been demonstrated to augment their clearance by 
Mφ (Moosig et al., 2000). This effect was associated with increased production of 
TNF-α. TNF-α may then stimulate recruitment of further neutrophils, which are 
cleared in a similar way stimulating further release of TNF-α and exacerbation of 
inflammation. Interestingly, in this study phagocytosis of apoptotic cells opsonised 
with IgG did not result in induction of TNF-α release but since other studies suggest 
otherwise no final consensus has been reached with this regard. Data presented in this 
PhD thesis demonstrate that TNF-α inhibits clearance of apoptotic neutrophils, but 
not opsonised erythrocytes. These results suggest that even though TNF-α inhibits 
phagocytosis of apoptotic cells, these cells may undergo opsonisation and be cleared 
via Fc receptors (preventing secondary necrosis and exacerbation of inflammation). 
Yet, in the recent study by McPhilips et al, mice injected intraperitoneally with TNF-
α and apoptotic thymocytes were characterised by decreased phagocytosis in 
comparison to control animals (McPhillips et al., 2007). These findings indicate that 
over expression of TNF-α in inflamed tissue may indeed lead to accumulation of 
apoptotic cells, their secondary necrosis and exacerbation of inflammation. Thus, 
further in vivo studies are required in order to fully establish immunological 
consequences of the inhibition of apoptotic cell clearance by TNF-α in humans.  
 In summary, data presented in this chapter demonstrate that the presence of 
TNF-α during monocyte differentiation into Mφ significantly affects their ability to 
phagocytose apoptotic neutrophils but not human IgG-opsonised erythrocytes. 
Interestingly, the general pro-inflammatory activators of Mφ, namely LPS, LTA and 
PGN were shown to exert similar albeit delayed inhibitory properties (the next 
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chapters give more insight into this phenomenon). One important finding presented in 
this chapter is a differential effect of TNF-α and LPS on clearance of apoptotic and 
opsonised targets. If this occurs in vivo, it is likely that at the inflammatory site TNF-
α blocks clearance of apoptotic neutrophils by Mφ enabling more efficient removal of 
foreign organisms or opsonised particles. The latter effect seems to be more 
beneficial at the onset of inflammation, when phagocytosis of apoptotic immune cells 
is not necessary. However, if inflammatory processes are associated with excessive or 
prolonged exposure to TNF-α, removal of apoptotic cells is impaired leading to cell 
necrosis, subsequent tissue damage and development of many pathological 
conditions. Alternatively, apoptotic neutrophils may bind numerous opsonins and be 
cleared via other phagocytic receptors. The immunological outcome of the latter 
process may vary depending on numerous factors (e.g., type of opsonins) and in some 
circumstances it may be associated with the release of pro-inflammtory mediators and 
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 Data presented in chapter 3.3 demonstrate that treatment of MDMφ with the 
pro-inflammatory cytokine TNF-α significantly decreases MDMφ ability to 
phagocytose apoptotic neutrophils. This effect was observable as early as 6 hours 
after TNF-α treatment. Interestingly, when Mφ were treated with other Mφ activators 
such as LPS, LTA or PGN, inhibitory effects also occurred, yet, after much longer 
incubation (LPS > 96 hours, LTA > 16 hours, PGN > 16 hours). It is noteworthy that 
LPS, LTA and PGN are well-known inducers of TNF-α production. Inhibition of 
phagocytosis was the strongest and, intriguingly, the most delayed when Mφ were 
treated with LPS. Thus, I have chosen LPS for further investigation.  
 A number of studies have demonstrated that LPS-treated cells release TNF-α 
as early as 2 hours following stimulation and TNF-α production is maximal after 6 
hours (de Waal et al., 1991). Interestingly, in this PhD thesis, phagocytosis by LPS-
treated MDMφ has not been significantly reduced at such early time points. These 
observations suggest that, in my system, LPS-induced inhibition of phagocytosis is 
not necessarily mediated by TNF-α production. Alternatively, other mechanisms may 
interfere with either production or action of TNF-α.  
 In experiments presented in chapter 4 I attempted to establish whether LPS-
induced inhibition of phagocytosis is mediated by induction of TNF-α production. 
Specifically, I sought to investigate if depletion of biologically active TNF-α in 
MDMφ culture rescued phagocytosis inhibited by LPS treatment. For this purpose 
several reagents have been used including two soluble TNF R1 (sTNF-R1/Fc and 
sTNF-R1) and the TACE inhibitor, TOPI-0. The sTNF-Rs bind sTNF-α in culture 
supernatants and reduce its bioactivity. Their role in treatment of chronic 
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inflammatory conditions characterised by an excess of TNF-α is well-established and 
discussed in section 1.5.3. In contrast, TACE inhibitors block processing of 26 kDa, 
membrane-bound TNF-α into its soluble form and consequently reduce sTNF-α 
concentration in culture supernatants. All experiments presented in chapter 4 have 
been performed with human blood monocytes, differentiated into MDMφ over 6 day 
culture and treated with LPS and increasing concentrations of the specific TNF-α 
inhibitor. On day 6 of the culture phagocytosis of human apoptotic neutrophils were 
assessed by flow cytometry. The levels of phagocytosis were compared to medium 
control or LPS treated samples. The ability of TNF-α inhibitors to bind and reverse 
the effects of TNF-α present in culture medium was evaluated by treatment of 










4.2.1 ISOLATION AND CULTURE OF HUMAN BLOOD 
CELLS  
 Human blood cells were isolated by Percoll™ gradient centrifugation, 
following a protocol described in section 2.2.1.1. Subsequently, human monocytes 
were cultured for 6 days in culture medium (see section 2.2.1.3 for culture conditions) 
undergoing differentiation into mature human MDMφ. During this time MDMφ were 
treated with a number of pro- and anti-inflammatory agents. In experiments described 
in this chapter human monocytes were treated with TNF-α and LPS at a concentration 
of 10 ng/ml (96-144 hours), sTNF-R1/Fc using a range of concentrations: 5–500 
ng/ml (96-144 hours), sTNF-R1 using a range of concentrations: 62.5-1000 ng/ml 
(96-144 hours) or TACE inhibitor–TOPI-0 using a range of concentrations: 0.1–10 
ng/ml (96-144 hours).  
 On day 6, MDMφ were assessed for their ability to phagocytose human 
apoptotic neutrophils that had undergone constitutive apoptosis for 20 hours of 
culture (see section 2.2.1.3 for culture conditions).  
 
4.2.2 ASSESSMENT OF APOPTOSIS AND NECROSIS 
 Prior to the phagocytosis assay, the % of apoptotic cells within neutrophil 
populations was assessed by morphology (see section 2.3.1 for experimental 
protocol) or alternatively by Annexin-V binding assessed by flow cytometry (see 
section 2.3.2 for experimental protocol). The % of necrotic cells was assessed by PI 
staining assessed by flow cytometry. Only neutrophils with less than 5 % of necrosis 
were used in the phagocytosis assay. 
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4.2.3 ASSESSMENT OF PHAGOCYTOSIS BY FLOW 
CYTOMETRY 
 In all the experiments described in this chapter phagocytosis was assessed by 
flow cytometric analysis that employs labelling of phagocytic targets with FL1+ Cell 
Tracker™ Green (CMFDA) prior to the phagocytosis assay. Following the 
phagocytosis assay, the % of FL1+ MDMφ (MDMφ that had engulfed phagocytic 
targets) within the entire MDMφ population was assessed by flow cytometry as 
described in section 2.4.1.1.  
 
4.2.4 BINDING OF sTNF-R1/Fc AND IC TO THE 
SURFACE OF HUMAN APOPTOTIC NEUTROPHILS  
 The sTNF-R1/Fc is a chimeric protein containing an Fc region of human 
IgG1. Thus, it is potentially able to induce Fc-mediated phagocytosis in similar way 
to immune-complexes (IC, heat-aggregated IgG) (Hart et al., 2004a). I therefore 
compared binding of sTNF-R1/Fc and IC to the surface of human apoptotic 
neutrophils, cultured for 20 hours (see section 2.2.1.3 for culture conditions) prior to 
the binding assay described in section 2.6.  
 
4.2.5 MEASUREMENT OF CYTOKINE LEVELS AFTER 
LPS STIMULATION  
 In experiments described in section 4.3 MDMφ were treated for 120 hours 
with 10 ng/ml LPS. Prior to assessment of MDMφ efferocytosis, cytokine levels in 
MDMφ culture supernatants were determined. To quantify cytokine concentrations, a 





4.3.1 THE ABILITY OF MDMΦ TO PHAGOCYTOSE 
APOPTOTIC NEUTROPHILS IS CORRELATED WITH 
THE LEVELS OF TNF-α IN CULTURE MEDIUM 
 Figure 4.1 depicts a scatter diagram where paired data showing % 
efferocytosis upon treatment with 10 ng/ml LPS (96–144 hours) versus % 
efferocytosis in control conditions are plotted (n = 40). MDMφ were cultured for 6 
days and phagocytosis was assessed by flow cytometry. Even though the inhibitory 
effect of LPS is highly significant (p<0.001), some variation was found in MDMφ 










FIGURE 4.1 Variability of LPS effects upon efferocytosis. The scatter diagram 
demonstrates paired data (control efferocytosis versus efferocytosis upon LPS treatment) 
from 40 experiments. 
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 I hypothesised that the extent of inhibition of efferocytosis induced by LPS 
was dependent on endogenous TNF-α production by cultured MDMφ and 
consequently on the concentration of TNF-α in culture medium prior to the 
phagocytosis assay. To test this, monocytes were isolated from 6 selected donors, 
where I previously observed variability in response to LPS. Monocytes were cultured 
for 6 days, treated with 10 ng/ml LPS for 120 hours. On day 6 we performed paired 
experiments (schematic representation is displayed in Figure 4.2) that involved 
collection of culture supernatants, measurement of cytokines by CBA and, in parallel, 
assessment of MDMφ ability to phagocytose apoptotic neutrophils by flow 
cytometric analysis. As shown in Figure 4.3 the % of MDMφ ingesting apoptotic 
neutrophils was negatively correlated with the concentration of TNF-α in the 
supernatants (R2 = 0.84). In addition, I observed an interesting correlation between 
efferocytosis and concentrations of TNF-α and IL-10. Figure 4.4 depicts levels of 
TNF-α and IL-10 in MDMφ culture supernatants for two separate experiments. In the 
first experiment (Figure 4.4A), LPS treatment exerted a strong inhibitory effect upon 
efferocytosis and culture supernatants were characterised by high concentrations of 
TNF-α (above 15 ng/ml) and low levels of IL-10 (approximately 0.3 ng/ml). In the 
second experiment (Figure 4.4B), LPS treatment was associated with augmentation of 
phagocytosis and, interestingly, levels of TNF-α in culture supernatants were 




FIGURE 4.2 Schematic representation of paired experiments performed to 
examine correlations between TNF-α concentrations and efferocytosis. MDMφ 
were cultured for 6 days and treated for 120 hours with 10 ng/ml LPS. On day 6, just 
prior to the efferocytosis assay: 1) culture supernatants were collected and subjected 
to CBA analysis, 2) apoptotic neutrophils (cultured for 20 hours) were added to 









FIGURE 4.3 The effect of LPS on MDMφ efferocytosis is associated with the 
concentrations of TNF-α in the culture medium. Monocytes isolated from blood of 
6 donors were cultured for 6 days and treated with 10 ng/ml LPS for 120 hours. On 
day 6, culture supernatants were collected and TNF-α levels were measured by CBA 
while efferocytosis was assessed by flow cytometry. Negative correlation (R2=0.84) 
was identified between efferocytosis levels and TNF-α concentrations. For 
comparisons, efferocytosis levels were normalised (medium control levels 








FIGURE 4.4 Low TNF-α production upon LPS treatment is associated with 
elevated IL-10 release. Human MDMφ were cultured for 6 days and treated with 10 
ng/ml LPS for 120 hours. On day 6, culture supernatants were collected and TNF-α 
and IL-10 levels were measured by CBA while efferocytosis was assessed by flow 
cytometry. Concentrations of TNF-α and IL-10 are demonstrated for two separate 
experiments, where LPS treatment induced A. strong inhibitory effect upon 




4.3.2 DEPLETION OF TNF-α IN CULTURE MEDIUM 
REVERSES THE INHIBITORY EFFECT OF LPS ON 
MDMΦ EFFEROCYTOSIS OF APOPTOTIC 
NEUTROPHILS  
 Having found that exogenous TNF-α inhibits MDMφ phagocytosis of 
apoptotic neutrophils (Figure 3.5) and that variability of responses to LPS treatment 
is correlated with various levels of TNF-α in culture supernatants (Figure 4.3), I 
hypothesised that LPS-mediated effects were dependent upon production of 
endogenous TNF-α by MDMφ. Thus, I next aimed to rescue MDMφ efferocytosis 
upon LPS treatment by reducing the biological activity of TNF-α produced by 
MDMφ. For this purpose I used sTNF-R1/Fc that binds TNF-α present in the culture 
medium. Human monocytes were cultured for 6 days in culture medium (control) or 
co-treated for 120 hours with 10 ng/ml LPS or 10 ng/ml TNF-α +/- increasing 
concentrations of sTNF-R1/Fc. I showed that addition of 500 ng/ml sTNF-R1/Fc 
reversed both exogenous TNF-α and LPS-mediated inhibition of efferocytosis back to 
control levels (30.5 ± 3.5 %). The % of phagocytosis when cells were treated with 
LPS alone was 11.4±1.1 % and for TNF-α alone was 14.2±2.3 % whereas addition of 
sTNF-R1/Fc enhanced efferocytosis up to 32.1±4.1 % and 30.1±5.0 % respectively 
(p<0.01; n = 4) (Figure 4.5A). Addition of sTNF-R1/Fc to control MDMφ (no LPS or 
TNF-α treatment) did not augment efferocytosis per se (28.9 ± 3.5 %). Representative 
flow cytometric dot-plot profiles demonstrating reversal of inhibitory effects of LPS 






FIGURE 4.5 Neutralization of TNF-α released by LPS-stimulated MDMφ rescue 
efferocytosis. A. Human MDMφ were cultured for 6 days in culture medium alone or 
treated on average for the duration of 96-144 hours with 10 ng/ml LPS or 10 ng/ml 
TNF-α +/- increasing concentrations of sTNF-R1/Fc, as indicated. On day 6 MDMφ 
efferocytosis was assessed by flow cytometric analysis. Data shown as mean ± SEM 
for n=4 separate experiments. Significant differences for comparisons to appropriate 
controls (treatments with LPS or TNF-α alone) are represented by **p<0.01. B. 
Representative flow cytometric dot-plot profiles demonstrating levels of efferocytosis 
for controls and treatments with either 10 ng/ml LPS alone or 10 ng/ml LPS with 500 
ng/ml sTNF-R1/Fc. aNφ – apoptotic neutrophils. 
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4.3.3 sTNF-R1/Fc DOES NOT INDUCE Fc-DIRECTED 
PHAGOCYTOSIS AND PRIMARILY DEPLETES TNF-α IN 
CULTURE MEDIUM  
 sTNF-R1/Fc is a chimeric protein containing two subunits of sTNF-R1 and an 
Fc region of human IgG1. Dimeric sTNF-R1s were previously shown to be 
approximately 45-fold more potent inhibitors of TNF-α than the monomeric sTNF-
R1s (Aggarwal & Natarajan, 1996). However, the presence of an Fc region in sTNF-
R1/Fc raises the possibility that, in my system, reversal of the inhibitory effect of LPS 
and TNF-α is accomplished not only by a decrease in TNF-α activity but also by 
induction of Fc mediated phagocytosis, similar to augmentation of phagocytosis by 
immune-complexes (heat-aggregated IgG) (Hart et al., 2004a). It has been reported 
that binding of ICs to Fc receptors is a rapid process and 0.5 hour is sufficient to 
obtain optimal opsonisation (Hart et al., 2004a). Thus, a series of controls were 
performed comparing effectiveness of sTNF-R1/Fc (500 ng/ml) on reversal of LPS- 
or TNF-α-induced inhibition of phagocytosis. In all the experiments monocytes were 
cultured for 6 days in culture medium alone or treated for 96 hours with either TNF-α 
(10ng/ml) or LPS (10 ng/ml). sTNF-R1/Fc was added either synchronically with LPS 
(10 ng/ml) or TNF-α (10ng/ml) for 96 hours to monocyte culture or only for the last 
30 minutes of the MDMφ or neutrophil culture, just prior to the phagocytosis assay. 
Alternatively, sTNF-R1/Fc was added directly to the phagocytosis assay (1 hour), 
where both MDMφ and apoptotic neutrophils were present. As indicated in Figure 
4.6A, the presence of sTNF-R1/Fc in monocyte culture for 96 hours significantly 
reversed the inhibitory effects of LPS and TNF-α. However, sTNF-R1/Fc added for 
short durations of time (0.5 and 1 hour), sufficient for binding to the cell surface 
receptors, but not sufficient to neutralise TNF-α throughout the culture, did not have 
any effect on efferocytosis in comparison to appropriate controls. Furthermore, I 
compared binding of sTNF-R1/Fc and heat aggregated IgGs (immune complexes), to 
the aged (20 hours) neutrophils. Neutrophils, in this experiment, were cultured in 
IMDM with 10 % FCS (human IgG free). As shown in Figure 4.6B, following 30 min 
incubation, more than 98% of neutrophils (viable and apoptotic) were opsonised with 
 141
ICs whereas more than 98% did not bind sTNF-R1/Fc, excluding possibility of Fc 
induced augmentation of efferocytosis in my study. Since nonspecific binding of anti-
human IgG antibodies to necrotic cells (less than 10 %) were detected (no difference 










FIGURE 4.6 sTNF-R1/Fc does not facilitate Fc mediated efferocytosis (next 
page). A. Human MDMφ were cultured for 6 days in culture medium or treated for 
the duration of 96 hours with either 10 ng/ml LPS or 10 ng/ml TNF-α alone. sTNF-
R1/Fc was added to MDMφ or alternatively to apoptotic (20 hours culture) 
neutrophils at various times or was present in the efferocytosis assay, as indicated. On 
day 6 MDMφ efferocytosis was assessed by flow cytometric analysis. Data shown as 
mean ± SEM for n=4 separate experiments. Significant differences for comparisons 
to appropriate controls (samples treated only with LPS or TNF-α) are represented by 
*p<0.05 and ***p<0.001. B. Apoptotic neutrophils, cultured for 20 hours in Iscove’s 
DMEM with 10% FCS, were incubated for 20 minutes in flow buffer alone (control) 
or with 500ng/ml sTNF-R1/Fc or 100µg/ml heat aggregated IgGs-immune-
complexes, washed twice and incubated with anti-human IgG antibody. Percentage of 
apoptotic neutrophils was assessed by annexin-V binding assay. Nφ–neutrophils, 




























4.3.4 THE EFFECT OF MONOMERIC sTNF-R1 ON LPS- 
OR TNF-α-INDUCED INHIBITION OF MDMφ 
EFFEROCYTOSIS 
 Having successfully reversed the inhibitory effect of LPS and TNF-α on 
efferocytosis with the use of sTNF-R1/Fc I aimed to investigate if its monomeric 
form – sTNF-R1 would have a similar effect. Previously published data showed that 
the monomeric form of sTNF-R1 is a much weaker inhibitor of the biological action 
of TNF-α in comparison to its chimeric form (Aggarwal & Natarajan, 1996). To 
examine this, human blood monocytes were differentiated for 6 days and co-treated 
on average for 96-144 hours with 10 ng/ml LPS or 10 ng/ml TNF-α alone or with 
addition of increasing concentrations (125, 250, 500 and 1000 ng/ml) of sTNF-R1. 
As indicated in Figure 4.7 treatment with sTNF-R1 did not significantly rescue 
efferocytosis that was inhibited with LPS or TNF-α treatment. However, it is 
noteworthy that in the presence of sTNF-R1, Mφ in samples treated with either LPS 
or TNF-α showed a slight tendency for an increase in efferocytosis levels. The effect 
appears to be concentration-dependent; 1 µg/ml sTNF-R1 had the most prominent 
effect and increased efferocytosis upon LPS treatment from 14.1 ± 5.6 % up to 21.8 ± 
8.5 % and upon TNF-α treatment from 18.3 ± 3.2 % up to 22.9 ± 4.9%. Medium 
control levels were 36.6 ± 2.1% and interestingly MDMφ treated with 1 µg/ml sTNF-








FIGURE 4.7 Effect of sTNF-R1 on LPS– or TNF-α–induced inhibition of 
MDMφ efferocytosis. A. Human MDMφ were cultured for 6 days in culture medium 
alone or treated on average for the duration of 96-144 hours with 10 ng/ml LPS or 10 
ng/ml TNF-α +/- increasing concentrations of sTNF-R1, as indicated. On day 6 
MDMφ efferocytosis was assessed by flow cytometric analysis. Data shown as mean 
± SEM for n=4 separate experiments  
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4.3.5 THE EFFECT OF TNF-α CONVERTING ENZYME 
INHIBITOR ON LPS- OR TNF-α-INDUCED INHIBITION 
OF MDMΦ EFFEROCYTOSIS  
 Another approach has been also applied to rescue efferocytosis upon LPS 
treatment involving inhibition of the activity of TNF-α Converting Enzyme (TACE). 
TACE processes membrane bound proTNF-α to its active soluble form (TNF-α) and 
therefore TACE inhibitors reduce TNF-α production by LPS-stimulated cells 
(Newton et al., 2001). Thus, I hypothesised that a TACE inhibitor would interfere 
with the inhibitory effect of LPS but not exogenous TNF-α on MDMφ efferocytosis. 
To verify this, human blood monocytes were differentiated for 6 days and co-treated 
for 96-144 hours with 10 ng/ml LPS or 10 ng/ml TNF-α alone or with addition of 
increasing concentrations (0.1, 1 and 10 ng/ml) of TACE inhibitor–TOPI-0. As 
indicated in Figure 4.8 treatment with TOPI-0 did not significantly reverse LPS- or 
TNF-α–induced inhibition of efferocytosis. However, I observed a tendency for the 
elevation of phagocytosis levels when increasing concentrations of TOPI-0 were 
added into LPS treated samples. The phagocytosis levels were 19.1 ± 2.2 % for LPS 
treatment and increased up to 27.5 ± 3.5 % for combined LPS and 10 ng/ml TOPI-0 
treatments. Interestingly, control treatment with 10 ng/ml TOPI-0 alone reduced 
efferocytosis from control levels 33.9 ± 1.4 % to 27.9 ± 3.0 %. A similar pattern was 
identified for samples treated with TNF-α, where in samples treated with TNF-α 
alone levels of efferocytosis were 19.6 ± 2.8 % and addition of 10 ng/ml TOPI-0 









FIGURE 4.8 Effect of the TNF-α converting enzyme (TACE) inhibitor, TOPI-0, 
on inhibition of MDMφ efferocytosis by LPS and TNF-α. Human MDMφ were 
cultured for 6 days in culture medium alone or treated on average for the duration of 
96-144 hours with 10 ng/ml LPS or 10 ng/ml TNF-α +/- increasing concentrations of 
TOPI-0, as indicated. On day 6 MDMφ efferocytosis was assessed by flow 









4.3.6 SUMMARY OF THE RESULTS 
 
 The LPS inhibitory effect on phagocytosis is positively correlated with the 
TNF-α concentration in MDMφ culture supernatants. In addition, decreased TNF-α 
concentrations and a lack of LPS inhibitory effects on phagocytosis are associated 
with elevated IL-10 concentrations. 
 
 The addition of sTNF RI/Fc to MDMφ treated with either LPS or TNF-α 
rescues MDMφ ability to phagocytose apoptotic neutrophils. This effect occurs only 
if sTNF RI/Fc is present during the entire duration of either LPS or TNF-α treatment. 
sTNF RI/Fc does not bind to the surface of apoptotic neutrophils and, thus, does not 
trigger Fc-mediated phagocytosis. 
 
 The addition of monomeric sTNF RI or the TACE inhibitor, TOPI-0, to 
MDMφ treated with either LPS or TNF-α does not rescue MDMφ ability to 






 TNF-α is one of the most rapidly released cytokines after trauma or infection 
(e.g., exposure to bacterial derived LPS) and is one of the most abundant mediators in 
inflamed tissues (Feldmann et al., 1994). The data presented in chapter 3, as well as 
recent findings by McPhillips and colleagues, clearly demonstrate that treatment of 
Mφ with TNF-α greatly reduces their ability to phagocytose apoptotic neutrophils 
(McPhillips et al., 2007). LPS, LTA or PGN are activators of Mφ and short-time 
stimulation is sufficient to induce significant TNF-α release from these cells (de Waal 
et al., 1991;Wang et al., 2000). However, in this PhD thesis, inhibition of 
phagocytosis by LPS appeared after at least 96 hours incubation. Therefore, in the 
experiments presented in chapter 4, I tried to establish whether TNF-α primarily 
mediates inhibitory effects of LPS on phagocytosis in my system.  
 One interesting aspect of LPS-induced inhibition was the variability of the 
responses. As demonstrated in figure 4.1., when Mφ were treated with 10 ng/ml LPS 
the levels of phagocytosis varied between donors. Even though LPS exerted its 
inhibitory effects in the majority of experiments, in some cases I did not observe 
inhibition. This has been investigated further (paired experiments presented in figure 
4.2) and significant positive correlation has been identified between levels of 
inhibition and concentrations of TNF-α in Mφ culture supernatants. It is noteworthy, 
that in samples, in which presence of LPS did not cause inhibition, TNF-α levels were 
undetectable. This led to the formation of a hypothesis that upon LPS treatment, 
TNF-α may indeed, at least in part, mediate inhibition of phagocytosis in my system. 
To investigate this further, several approaches have been used, all of them aiming at 
reduction of either the concentration or bioactivity of TNF-α released by Mφ into 
culture medium upon treatment with LPS. 
 One regulator of TNF-α action occurring in physiological conditions is a 
sTNF-R (Tracey et al., 2008). It is believed that soluble cytokine receptors act as 
cytokine ‘carriers’ and change the biodistribution of the interacting cytokine in 
natural settings. It has been also demonstrated that in vivo administration of 
recombinant soluble receptors may antagonise immune and inflammatory processes. 
In this PhD thesis, two different sTNF-R1s were used to reduce biologic activity of 
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TNF-α, namely monomeric sTNF-R1 and a dimeric sTNF-R1/Fc. The latter is a 
fusion protein, composed of two subunits of sTNF-R1 and Fc portion of human IgG1. 
As indicated in Figure 4.5, the presence of sTNF-R1/Fc at its highest concentration 
(500 ng/ml) reversed the inhibitory effects of both LPS and exogenous TNF-α in our 
system, suggesting its ability to bind TNF-α in culture medium. Interestingly, when 
monomeric sTNF-R1 was used no significant reversal of the inhibitory effects of LPS 
and TNF-α on phagocytosis was observed (Figure 4.7). A few possible explanations 
behind this observation are presented in the following paragraphs.  
 The sTNF-R1/Fc, in contrast to sTNF-R1, contains the Fc portion of human 
IgG1. Therefore, one may speculate that the augmentation of phagocytosis observed 
upon addition of sTNF-R1/Fc to LPS treated Mφ may result from induction of Fc-
mediated phagocytosis. This process occurs when phagocytic targets are opsonised 
with IgG antibodies, which Fc portions are recognised by Fc receptors on the surface 
of Mφ, e.g., phagocytosis of immune-complexes (IC) (Hart et al., 2004a). A couple of 
control experiments have been performed to investigate if in our study Fc-mediated 
phagocytosis plays an important role in the reversal of LPS- and TNF-α- induced 
inhibitory effects. As shown in Figure 4.6, I was able to demonstrate that sTNF-
R1/Fc, in contrast to ICs, does not have the ability to opsonise human apoptotic 
neutrophils. In addition, sTNF-R1/Fc reversed inhibitory effects of LPS providing it 
was added concurrently with LPS. Even though opsonisation is a very quick process, 
30-60 minutes incubation of cells with sTNF-R1/Fc at the end of the culture or during 
the phagocytosis assay was not sufficient to achieve augmentation of phagocytosis. 
Taken together, the above findings clearly suggest that sTNF-R1/Fc reduces the 
biological activity of TNF-α in our system and that this effect is primarily implicated 
in the reversal of the inhibitory effects of LPS and TNF-α on phagocytosis.  
 The sTNF-R1/Fc used in this thesis is composed of two subunits of sTNF-R1. 
This is in contrast to sTNF-R1, which is a monomeric molecule. This difference may 
contribute, at least in part, to the much greater ability of sTNF-R1/Fc to bind TNF-α 
and reverse inhibitory effects of LPS on phagocytosis. Naturally occurring TNF-Rs 
are type I membrane receptors, which are characterised by one to six extracellular 
cysteine-rich domains (CRDs) (Chan, 2007). These domains and especially the 
membrane-distal first CRD, termed pre-ligand assembly domain (PLAD), have been 
 150
demonstrated to play an important role in the formation of homotypic, ligand-
independent receptor complexes. For instance, the unliganded structure of TNF-R1 
was demonstrated to be a dimer (Naismith et al., 1996). Therefore, the structure of 
sTNF-R1/Fc used in this study is similar in its structure to the naturally occurring 
membrane-bound dimeric receptors. The latter may explain the high affinity of sTNF-
R1/Fc to TNF-α. Furthermore, several studies reported that monomeric TNF-Rs, in 
comparison to its dimeric forms, have severely compromised ability to bind ligands 
(Scallon et al., 1995b;Mohler et al., 1993). Furthermore, linkage of the Fc portion of 
IgG to the sTNF-R has been shown to change its pharmacokinetic parameters and 
significantly prolong its serum half-life. The latter likely contribute to the greater 
efficacy in neutralising TNF-α (Jacobs et al., 1993). 
 Another interesting difference between sTNF-R1 and sTNF-R1/Fc used in 
this PhD thesis is their effects on control Mφ. As demonstrated in Figure 4.5 and 4.7 
greater concentrations of monomeric sTNF-R1 reduced ability of Mφ to phagocytose 
apoptotic neutrophils whereas sTNF-R1/Fc did not exert such an effect. Interestingly, 
the study by Mohler and colleagues reports that monomeric sTNF-R2 or low 
concentrations of sTNF-R2/Fc have agonistic effects on release of TNF-α (Mohler et 
al., 1993), which could potentially explain the reduction in phagocytosis levels in our 
control samples. It is possible that in the case of high concentrations of sTNF-R1 two 
independent albeit opposing processes take place, induction of TNF-α release and 
binding of released TNF-α. Since LPS per se is a strong inducer of TNF-α production 
and therefore greatly inhibits phagocytosis, it is likely that in LPS treated samples 
sTNF-R1 does not further augment TNF-α release and the inhibitory effect of sTNF-
R1 on phagocytosis does not occur. However, the concentrations and bioactivity of 
TNF-α in culture supernatants have not been measured and I was not able to draw any 
final conclusions with this regard.  
 In summary, my findings suggest that TNF-α is a primary mediator involved 
in the inhibition of phagocytosis by LPS. I was able to demonstrate the successful 
reversal of LPS- or TNF-α-induced inhibition of phagocytosis with the use of sTNF-
R1/Fc but not sTNF R1. This is in agreement with previously published data 
suggesting that dimeric sTNF-Rs are more powerful inhibitors of TNF-α than 
monomeric sTNF-Rs. TNF-α is not only a ‘master regulator’ of pro-inflammatory 
 151
cytokine production (Maini et al., 1995) but also regulates many inflammatory 
processes such as inflammatory cell activation and recruitment and, thus, is likely a 
key molecule involved in development of chronic inflammation (Clark, 2007). 
Consequently, TNF-α inhibitors such as infliximab (mouse-human chimeric 
antibody), adalimumab (human monoclonal antibody) or etanercept (TNF receptor II-
IgG fusion protein) have been shown to have therapeutic benefit in treatment of 
chronic inflammatory conditions (Feldmann, 1996;Feldmann & Maini, 2003). 
Etanercept is a bivalent receptor that binds TNF-α with 50-1000 times higher affinity 
to TNF-α than monomeric sTNF-Rs and linkage of Fc portion of IgG significantly 
prolongs its half-life (Mazzon & Cuzzocrea, 2008). So far, it has not been fully 
understood why binding and deactivation of TNF-α at inflamed tissues leads to 
resolution of inflammation. Here, evidence is given that excess TNF-α in inflamed 
tissue may result in insufficient clearance of apoptotic neutrophils and potentially 
other apoptotic cells and that neutralisation of TNF-α by means of TNF-α inhibitors 
rescues phagocytosis. As shown in Figure 4.5, sTNF-R1/Fc reduces the biological 
activity of TNF-α and reverses the inhibitory effects of pro-inflammatory stimuli 
(LPS) on efferocytosis. Moreover, one study demonstrates that binding of mTNF-α 
on the cell surface induces antibody-dependent and complement-dependent 
cytotoxicity and results in lysis of cell expressing TNF-α (Scallon et al., 1995a). The 
latter may provide an additional mechanism contributing to the therapeutic effects of 
TNF-α inhibitors. 
 The efficacy of TNF-α inhibitors (infliximab, adalimumab or etanercept), 
showed that the blockade of TNF-α was a successful approach for the control of 
certain chronic inflammatory conditions. Yet, their major disadvantage is the 
intravenous way of administration. There is growing interest in development of 
selective, orally administered, small molecule inhibitors of TNF-α, namely TACE 
inhibitors. As described in more detail in section 1.2.2, TNF-α is produced as a 
memebrane-bound precursor, which is then proteolytically cleaved by TACE into 
soluble TNF-α. Inhibition of TACE would, therefore, reduce the amount of soluble 
TNF-α released from stimulated cells. In this PhD thesis, a pilot experiment was 
performed, in which I sought to establish if the TACE inhibitor, TOPI-0, can interfere 
with LPS-induced inhibition of Mφ phagocytosis. As shown in Figure 4.8, when 
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samples were treated with increasing concentrations of TOPI-0 and LPS I could 
observe a trend towards increased phagocytosis, yet, it was not significant in 
comparison to controls. Interestingly, when the highest concentrations of TOPI-0 
were added to either control or TNF-α treated samples, I observed a small, non-
significant decrease in the phagocytosis levels. These findings could be explained, at 
least in part, by the fact that TOPI-0 is a broad spectrum inhibitor of matrix 
metalloproteinases (MMP) and blocks the activity of several MMP at the same time. 
One may therefore speculate that in unstimulated or TNF-α-treated samples TOPI-0 
may inhibit phagocytosis by blocking enzymes other than TACE. Upon LPS-
treatment, when Mφ produce TNF-α, TOPI-0 counteracts this process by blocking 
TACE activity and consequently augments phagocytosis. The latter effect is, 
however, masked by the concurrent ability of TOPI-0 to reduce phagocytosis.  
 In addition, several studies provide data that could potentially explain why, in 
this PhD thesis, TOPI-0 did not significantly reverse inhibitory effects of LPS on 
phagocytosis. For instance, Williams and colleagues have demonstrated that TACE 
inhibitor BB-2275 not only inhibits formation of the soluble TNF-α but also shedding 
of TNF-R1 and TNF-R2 from the cell membrane (Williams et al., 1996). As a 
consequence, higher levels of membrane-bound TNF-α (mTNF-α) and TNF-Rs 
(mTNF-R) accumulated on the surface of cells. Interestingly, upon treatment with 
BB-2275, cells expressed higher surface levels of mTNF-R and were more sensitive 
to the cytotoxic effect of sTNF-α. Furthermore, mTNF-α was able to signal through 
mTNF-R and induce production of downstream cytokines, i.e., IL-1, IL-6 and IL-8. 
The above findings clearly suggest that although the studied TACE inhibitor, BB-
2275, is able to reduce the release of sTNF-α from cells, it may not necessarily block 
TNF-α signalling and therefore exert some unwanted pro-inflammatory effects. This 
is of particular interest since exposure to LPS has been reported to induce 
internalisation of mTNF-Rs in several cell types, i.e., the mouse Mφ-like cell line 
RAW 264.7 or primary human or murine Mφ (Ding et al., 1989). It is possible that in 
this PhD thesis, when Mφ are treated with LPS and TOPI-0 two opposing processes 
are taking place; TOPI-0 blocks TNF-α release but also increase the levels of mTNF-
Rs that would normally be decreased by LPS treatment alone. On the contrary, 
Dekkers and colleagues have demonstrated that, in humans, oral administration of 
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MMP inhibitor, GI5402, followed by a bolus intravenous injection of LPS, reduced 
the plasma concentrations of sTNF-α and sTNF-Rs but did not increase the levels of 
mTNF-α and mTNF-Rs in comparison to LPS treatment alone (Dekkers et al., 1999). 
This observation indicates that the alterations in the release of sTNF-Rs and levels of 
mTNF-Rs upon MMP inhibitor treatment are not directly correlated phenomena. 
Furthermore, the ‘net’ effect of MMP inhibitors on TNF-α and its receptors may vary 
depending on experimental settings (in vivo or ex vivo) or differences in modes or 
spectrum of action of particular agents. Therefore, in order to draw a final conclusion 
with regard to the effects of TOPI-0 on the LPS-induced inhibition phagocytosis 
further work should be performed including measurement of concentrations of both 
soluble (culture supernatants) and Mφ membrane-bound TNF-α and TNF Rs.  
 In summary, data presented in chapter 4 show that the inhibitory effect of LPS 
on phagocytosis is dependent upon TNF-α release and is positively correlated with 
the concentration of TNF-α in culture medium just prior to the phagocytosis assay. 
Reduction of TNF-α bioactivity in culture supernatants with sTNF-R1/Fc 
significantly augmented phagocytosis levels. Further experiments with sTNF-R1 
confirmed findings by others demonstrating that sTNF-R1 is a much weaker inhibitor 
of TNF-α than sTNF-R1/Fc. In addition sTNF-R1 appears to exert some inhibitory 
effect on phagocytosis itself. Similarly, the TACE inhibitor, TOPI-0, did not 
significantly reverse LPS-induced inhibition and reduced phagocytosis levels when 
Mφ were treated with greater concentrations of TOPI-0 alone. Further work should be 
performed in order to establish changes in soluble and membrane-bound TNF-α and 
TNF-Rs upon treatment with sTNF-R1 and TOPI-0 to provide more insight into my 
observation. Even though an important role for TNF-α in the regulation of Mφ ability 
to phagocytose apoptotic neutrophils has been demonstrated, it still remains to be 
established why this effect occurred after at least 96 hours incubation with LPS. In 
order to shed more light into this phenomenon I performed the experiments presented 
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 Data presented in chapter 4 demonstrate that LPS-induced inhibition of 
efferocytosis by MDMφ is, at least in part, mediated by the release of TNF-α. First of 
all, the extent to which LPS inhibits phagocytosis was correlated with the levels of 
TNF-α in culture medium. Second, depletion of biologically-active TNF-α in culture 
medium with the use of sTNF-R1/Fc rescued phagocytosis. Interestingly, when Mφ 
were treated with LPS the inhibitory effect of TNF-α was observed only if treatment 
was performed for a duration of 96 hours or longer. Since LPS is a general activator 
of Mφ we hypothesised that upon LPS treatment, MDMφ produce/release mediators 
that either interfere with TNF-α production or negate TNF-α function.  
 Numerous reports throughout the literature demonstrate an important role of 
cytokines with anti-inflammatory properties (e.g., IL-10, IL-4 or TGF-β) as negative 
regulators of TNF-α production. For instance, the study by Ebert investigated the 
release of TNF-α by resting T-cells and monocytes in the presence of antibodies 
neutralising IL-10, IL-4 or TGF-β and demonstrated elevated release of TNF-α in 
such conditions (Ebert, 2005). Interestingly, the authors of this study reported that 
when IL-4 or TGF-β were neutralised with appropriate antibodies, elevated levels of 
IL-10 were produced by monocytes, providing an additional protection against the 
release of exceptionally high amounts of TNF-α by these cells. The importance of IL-
10 as an endogenous regulator of TNF-α is further supported by the findings that, in 
humans, subjects deficient in serum IL-10 levels are more prone to develop chronic 
inflammatory diseases, e.g., ulcerative colitis (Tagore et al., 1999;Ebert et al., 2009). 
IL-10 has been also reported to augment phagocytosis of apoptotic cells by Mφ 
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(Ogden et al., 2005;Xu et al., 2006). In experiments presented in chapter 4 I 
correlated TNF-α and IL-10 concentrations with phagocytosis levels upon LPS 
treatment. As indicated in Figure 4.4, high levels of phagocytosis were correlated 
with low concentrations of TNF-α and, interestingly, elevated concentrations of IL-
10. We hypothesised that IL-10 might block TNF-α production or release and 
therefore interfere with inhibitory effect of LPS in our system.  
 In this chapter, I aimed to establish whether production/release of IL-10 by 
LPS-activated MDMφ delayed the inhibitory effects of LPS on phagocytosis of 
apoptotic neutrophils. For this purpose concentrations of TNF-α and IL-10 in MDMφ 
culture supernatants were measured during LPS stimulation. Next, I investigated the 
effects of IL-10 on LPS-induced inhibition of phagocytosis by using either exogenous 
IL-10, IL-10 receptor blocking antibodies (anti-IL-10-R1Ab) or by comparing 
phagocytosis by wt and IL-10-/- murine BMDMφ. In addition, I compared the effects 









5.2.1 ISOLATION AND CULTURE OF HUMAN BLOOD 
CELLS  
 Human blood cells were isolated by Percoll™ gradient centrifugation, 
following the protocol described in section 2.2.1.1. Subsequently, human monocytes 
were cultured for 6 days in culture medium (see section 2.2.1.3 for culture conditions) 
undergoing differentiation into mature human MDMφ. During this time MDMφ were 
treated with a number of pro- and anti- inflammatory agents. In experiments 
described in this chapter human monocytes were treated with LPS using a range of 
concentrations: 0.01–100 ng/ml (6, 24, 48, 72, 96, 120 and 144 hours), both LTA 
(100 µg/ml) and PG (10 µg/ml) for 1, 6, 16, 32, 48, 72 and 96 hours, TNF-α using a 
range of concentrations: 0.1–100 ng/ml (72, 120 hours), anti-IL-10-R1Ab at a 
concentration 10 µg/ml (treatment was added every 48 hours), IL-1β at a 
concentration of 10 ng/ml (120 hours), IL-10 at a range of concentrations: 0.1–100 
ng/ml (72, 120 hours), 1 µM dexamethasone using a range of concentrations: 0.001–1 
µM (96-144 hours), aspirin, ibuprofen, paracetamol using a range of concentrations: 
10–1200 µM, indomethacin using a range of concentrations: 10–100 µM, SC-650 and 
NS-398 using a range of concentrations 2.5–250 µM for 48-72 hours.  
On day 6, MDMφ were assessed for their ability to phagocytose apoptotic neutrophils 
that had undergone constitutive apoptosis for 20 hours of culture (see section 2.2.1.3 
for culture conditions).  
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5.2.2 ISOLATION AND CULTURE OF MOUSE BONE 
MARROW CELLS 
 In experiments described in section 5.3.4, efferocytosis by wt and IL-10-/- 
murine BMDMφ have been compared, for control and pro-inflammatory conditions. 
Bone marrow cells were isolated from mouse femurs, cultured in Teflon pots for 4 
days and then transferred to 48-well plates and cultured for the next 4 days as 
described in section 2.2.2. BMDMφ were treated for 24 or 48 hours with 10 ng/ml 
LPS or 10 ng/ml mouse recombinant TNF-α. On the last day of culture BMDMφ 
were assessed for their ability to phagocytose human apoptotic neutrophils that had 
undergone constitutive apoptosis for 20 hours of culture (see section 2.2.1.3 for 
culture conditions).  
 
5.2.3 ASSESSMENT OF APOPTOSIS AND NECROSIS 
 Prior to the phagocytosis assay, the % of apoptotic cells within neutrophil 
populations was assessed by morphology (see section 2.3.1 for experimental 
protocol) or alternatively by Annexin-V binding assessed by flow cytometry (see 
section 2.3.2 for experimental protocol). The % of necrotic cells was assessed by PI 
staining as described in section2.3.2. Only neutrophils with less than 5 % of necrosis 
were used in phagocytosis assay.   
 
5.2.4 ASSESSMENT OF PHAGOCYTOSIS BY FLOW 
CYTOMETRY 
5.2.4.1 HUMAN MDMΦ 
 In all the experiments described in this chapter efferocytosis was assessed by 
flow cytometric analysis that employs labelling of phagocytic targets with FL1+ Cell 
Tracker™ Green (CMFDA) prior to the phagocytosis assay. Following the 
phagocytosis assay the % of FL1+ MDMφ (MDMφ that had engulfed phagocytic 
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targets) within the entire MDMφ population was assessed by flow cytometry as 
described in chapter 2.4.1.1.  
 
5.2.4.2 MURINE BMDMΦ 
 Efferocytosis by BMDMφ was assessed by 2 colour flow cytometric assay as 
described in chapter 2.4.2. Human apoptotic neutrophils, used as phagocytic targets, 
overlap with mouse BMDMφ when plotted SS against FS. Therefore two fluorescent 
labels were used: Cell Tracker™ Far Red (for labelling of BMDM, FL-4+) and Cell 
Tracker™ Green (for labelling of human neutrophils, FL-1+). This allowed the gating 
of BMDMφ as a population of FL-4+ positive cells and then assessing the percentage 
of the FL-1+ cells within entire FL-4+ population. Only BMDMφ that were both FL-
4+ and FL-1+ positive were deemed to have engulfed apoptotic neutrophils.   
 
5.2.5 MEASUREMENT OF TNF-α AND IL-10 
CONCENTRATIONS IN CULTURE SUPERNATANTS  
 In experiments described in this chapter I assessed changes in TNF-α and IL-
10 levels at different time points after LPS, LTA and PGN stimulation (see sections 
5.3.1 and 5.3.2) and examined the effect of exogenous IL-10 (see sections 5.3.3) and 
dexamethasone (see sections 5.3.6) on TNF-α production by LPS–stimulated MDMφ. 
In all these experiments, culture supernatants were collected and processed as 
described in section 2.5.2. Cytokine concentrations were measured by specific ELISA 
following the manufacturer’s instruction (see section 2.5.2 for more details).   
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5.3 RESULTS  
 
5.3.1 CHARACTERISATION OF TNF-α AND IL-10 
PRODUCTION BY MDMΦ STIMULATED WITH LPS  
 Experiments in chapter 4 show that the % of MDMφ ingesting apoptotic 
neutrophils was negatively correlated with the concentration of TNF-α in the 
supernatant (R2 = 0.84, Figure 4.3). I also noted that culture supernatants containing 
low concentrations of TNF-α were characterised by increased levels of IL-10 (Figure 
4.4). Interestingly, IL-10 was previously reported to augment uptake of apoptotic 
cells by Mφ (Ogden et al., 2005;Xu et al., 2006). In this PhD thesis, one of the most 
striking characteristic of LPS-induced inhibition of phagocytosis is significant delay 
in comparison to TNF-α-induced inhibition. Therefore, I sought to investigate 
whether LPS-stimulated MDMφ produce IL-10 and if this cytokine interferes with 
the LPS inhibitory effect upon efferocytosis. To answer these questions I first aimed 
to measure the production of TNF-α and IL-10 by MDMφ in response to LPS 
treatment. For this purpose human blood monocytes were cultured for 6 days and 
LPS (10 ng/ml) was added at a number of time points: 1, 6, 12, 24, 48, 72, 96 and 120 
hours before the phagocytosis assay. On day 6, culture supernatants were collected 
and TNF-α and IL-10 levels measured by ELISA. Figure 5.1 shows changes in 
concentrations of TNF-α and IL-10 throughout the culture. The first significant 
increase in TNF-α levels appears at the 6 hour time point (18.1±7.2 ng/ml in 
comparison to the 1 hour time point 0.4±0.3 ng/ml, p<0.01, n=7), followed by a 
steady decrease. TNF-α concentration markedly rises again at the 96 hour time point 
(16.8±7.5 ng/ml in comparison to 1 hour control, p<0.05, n=7). I also found 
significant elevation in IL-10 levels at the 12 hour time point (15.3±3.1 ng/ml in 
comparison to 1 hour control 0.01±0.004 ng/ml, p<0.01, n=7) with maximum 
concentrations at 24 hours (21.4±5.0 ng/ml in comparison to 1 hour control 
0.01±0.004 ng/ml, p<0.01, n=7), followed by a steady decline (3.9 ± 1.4 ng/ml at 120 
hour time point). As shown in Figure 5.1A, the increases in the IL-10 levels are 
associated with decreases in TNF-α levels and vice versa. In addition, I measured 
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concentrations of TNF-α and IL-10 following 96 hours treatment with increasing 
concentrations of LPS. As indicated in Figure 5.1B TNF-α concentrations are 
positively correlated with LPS concentrations and rise significantly from 0.09±0.07 
ng/ml (medium control) to 5.2±1.5 ng/ml for 10 ng/ml LPS (p<0.05, n=4) or to 
6.0±2.7 for 100 ng/ml LPS (p<0.01, n=4). The increases in TNF-α concentration are 
also associated with low levels of IL-10. It is noteworthy that in the latter experiment 
LPS (1-100 ng/ml) significantly inhibited MDMφ ability to phagocytose apoptotic 









FIGURE 5.1 Production of TNF-α and IL-10 by LPS stimulated MDMφ (next 
page). Human MDMφ were cultured for 6 days and treated for increasing durations 
of time with 10 ng/ml LPS (A) or treated for 96 hours with increasing concentrations 
of LPS (B). On day 6, culture supernatants were collected and TNF-α and IL-10 
concentrations were measured by ELISA. Concentrations of TNF-α and IL-10 are 
expressed as the mean concentration ± SEM for n=7 (A) or n=4 (B) experiments. 
Significant differences for comparisons to respective concentrations at 1hour time-




































5.3.2 CHARACTERISATION OF TNF-α AND IL-10 
PRODUCTION BY MDMΦ STIMULATED WITH LTA OR 
PGN  
 Experiments described in chapter 3 (sections 3.3.2 and 3.3.3) showed that 
inhibitory effects of LTA and PGN on efferocytosis depend on the duration of 
treatment. Upon treatment with either LTA or PGN reduction in efferocytosis levels 
occurred quicker (16 hours after treatment) than upon LPS treatment. I therefore 
aimed to establish if the timing of TNF-α or IL-10 production/release by LTA- or 
PGN–stimulated MDMφ is different from that obtained for LPS. For this purpose 
human blood monocytes were cultured for 6 days and either 100 µg/ml LTA or 10 
µg/ml PGN were added at several time points: 1, 6, 16, 32, 48, 72, 96 hours before 
assessing phagocytosis. On day 6, culture supernatants were collected and TNF-α and 
IL-10 levels were measured by ELISA.  
 Figure 5.2A shows changes in concentrations of TNF-α and IL-10 throughout 
the culture upon treatment with 100µg/ml LTA. The first significant increase in TNF-
α levels appears at the 6 hour time point (6.2±0.6 ng/ml in comparison to 1 hour time 
point 0.025±0.008 ng/ml; p<0.01, n = 4), and further increases at 32 hours up to 
7.2±1.6 ng/ml (p<0.01, n = 4, in comparison to 1 hour control) and then markedly 
decreases at the 48 hour time point (0.9±0.1 ng/ml). Levels of TNF-α do not increase 
again at later time points of the culture. I also found significant and maximal 
elevation in IL-10 concentrations at 16 hours after LTA treatment (6.5±2.5 ng/ml in 
comparison to 1 hour control 0.10±0.04 ng/ml, p<0.05, n=4), followed by a steady 
decline. Similar to TNF-α, levels of IL-10 do not rise again at later time points of the 
culture.  
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 Figure 5.2B shows changes in concentrations of TNF-α and IL-10 throughout 
the culture upon treatment with 10 µg/ml PGN. The first significant increase in TNF-
α levels appears at the 6 hour time point (12.7±1.7 ng/ml in comparison to 1 hour 
time point 0.035 ± 0.002 ng/ml; p<0.01, n=4), and further increases at the 16 hour 
time point up to 13.4±1.6 ng/ml (p<0.01, n = 4 in comparison to 1 hour control) and 
then declines and remains low at 32, 48 and 72 hours after PGN treatment. However, 
levels of TNF-α rise again at the end of the culture at 96 hour time point up to 
10.9±1.9 ng/ml (p<0.01, n=4 in comparison to 1 hour control). Significant elevation 
in IL-10 concentration was identified at 16 hour time point after PGN treatment 
(6.4±0.8 ng/ml in comparison to 1 hour control 0.09±0.02 ng/ml, p<0.01, n=4), 
followed by further increase at the 32 hour time point up to 9.1±1.7 ng/ml (p<0.01, 
































Figure 5.2 Production of TNF-α and IL-10 by LTA or PGN stimulated MDMφ. 
Human MDMφ were cultured for 6 days and treated for increasing durations of time 
with 100 µg/ml LTA (A) or 10 µg/ml PGN (B). On day 6, culture supernatants were 
collected and TNF-α and IL-10 concentrations were measured by ELISA. 
Concentrations of TNF-α and IL-10 are expressed as the mean concentration±SEM 
for n=4 experiments. Significant differences for comparisons to respective 







5.3.3 PRESENCE OF EXOGENOUS IL-10 INHIBITS 
TNF-α PRODUCTION AND RESCUES INHIBITION OF 
MDMΦ EFFEROCYTOSIS INDUCED BY LPS 
 Measurement of TNF-α and IL-10 concentrations in culture supernatants upon 
MDMφ treatment with either LPS, LTA or PGN revealed intriguing interplay 
between them. As described in sections 5.3.1 and 5.3.2, TNF-α was produced at early 
time points and reached maximum concentration approximately 6 hours after 
treatment, whereas the first peak of IL-10 levels occurred later on, approximately 12-
16 hours after treatment. The increase in IL-10 levels was accompanied by decrease 
in TNF-α concentration and either subsequent decrease in IL-10 levels (LPS and PGN 
treatment) or alternatively reductions in TNF-α and IL-10 levels were synchronised 
(LTA treatment). Thus, I hypothesised that, in our system, IL-10 is a negative 
regulator of TNF-α production by MDMφ exposed to pro-inflammatory stimuli such 
as LPS. To investigate this further, human blood monocytes were differentiated for 6 
days into MDMφ. MDMφ were cultured in medium (control) or treated with either 10 
ng/ml LPS (LPS control) or 10 ng/ml TNF-α (TNF-α control). Increasing 
concentrations of IL-10 (0.1-100 ng/ml) were added to appropriate samples, as 
indicated in Figure 5.3A. Treatment was performed for the duration of 120 hours and 
efferocytosis was assessed by flow cytometry. IL-10 alone significantly increased 
MDMφ uptake of apoptotic cells from 24.0±3.17 % (medium control) to 37.9±2.9 % 
at a concentration of 100 ng/ml (p<0.05; n=5). Furthermore, IL-10 rescued 
efferocytosis in LPS treated MDMφ in a concentration-dependent manner but not in 
TNF-α (10 ng/ml) treated MDMφ. Upon LPS treatment, efferocytosis was decreased 
to 10.7±2.1 % but addition of IL-10 at concentrations 10 ng/ml or 100 ng/ml 
increased phagocytosis in LPS treated MDMφ up to 36.1±4.3 % (p<0.001; n=5) and 
36.0±7.4 % (p<0.001; n=5) respectively. It is noteworthy that these levels of 
efferocytosis are similar to those represented by MDMφ treated with 10 ng/ml or 100 
ng/ml IL-10 alone. To further verify that IL-10 indeed inhibited production of TNF-α 
in LPS treated (120 hours) MDMφ, I measured TNF-α concentrations in MDMφ 
culture supernatants. As demonstrated in Figure 5.3B, IL-10 reduced production of 
TNF-α by LPS-treated MDMφ in a concentration-dependent manner. IL-10 (0.1 
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ng/ml and 1 ng/ml) significantly decreased TNF-α production by MDMφ from 
22.0±4.8 ng/ml for LPS alone to 11.5±3.5 ng/ml (p<0.05, n=4) and 3.6±0.9 ng/ml 
(p<0.001, n=4) respectively. However, as shown in Figures 3.3A and 5.3A these 
levels of TNF-α are still capable of inhibiting efferocytosis. Higher concentrations of 
IL-10, 10 and 100 ng/ml, further decreased TNF-α concentrations to 1.6±0.5 ng/ml 
(p<0.001, n=4) and 1.1±0.2 ng/ml (p<0.001, n=4) respectively and effectively 
reversed LPS-mediated inhibition of phagocytosis.  
 Since the concentration response for TNF-α (Figure 3.3A) clearly indicates 
that TNF-α, at 1 ng/ml, significantly inhibits uptake of apoptotic neutrophils, I 
examined this phenomenon further. Human monocytes were cultured for 6 days and 
treated for 72 hours with increasing concentrations of TNF-α alone or with addition 
of IL-10 (100 ng/ml). As indicated in Figure 5.4, IL-10 at this concentration does not 
override the effect of higher concentrations of TNF-α (10 and 100 ng/ml), but did 
significantly reverse the inhibition of efferocytosis caused by 1 ng/ml TNF-α (p<0.01, 
n = 4). Note that control (no treatment) samples and samples co-treated with 1 ng/ml 



















FIGURE 5.3 Presence of exogenous IL-10 reverses the inhibition of efferocytosis 
and production of TNF-α induced by LPS. Human MDMφ were cultured for 6 
days in culture medium alone or treated for 120 hours with either 10 ng/ml LPS or 10 
ng/ml TNF-α alone +/- increasing concentrations of IL-10. A. Efferocytosis was 
assessed on day 6 by flow cytometry. Data shown as mean±SEM for n=5 separate 
experiments (*p<0.05 compared with medium control and ***p<0.001 compared 
with samples treated only with LPS). B. Culture supernatants were collected on day 6 
just before efferocytosis assay and TNF-α concentration measured by ELISA. Data 
shown as mean concentration±SEM for n=4 separate experiments (*p<0.05 













FIGURE 5.4 IL-10 masks inhibitory action of low concentrations of TNF-α. 
Human MDMφ were cultured for 6 days and treated for 72 hours with increasing 
concentrations of TNF-α alone or with addition of 100 ng/ml IL-10. Efferocytosis 
was assessed on day 6 by flow cytometry. Data shown as mean±SEM for n=5 
separate experiments. Significant differences for comparisons to medium control are 





5.3.4 PRESENCE OF MONOCLONAL ANTI-HUMAN IL-
10-R1 ANTIBODY AUGMENTS THE INHIBITORY 
EFFECT OF LPS 
 Having found that the presence of exogenous IL-10 rescues efferocytosis in 
LPS-treated MDMφ and that this effect is associated with a reduction in TNF-α 
concentration, I next sought to investigate if endogenous production of IL-10 upon 
LPS stimulation is responsible for the observed delay of LPS inhibitory effect. For 
this purpose MDMφ were treated with LPS and the biological activity of 
endogenously produced IL-10 was blocked with the use of anti-human IL-10-R1 
antibody (anti-IL-10-R1Ab). Human blood monocytes were differentiated for 6 days 
and cultured with 10 ng/ml LPS either alone or in the presence of 10 µg/ml anti-IL-
10-R1Ab for different durations of time: 24, 48, 72 and 96 hours. Efferocytosis was 
assessed on day 6 by flow cytometry. Interestingly, in the presence of anti-IL-10-
R1Ab, LPS treatment causes significant inhibition at the 24 hour time point 
(24.2±3.3% in comparison to control level 34.9±4.9%, p<0.05, n=8, Figure 5.5) and 
this effect was maintained at 48, 72 and 96 hours after treatment. Concurring with 
data presented in Figure 3.2B samples treated with LPS alone showed decrease in 
efferocytosis only after 96 hours of treatment (24.2±3.3%, p<0.05, n=8, in 
comparison to medium control, Figure 5.5). Moreover, at the 96 hour time point, LPS 
induced much greater inhibition in the presence of anti-IL-10-R1Ab (14.2±2.5%, 







Figure 5.5 IL-10 produced by LPS stimulated MDMφ delays LPS–induced 
inhibition of efferocytosis. Human MDMφ were cultured for 6 days and treated for 
24, 48, 72 and 96 hours with 10 ng/ml LPS alone or with addition of 10µg/ml anti-IL-
10-R1Ab. Efferocytosis was assessed on day 6 by flow cytometry. Data are expressed 
as mean±SEM of n=8 separate experiments. Significant differences for comparisons 




5.3.5 BMDMΦ FROM IL-10 -/- MICE ARE 
CHARACTERISED BY LOWER CAPACITY FOR 
PHAGOCYTOSIS IN COMPARISON TO BMDMΦ FROM 
WILD TYPE MICE 
 Having identified the importance of endogenous IL-10 production on 
protection of MDMφ ability to phagocytose apoptotic neutrophils I investigated this 
phenomenon further. I compared efferocytosis by wt and IL-10 deficient murine 
BMDMφ in control and pro-inflammatory conditions. Bone marrow cells were 
isolated from wt and IL-10-/- mice, differentiated them into BMDMφ for 8 days and 
treated with LPS or TNF-α for 24 or 48 hours prior to phagocytosis assay. 
Phagocytosis was assessed in a similar way as in the experiments using MDMφ and 
human apoptotic neutrophils were used as phagocytic targets. The obtained data 
clearly show that IL-10 deficient BMDMφ have a much lower ability to phagocytose 
apoptotic neutrophils in comparison to wt BMDMφ. As indicated in Table 5.1 
decrease in efferocytosis levels was observed for all experimental conditions and % 
of inhibition varied from 37.3±5.9 % for 24 hours treatment with LPS up to 75.7±9.4 



















TABLE 5.1 Comparison of efferocytosis by wt and IL-10 -/- BMDMφ. 
Treatment  
and genotype  
%Phagocytosis 1 % Inhibition 2 
Control wt 36.3 ± 1.4  
Control IL-10 -/- 17.3 ± 3.3 52.6 ± 8.4 
   
LPS 24 wt 24.4 ± 4.3  
LPS24 IL-10 -/- 15.0 ± 2.2 37.3 ± 5.9 
   
LPS 48 wt 4.5 ± 2.1  
LPS 48 IL-10 -/- 2.1 ± 0.9 50.2 ± 3.0 
   
TNF-α 24 wt 23.3 ± 2.4  
TNF-α 24 IL-10 -/- 12.0 ± 0.7 47.4 ± 5.5 
   
TNF-α 48 wt 7.5 ± 3.0  
TNF-α 48 IL-10 -/- 1.9 ± 0.5 75.7 ± 9.4 
 
Phagocytosis by BMDMφ was assessed by flow cytometry. Data are expressed 
as 1 mean % efferocytosis±SEM, 2 mean % inhibition of efferocytosis±SEM, 
where corresponding wt and IL-10-/- treatments were compared. Three animals / 







5.3.6 DEXAMETHASONE RESCUES THE ABILITY OF 
LPS AND TNF-α TREATED MDMΦ TO PHAGOCYTOSE 
APOPTOTIC NEUTROPHILS  
 Glucocorticoids, including the synthetic glucocorticoid, dexamethasone, are 
recognised for their anti-inflammatory properties and ability to inhibit production of 
pro-inflammatory cytokines such as TNF-α (Barnes, 1998). Furthermore, they are 
reported to increase non-phlogistic phagocytosis of apoptotic cells (Heasman et al., 
2004;Giles et al., 2001;Liu et al., 1999). I therefore aimed to determine, whether 
dexamethasone was able to exert similar effects as IL-10 and rescue LPS-inhibited 
efferocytosis through inhibition of TNF-α production or reverse the inhibitory effect 
of TNF-α. To answer these questions human monocytes were treated for 120 hours 
with increasing concentrations of dexamethasone alone or in combination with either 
10 ng/ml LPS or 10 ng/ml TNF-α. Dexamethasone, as expected, augmented 
efferocytosis in a concentration-dependent manner with the most prominent effect at 
0.1 µM concentration or higher. When MDMφ were pre-treated with LPS and 
dexamethasone (Figure 5.6A), efferocytosis levels were markedly increased from 
22.1±0.8 % for LPS alone (control level–43.9±4.1 %) up to 61.8±3.5 % for combined 
LPS and 1 µM dexamethasone (p<0.001; n=5). Levels of phagocytosis for treatment 
with 1 µM dexamethasone alone were 72.6±2.8 %.  
 As indicated in Figure 5.6A dexamethasone also reversed the inhibitory effect 
of TNF-α on efferocytosis in a concentration-dependent fashion. With TNF-α 
treatment phagocytosis was inhibited (18.5±2.9 %) in comparison to control and was 
significantly enhanced by the presence of 1 μΜ dexamethasone up to 68.7 ± 2.7 % 
(p<0.001, n = 4). 
 Since I was able to demonstrate that the presence of dexamethasone reversed 
the inhibitory effects of LPS and TNF-α on efferocytosis of apoptotic neutrophils, I 
next sought to investigate if dexamethasone treatment alters production of TNF-α or 
IL-10 by MDMφ stimulated with LPS. For this purpose human blood monocytes 
were differentiated for 6 days and cultured in medium (control) or treated with either 
1 µM dexamethasone alone (DX control) or 10 ng/ml LPS alone or with both LPS 
and dexamethasone for 120 hours. Subsequently, culture supernatants were collected 
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and cytokine levels measured by CBA. The TNF-α and IL-10 levels in both controls 
were barely detectable (data not shown). However, as shown in Figure 5.6B, I found 
that dexamethasone did not change production of IL-10 but partially decreased 
production of TNF-α in LPS-stimulated MDMφ from 44.5±21.1 ng/ml to 14.5±10.5 
ng/ml (p<0.05; n=5). This effect was accompanied by increases in efferocytosis, even 
though TNF-α at this concentration greatly inhibits MDMφ uptake of apoptotic 




FIGURE 5.6 Dexamethasone reverses the inhibitory effects of TNFα and LPS on 
efferocytosis (next page). A. Human MDMφ were cultured for 6 days and treated for 
120 hours with increasing concentrations of dexamethasone alone or with addition of 
either 10 ng/ml LPS or 10 ng/ml TNF-α. Efferocytosis was assessed on day 6 by flow 
cytometry. Data are expressed as mean±SEM of n=4-8 separate experiments. 
Significant differences for comparisons to respectively medium, TNF-α or LPS 
control are represented by *p<0.05, **p<0.01 and ***p<0.001. B. Human MDMφ 
were cultured for 120 hours in the presence of 10 ng/ml LPS alone or with addition of 
1 µM dexamethasone. After 120 hours supernatants were collected and TNF-α and 
IL-10 concentrations were measured by CBA. Data shown as mean 
concentration±SEM for n=5 separate experiments. Combined LPS and 
dexamethasone treatment at 120 hours significantly changed TNF-α (*p<0.05) but 





















5.3.7 DEXAMETHASONE RESCUES THE ABILITY OF 
IL-1β TREATED MDMΦ TO PHAGOCYTOSE 
APOPTOTIC NEUTROPHILS  
 As described in chapter 3 (section 3.3.6) treatment of MDMφ with exogenous 
IL-1β decreased their ability to phagocytose apoptotic neutrophils, similar to LPS or 
TNF-α treatments. I therefore sought to investigate if the presence of dexamethasone 
would have any effect on inhibition of efferocytosis by IL-1β. For this purpose we 
cultured human blood monocytes for 6 days and treated them for 120 hours with 
either 10 ng/ml IL-1β alone or with addition of 1 µg/ml dexamethasone. Efferocytosis 
was assessed on day 6 by flow cytometry. Obtained results clearly showed that when 
MDMφ were treated with IL-1β efferocytosis was reduced from 23.3±6.2 % (control) 
to 8.3±0.7 %. Dexamethasone significantly augmented uptake of apoptotic 
neutrophils in both groups up to 51.6±8.6 % for control samples (p<0.01; n=4; in 
comparison to medium control) and 57.4±7.4 % for IL-1β treated samples (p<0.001; 
n=4; in comparison to IL-1β treatment). It is noteworthy, that when MDMφ were pre-
treated with IL-1β augmentation of efferocytosis was even greater than for control 

















FIGURE 5.7 Dexamethasone reverses the inhibitory effects of IL-1β on 
efferocytosis. Human MDMφ were cultured for 6 days in culture medium or treated 
for 120 hours with 10 ng/ml IL-1β +/- 1µM dexamethasone. Efferocytosis was 
assessed on day 6 by flow cytometry. Data are expressed as mean±SEM of n=4 
separate experiments. Significant differences for comparisons to medium or IL-1β 
control are represented by **p<0.01 and ***p<0.001. DX-dexamethasone. 
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5.3.8 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
DO NOT AUGMENT MDMΦ PHAGOCYTOSIS OF 
APOPTOTIC NEUTROPHILS  
 Data described in chapter 5.3.6 demonstrate that dexamethasone, an anti-
inflammatory steroid, not only augments MDMφ efferocytosis of apoptotic 
neutrophils per se but also reverses inhibitory effects of LPS and TNF-α upon this 
process. In contrast, this section focuses on non-steroidal anti-inflammatory drugs 
(NSAID) and their effects on MDMφ efferocytosis. These drugs act mainly through 
inhibition of COX–1 and COX-2 enzymes (i.e., aspirin, ibuprofen or indomethacin), 
therefore, for comparison, I also analysed effects of the selective COX-1 (SC-650) 
and the COX-2 (NS-398) inhibitors. Furthermore, I investigated the effect of 
paracetamol, an analgesic, which arguably blocks the COX-3 enzyme as described in 
detail in section 1.5.2. 
 In order to assess the effects of aspirin, ibuprofen, indomethacin, SC-650, NS-
398 and paracetamol on MDMφ efferocytosis of apoptotic neutrophils we cultured 
human blood monocytes for 6 days and treated them for 48-72 hours with 1 µM 
dexamethasone or increasing concentrations of aspirin (10, 100, 1000 µM), ibuprofen 
(10, 100, 1000 µM), paracetamol (10, 100, 1000 µM), SC-650 (2.5, 25, 250 µM) or 
NS-398 (2.5, 25, 250 µM). Due to relatively high cell toxicity, indomethacin was 
used only at low concentrations (10, 50, 100 µM). Efferocytosis was assessed on day 
6 by flow cytometry. The control levels of efferocytosis in all experiments ranged 
between 27.7±2.5 % (Figure 5.8F) and 43.9±4.8 % (Figure 5.8A, B and C). 
Dexamethasone significantly augmented uptake of apoptotic neutrophils in all 
experiments and the levels of efferocytosis varied between 56.6±6.4 % (Figure 5.8E) 
and 67.6±5.4 % (Figure 5.8A, B and C) (p<0.001; n=4; in comparison to medium 
controls). All tested non-steroidal agents at lower concentrations did not exert any 
major effects on efferocytosis but significantly reduced this process when used at the 
highest concentrations. The levels of efferocytosis for treatment with 1000 µM 
aspirin were 25.1±6.8 % (p<0.05; n=4; in comparison to medium control, Figure 
5.8A), 1000 µM ibuprofen were 19.1±5.6 % (p<0.001; n=4; in comparison to 
medium control, Figure 5.8B), 100 µM indomethacin were 27.5±4.1 % (p<0.05; n=4; 
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in comparison to medium control, Figure 5.8C), 1000 µM paracetamol were 28.1±7.0 
% (p<0.05; n=4; in comparison to medium control, Figure 5.8D), 250 µM SC-650 
were 6.0±2.8 % (p<0.001; n=4; in comparison to medium control, Figure 5.8E) and 
250 µM NS-398 were 6.5±1.4 % (p<0.001; n = 4; in comparison to medium control, 
Figure 5.8F). Viability of MDMφ was confirmed just before the phagocytosis assay 
by staining with the vital dye-Trypan Blue and observation under light microscope. 
Percentage of distinctive blue cells (dead cells) within each tested population is 










FIGURE 5.8 (next pages) NSAID do not augment MDMφ efferocytosis of 
apoptotic neutrophils. Human MDMφ were cultured for 6 days in culture medium 
or treated for 48-72 hours with 1 µM dexamethasone, increasing concentrations of 
NSAID (aspirin (A), ibuprofen (B), indomethacin (C), paracetamol (D)) or selective 
COX–1 inhibitor SC-650 (E) and selective COX-2 inhibitor NS-398 (F). 
Efferocytosis was assessed on day 6 by flow cytometry. Data are expressed as 
mean±SEM of n=4 separate experiments. Significant differences for comparisons to 










































































TABLE 5.2 Viability of MDMφ confirmed by Trypan Blue staining 
Treatment Trypan blue positive 
MDMφ 
Control MDMφ (no treatment) 5.1 ± 0.5 % 
Aspirin 1000 µM 3.2 ± 0.2 % 
Ibuprofen 1000 µM 4.8 ± 0.4 % 
Indomethacin 100 µM 2.1 ± 0.1 % 
Paracetamol 1000 µM 4.5 ± 0.5 % 
SC-650 250 µM 2.9 ± 0.3 % 
NS-398 250 µM 2.4 ± 0.2 % 
 
Viability of MDMφ was confirmed by Trypan Blue staining. At least 500 cells 
were counted under light microscope. Data are presented as mean % Trypan 
Blue positive cells ± SEM of n=3 separate experiments.    
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5.3.9 ASPIRIN INTERFERES WITH THE INHIBITORY 
EFFECT OF TNF-α ON MDMφ EFFEROCYTOSIS OF 
APOPTOTIC NEUTROPHILS 
 Data described in section 5.3.6 demonstrate that the presence of 
dexamethasone interferes with inhibitory effects of LPS and TNF-α upon MDMφ 
phagocytosis. For comparison, I sought to investigate whether non-steroidal anti-
inflammatory drugs would exert similar effects. Results presented in this chapter 
show the influence of NSAID, namely aspirin, as well as SC-650 and NS-398 on 
TNF-α induced inhibition of phagocytosis.   
 In this series of experiments human blood monocytes were cultured for 6 days 
in culture medium alone or with addition of 10 ng/ml TNF for 72 hours. Increasing 
concentrations (300, 600, 1200 µM) of aspirin were added to both control and TNF–α 
treated samples for 72 hours. Efferocytosis was assessed on day 6 by flow cytometry. 
As shown in Figure 5.9A, upon TNF–α treatment, efferocytosis was significantly 
reduced from 40.1±2.2 % (control level) to 22.3±2.8 % (p<0.05, n=4 in comparison 
to control). Interestingly, the presence of aspirin at concentrations 300 µM and 600 
µM reversed the inhibitory effect of TNF–α and the levels of phagocytosis were 
36.3±2.4 % (combined treatment with 300 µM aspirin and 10 ng/ml TNF–α) and 
37.1±7.9 % (combined treatment with 600 µM aspirin and 10 ng/ml TNF–α). It is 
noteworthy that aspirin at the above concentrations does not inhibit phagocytosis by 
itself. Aspirin at the concentration 1200 µM significantly inhibited MDMφ 
efferocytosis (18.21±2.7 %, p<0.01, n=4 in comparison to control) and did not 
augment efferocytosis reduced by the presence of TNF–α (22.6±3.2 %, p<0.05, n=4 
in comparison to control).  
 Following the above observation, I sought to investigate whether the selective 
COX-1 inhibitor, SC-650, or the selective COX–2 inhibitor, NS-398, would exert 
similar effects as aspirin and rescue MDMφ phagocytosis in the presence of TNF–α. I 
performed pilot experiment in which human blood monocytes were cultured for 6 
days in culture medium alone or with addition of 10 ng/ml TNF for 72 hours. 
Increasing concentrations (2.5, 25, 250 µM) of SC-650 (Figure 5.9B) or NS-398 
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(Figure 5.9C) were added to both control and TNF – α treated samples for 72 hours. 
Efferocytosis was assessed on day 6 by flow cytometry. Preliminary data 
demonstrated in Figure 5.9B and C suggest that the presence of either compound, SC-
650 or NS-398, does not interfere with inhibition of MDMφ efferocytosis by TNF–α 
and that perhaps mechanisms other than inhibition of COX enzyme underlies the 














































FIGURE 5.9 Aspirin, at lower concentration, interferes with TNF–α inhibitory 
effect on MDMφ efferocytosis of apoptotic neutrophils. Human MDMφ were 
cultured for 6 days in culture medium or treated for 72 hours with increasing 
concentrations of aspirin (A), SC-650 (B) or NS-398 (C) +/- 10 ng/ml TNF–α. 
Efferocytosis was assessed on day 6 by flow cytometry. Data are expressed: A. as 
mean±SEM of n=4 separate experiments (*p<0.05, **p<0.01, compared with 
medium control). B and C. as mean±SD of n=1 experiment (duplicate). 
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5.3.10 SUMMARY OF THE RESULTS 
 
 During MDMφ treatment with pro-inflammatory agents an interesting 
interplay occurs between the concentrations of TNF-α and IL-10 in culture 
supernatants (the most prominent for LPS, the least for LTA treatment). Elevated IL-
10 concentrations are associated with a decrease in TNF-α levels and minimal 
inhibition of phagocytosis. On the contrary, at the time points where TNF-α levels are 
increased, IL-10 concentrations are reduced. 
 
 Exogenous IL-10 rescues the MDMφ phagocytosis inhibited by LPS 
treatment. This effect is associated with inhibition of TNF-α production by MDMφ. 
The effect of exogenous IL-10 on inhibition of phagocytosis by exogenous TNF-α- is 
less prominent.  
 
 IL-10 deficient murine BMDMφ are characterised by a decreased ability to 
phagocytose apoptotic neutrophils in comparison to wt BMDMφ, in both control and 
pro-inflammatory conditions.  
 
 The anti-IL-10-R1Ab potentiates LPS–induced inhibition of MDMφ 
phagocytosis. In addition, upon treatment with anti-IL-10-R1Ab, the LPS inhibitory 
effect occurs at much earlier time points in comparison to samples treated only with 
LPS.  
 
 Dexamethasone rescues phagocytosis by MDMφ treated with LPS but only 
partially inhibits TNF-α production. Dexamethasone also rescues phagocytosis by 
MDMφ treated with exogenous TNF-α or IL-1β. 
 
 In contrast to dexamethasone, NSAID per se do not augment MDMφ 
phagocytosis of apoptotic neutrophils. Preliminary data suggest that aspirin reverses 
the inhibitory effect of TNF-α on phagocytosis by mechanism other than an inhibition 
of COX1 and/or COX2. 
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5.4 DISCUSSION 
 In chapter 3 of this PhD thesis, pro-inflammatory stimuli, namely LPS, LTA 
and PGN as well as TNF-α, have been shown to inhibit Mφ phagocytosis of apoptotic 
neutrophils. As demonstrated in chapter 4, LPS-induced inhibition was mediated by 
TNF-α release but intriguingly was significantly delayed (96 hours) in comparison to 
exogenous TNF-α-mediated effects (6 hours in our study). The inhibition of 
phagocytosis by LTA and PGN occurred at 32 and 16 hours respectively. Previously 
published data demonstrated that in monocytes maximal production of pro-
inflammatory TNF-α, IL-1α, IL-1β, IL-6 or IL-8 appears 4-8 hours after pro-
inflammatory challenge (i.e., LPS or interferon-γ) and is followed by maximal IL-10 
production 24-48 hours after activation (de Waal et al., 1991). Therefore, in chapter 
5, I sought to investigate the mechanism underlying the delay of the inhibition of 
phagocytosis by LPS. LPS has been chosen for the majority of experiments because 
its inhibitory effect was characterised by the most prominent delay. 
 As shown in Figure 5.1, when Mφ were treated with LPS an interesting 
interplay occurred between TNF-α and IL-10 concentrations in culture supernatants 
and inhibition of phagocytosis. TNF-α concentration rose twice during the Mφ 
culture (it was maximal 6 and 96 hours after treatment), while IL-10 concentrations 
increased between 12 and 24 hours (the latter effect was associated with decreased 
TNF-α levels). Interestingly, inhibition of phagocytosis was observed only during the 
second increase in TNF-α concentration. When Mφ were treated with PGN I 
observed two peaks of maximum TNF-α concentration (at 16 and 96 hours after PGN 
treatment) and both of them were associated with maximal inhibition of phagocytosis. 
IL-10 concentration was maximal at 32 and 48 hours after PGN treatment and 
correlated with normal efferocytosis levels. The interplay between TNF-α, IL-10 and 
phagocytosis was not so clear-cut with LTA treatment (perhaps because LTA was the 
weakest inductor of TNF-α production in our system). The TNF-α concentration rose 
only once during the culture (it was maximal 32 hours after LTA treatment) and it 
was associated with the maximum inhibition of phagocytosis. Although the 
maximum increase in IL-10 concentration was observed at 16 hours, the TNF-α 
concentration was decreasing between 32 and 48 hours after LTA treatment.  
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 The observed interplay between TNF-α and IL-10 may be explained, at least 
in part, by the phenomenon known as ‘endotoxin tolerance’ (Dobrovolskaia & Vogel, 
2002). It has been shown that pre-treatment of cells with LPS results in their 
hyporesponsiveness to LPS during subsequent stimulation (‘endotoxin tolerance’). It 
is interesting, especially in regard to data presented in this PhD thesis, that endotoxin 
tolerant and non-tolerant cells, when stimulated with LPS, differ in the pattern of 
expressed genes. During LPS treatment, Mφ that have been already exposed to LPS, 
fail to produce pro-inflammatory cytokines i.e., TNF-α, IL-1β, IL-6 or IL-12 while 
production of anti-inflammatory IL-10, IL-1 receptor antagonist or soluble TNF-R2 is 
normal or elevated. It is suggested that in endotoxin tolerant cells activation of 
transcription factor NF-κB is impaired by a number of mechanisms and this is 
associated with inhibition of TNF-α production (Dobrovolskaia et al., 2003). 
Furthermore, the phenomenon of tolerance is not specific for LPS but shared with 
other TLR agonists (Lehner et al., 2001). I therefore speculated that, in our system, 
cells responded to LPS, PGN and LTA treatments by producing TNF-α, then became 
hyporesponsive and produced increased amounts of IL-10. The latter was associated 
with inhibited release of TNF-α. Interestingly, the more powerful agent used (e.g., 
LPS) the earlier cells became tolerant (between 6-12 hours after LPS treatment). It is 
possible that observed tolerance is transient and the second spike of TNF-α occurred 
when cells regain sensitivity towards LPS or PGN. It still remains to be established 
why the second peak of TNF-α was not observed in case of LTA treatment. It is 
possible that the fact that this agent was the weakest inducer of TNF-α may be an 
important factor.   
 Interestingly, although TNF-α concentration rose twice during LPS treatment 
only the second peak of TNF-α was correlated with significant decrease of 
phagocytosis. This is in contrast to PGN-treated samples where both peaks of TNF-α 
were associated with significant inhibition of phagocytosis. However, it is 
noteworthy, that upon PGN treatment the initial increase in TNF-α concentration 
lasted longer (up to 16 hours following PGN treatment) than in case of LPS (up to 6 
hours following LPS treatment). The second important observation is that upon PGN 
treatment, during the first increase of TNF-α, significant reduction of phagocytosis 
appeared after 16 hours while phagocytosis was inhibited almost instantly during the 
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second rise in TNF-α concentration for both PGN and LPS treatments. Thus, it is 
possible that, in my system, some transient processes were taking place that made 
cells unresponsive to TNF-α during the first few hours of treatment and therefore 
played an important role in maintaining phagocytosis during the first few hours of 
LPS treatment. One potential mechanism here is internalisation of TNF-Rs, which 
has been reported in cells treated with LPS (Ding et al., 1989). If this is a case in my 
study it would be interesting to investigate it further and establish e.g., the duration of 
time needed for restoration of TNF-Rs on the cell surface and if this process is 
specific for LPS or perhaps shared with other TLR agonists such as PGN or LTA.  
 Since convincing evidence exists indicating that IL-10 can inhibit TNF-α 
production (Donnelly et al., 1999;Rossato et al., 2007;Raychaudhuri et al., 
2000;Kontoyiannis et al., 2001;Rossato et al., 2007) and up-regulate efferocytosis 
(Ogden et al., 2005;Xu et al., 2006) I hypothesised that in my system IL-10 opposed, 
at least in part, the LPS inhibitory effect on phagocytosis. I investigated this further 
and provided several lines of evidence demonstrating that IL-10 plays a crucial role in 
sustaining the clearance of apoptotic neutrophils by LPS-stimulated Mφ. First of all, 
addition of exogenous IL-10 reversed the LPS-induced inhibitory effect and this 
effect was associated with concentration-dependent inhibition of TNF-α production 
(see Figure 5.3). Of note, exogenous IL-10 had very limited ability to reverse the 
inhibition of phagocytosis induced by TNF-α already present in culture medium. 
Furthermore, presence of IL-10 in control samples augmented Mφ phagocytosis of 
apoptotic neutrophils in a concentration-dependent manner. Next, I blocked the 
activity of endogenous IL-10 produced by LPS-stimulated Mφ with an anti-IL-10-
R1Ab and observed much earlier and greater inhibition of phagocytosis (see Figure 
5.5). Finally, I compared the phagocytosis by wt and IL-10-/- BMDMφ and found that 
the latter had much lower ability to phagocytose apoptotic neutrophils in control and 
pro-inflammatory conditions (see Table 5.1). Thus, I concluded that IL-10 mediates 
its protective effects over phagocytosis mainly by inhibition of TNF-α production but 
does not have the ability to completely override the inhibitory effects of TNF-α 
already present in culture medium. However, since IL-10 per se augments 
phagocytosis of apoptotic neutrophils it can mask the effects of TNF-α to a small 
extent (see Figure 5.4). The above-described data are consistent with previously 
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published findings and show, for the first time, that phagocytosis of apoptotic 
neutrophils is dynamically regulated by the subtle balance between pro- and anti-
inflammatory cytokines, specifically TNF-α and IL-10. It is clear that exposure of 
cells to pro-inflammatory stimuli, such as LPS, induces production of pro-
inflammatory cytokines (e.g., TNF-α), followed by anti-inflammatory cytokines (e.g., 
IL-10). IL-10 then feeds back to inhibit pro-inflammatory responses. Here, I show 
that these events directly affect Mφ clearance of apoptotic neutrophils, the process 
which we believe to be essential for effective resolution of the inflammatory 
response.  
 My observation is supported by a recently published study by Fernandez-
Boyanapalli and colleagues demonstrating that in a murine model of X-linked chronic 
granulomatous disease (X-CGD) Mφ are characterised by increased production of 
pro-inflammatory cytokines and decreased ability to phagocytose apoptotic cells in 
vivo and ex vivo (Fernandez-Boyanapalli et al., 2009). Furthermore, the authors show 
that pre-treatment of X-CGD Mφ with anti-inflammatory cytokine IL-4 can change 
Mφ activation status and increase their ability to ingest apoptotic cells. When wt Mφ 
were cultured with IL-4 neutralising antibodies the phagocytosis was found to be 
significantly decreased, further supporting the role of IL-4 as a positive regulator of 
phagocytosis. Quite surprisingly, when the authors pre-treated X-CGD Mφ with IL-
10, phagocytosis did not increase. However, X-CGD Mφ were characterised by 
defective IL-4 expression in comparison to wt Mφ. It is possible that IL-10 acts in 
concert with IL-4 and, thus, pre-treatment of cells with IL-10 alone did not augment 
phagocytosis. Furthermore, Mφ isolated from X-CGD animals were plated for at least 
a few hours before addition of IL-10. Since these cells produced pro-inflammatory 
cytokines, e.g., TNF-α, it is likely that IL-10 was added to the Mφ already exposed to 
TNF-α. This is in agreement with data presented in this PhD thesis, where IL-10 had 
a limited ability to interfere with the effects of TNF-α and reversed inhibitory effects 
of LPS mainly by blocking TNF-α production.  
 It is now accepted that Mφ, depending on the type of cytokines that they are 
exposed to, may undergo either classical (Th1) or alternative (Th2) activation 
(Classen et al., 2009). The classically activated (pro-inflammatory) Mφ are obtained 
by stimulation with IFN-α or LPS, characterised by production of pro-inflammatory 
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cytokines e.g., TNF-α and, as demonstrated in this PhD thesis, by decreased clearance 
of apoptotic neutrophils. The classically activated Mφ produce NO and other 
intermediates, which destroy microorganisms at inflammatory sites and therefore play 
an important function at the onset of inflammation. On the contrary, anti-
inflammatory mediators such as IL-4, IL-10 or IL-13 are postulated to induce 
alternative activation of Mφ. Two subclasses of alternatively activated Mφ are 
currently recognised, regulatory and wound-healing Mφ (Mosser & Edwards, 2008). 
The wound-healing Mφ play an important role in tissue repair whereas regulatory Mφ 
in suppression of immune responses. Regulatory Mφ are characterised by decreased 
production of pro-inflammatory mediators such as TNF-α, increased release of IL-10 
and, as demonstrated in this PhD thesis, increased ability to phagocytose apoptotic 
neutrophils promoting resolution of inflammation. It is possible that in in vivo 
settings impaired production or signalling of IL-10 (or other alternative activators of 
Mφ) may lead to overexpression of TNF-α and consequential decreased clearance of 
apoptotic cells, secondary necrosis and exacerbation of inflammation. Several clinical 
trials have been conducted in order to establish efficacy of IL-10 in treatment of 
chronic inflammatory conditions such as Crohn’s disease or ulcerative colitis. 
However, IL-10 (when administered systemically) does not seem to be as a powerful 
anti-inflammatory agent as TNF-α inhibitors (see chapter 1.5.3 for more information). 
Based on the observation provided in this PhD thesis one may speculate that, in 
contrast to TNF-α inhibitors, IL-10 does not counteract the effects of TNF-α already 
present at inflamed tissue and therefore this cytokine may not be able to rescue 
phagocytosis of apoptotic cells and resolve inflammation. Yet, further in vivo studies 
should be performed in order to draw any final conclusion with this regard. 
 The mechanism(s) underlying LPS-stimulation of IL-10 production is not 
fully understood. It has been suggested that several of the LPS-induced pro-
inflammatory cytokines may stimulate IL-10 release, which, in turn, feeds back to 
inhibit further production of pro-inflammatory cytokines. Indeed, it has been shown 
that LPS-stimulated BMDMφ, which were characterised by impaired production or 
signalling of type I IFN produce excessive amounts of pro-inflammatory cytokines 
(Chang et al., 2007). Furthermore, some studies suggest a number of possible 
mechanisms underlying the opposing actions of IL-10 and LPS on many cellular 
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processes also including IL-10-induced inhibition of TNF-α production upon LPS 
activation. For instance, one study demonstrated that IL-10 blocks expression of the 
MyD88 adaptor protein, crucial for transduction of LPS-induced signalling (LPS 
signalling pathways are discussed in chapter 1.2.2.1). The authors reported that the 
levels of MyD88 mRNA in LPS-stimulated RAW 264.7 cells remained the same 
irrespective of pre-treatment of cells with IL-10. However, cells cultured in the 
presence of IL-10 were characterised by reduced levels of MyD88 protein resulting in 
affected LPS-signalling, impaired activation of NF-κB, p38 and stress-activated 
protein kinase (SAPK) (Dagvadorj et al., 2008). IL-10 may also exert some direct 
effects on NF-κB by blocking IκB kinase activity and by inhibiting NF-κB already 
present in the nucleus. The latter is a direct consequence of IL-10-induced nuclear 
translocation of repressive p50/p50 homodimers, which bind DNA and block its 
transcriptional activity (Driessler et al., 2004). Interestingly, it is been suggested that 
IL-10 induces the latter effect via stimulation of Bcl-3 expression. It has been shown 
that in LPS-activated Mφ, Bcl-3 interacts with p50 subunit of NF-κB and promotes 
its binding to the TNF-α promoter in the nucleus and subsequent inhibition of TNF-α 
expression (Kuwata et al., 2003). In contrast, some studies demonstrate that IL-10 
does not block the LPS-induced NF-κB activation but rather inhibits LPS signalling 
through stimulation of suppressor of cytokine signalling SOCS-3 (discussed in more 
detail in chapter 1.2.2.2) (Qin et al., 2006). It has been also demonstrated that IL-10 
counteracts the LPS-induced survival of neutrophils through a mechanism that 
involves inhibition of ERK activation (Ward et al., 2005). There is contradiction in 
literature whether IL-10 blocks TNF-α production in LPS stimulated cells via 
inhibition of activation of MAPK/SAPK (i.e., p38, JNK and ERK). While some 
studies suggest that IL-10 exerts direct inhibitory effects on these kinases 
(Kontoyiannis et al., 2001) another report demonstrates otherwise (Denys et al., 
2002). In this PhD thesis, we investigated MAPK/SAPK activation upon LPS 
treatment. As demonstrated in Figure 5.10, LPS treatment (10ng/ml) transiently 
activates p38, JNK and ERK MAPK/SAPK in MDMφ. These effects were correlated 
with an increase in TNF-α production (as confirmed by ELISA, data not shown). I 
also obtained preliminary data that show that inhibition of p38 phosphorylation with 
the kinase inhibitor SB202190 is associated with decreased culture medium 
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concentration of TNF-α (data not shown). This observation is supported by many 
others indicating the crucial role of p38 kinase in TNF-α expression (see chapter 
1.2.2.1 for more details). Yet, when I incubated Mφ with LPS and IL-10 no 
difference has been identified in p38 activation in comparison to samples treated only 
with LPS (see Figure 5.11). Since this was only a pilot experiment this data was not 
conclusive. Further work is required to fully establish if, in my system, IL-10 blocks 
production of TNF-α via inhibition of p38 activation. For instance various 
concentration of IL-10 and LPS or durations of incubation should be examined. It is 
also possible that IL-10 affects other MAPK/SAPK and, thus, future work should 
include blotting for ERK and JNK.  
 
 
Figure 5.10 MAPK/SAPK expression and activation in MDMφ following LPS 
stimulation (next page). Western blots were obtained with the use of 
phosphorylation status-dependent and independent antibodies against p38 (38 kDa, 
A), ERK1/2 (42 and 44 kDa, B) and JNK (46 and 54 kDa, C) kinases following pre-
treatment of MDMφ with LPS for 30, 60, 120 and 180 minutes as indicated. MM – 




























































Figure 5.11 p38 expression and activation in LPS-stimulated MDMφ in the 
presence of IL-10. Western blots were obtained with the use of phosphorylation 
status-dependent and independent antibodies against p38 following pre-treatment of 
MDMφ with either LPS or concurrently with LPS and IL-10 for 15 and 30 minutes as 
indicated. MM – molecular weight size marker, MC – medium control, (p) - 
phosphorylated form of p38. 
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 Having found that IL-10, at least in part, rescued phagocytosis upon LPS 
treatment I sought to investigate whether another powerful anti-inflammatory agent, 
dexamethasone would exert similar effects. This synthetic glucocorticosteroid exerts 
numerous anti-inflammatory effects and in many ways resembles the anti-
inflammatory cytokine IL-10. For instance, it has been demonstrated that both 
glucocorticoids and IL-10 stimulate expression of glucocorticoid-induced leucine 
zipper (GILZ), which plays an essential role in the inhibition of transcription factors 
AP-1 and NF-κB (Godot et al., 2006). Dexamethasone has been also reported to 
augment, in a concentration- and time-dependent manner, Mφ efferocytosis (Giles et 
al., 2001;Liu et al., 1999) as well as inhibit production of pro-inflammatory cytokines 
in Mφ (Barnes, 1998). In this study, I have demonstrated that dexamethasone, like IL-
10, reversed the inhibitory effect of LPS on Mφ phagocytosis. However, in contrast to 
IL-10, dexamethasone turned out to be a powerful suppressor of TNF-α-induced 
inhibition of phagocytosis. Since dexamethasone did not completely inhibit the TNF-
α production in LPS-treated MDMφ (see Figure 5.6) and increased the uptake of 
IgG-opsonized erythrocytes (see Figure 3.7) it is possible that that its effect is more 
complex and likely involves modulation of several signalling pathways. For instance, 
glucocorticoids exert some of their anti-inflammatory effects via stimulating Anx 1 
production (Parente & Solito, 2004). Anx 1 was originally identified as a 
phospholipase A2 (PLA2) inhibitory protein (PLA2 plays an important role in the 
release of AA from plasma membrane phospholipids and subsequent yield of its 
active metabolites; see chapter 1.5.2 for further information). Now, it appears that 
Anx 1 also inhibits the expression and/or activity of other inflammatory enzymes 
such as inducible nitric oxide synthetase (iNOS) or COX2. Some of these effects may 
be related, at least in part, to Anx 1-induced IL-10 production (Parente & Solito, 
2004). Future work would therefore include investigation of the exact mechanism 
underlying the dexamethasone-induced augmentation of efferocytosis and reversal of 
LPS and TNF-α inhibitory effects. However, I hypothesise that at least a few 
processes may be here involved and they are briefly discussed below.  
 It has been demonstrated that dexamethasone, possibly due to enhanced Anx 1 
expression, stimulates production of IL-10 in Mφ (Mozo et al., 2004;Xia et al., 
2005). In this PhD thesis, I have shown that IL-10 augments Mφ clearance of 
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apoptotic neutrophils per se as well as inhibits production of TNF-α by LPS-
stimulated Mφ. Yet, as shown in Figure 5.6 I did not identify elevated levels of IL-10 
in samples treated with dexamethasone just prior to the phagocytosis assay. It is 
possible that experimental conditions e.g., duration of treatment or type of cells play 
an important role in IL-10 induction by dexamethasone. Thus, more experiments 
should be performed in order to fully answer the question whether increased IL-10 
production contributes to dexamethasone-induced reversal of inhibitory effects of 
LPS or TNF-α on phagocytosis. For instance, IL-10 concentrations should be 
measured at earlier time points after dexamethasone treatment. 
 Furthermore, Anx 1 has been reported to be directly involved in the 
phagocytosis process by serving as a bridge molecule between ‘eat me’ signals on the 
surface of apoptotic cells and phagocytic receptors on Mφ (see chapter 1.3.2.2 for 
more information). There is also evidence that Anx 1 is recognised by a G protein–
coupled receptor (ALXR, originally identified as low-affinity N-formyl-methinyl-
leucyl-phenylalanine receptor-like 1), which also binds LXA4 and ATLs (Scannell & 
Maderna, 2006). Lipoxins are well-known for their pro-phagocytic properties 
(Godson et al., 2000). It is therefore possible that Anx 1-induced phagocytosis 
involves the same pathways as lipoxin-induced phagocytosis (Scannell & Maderna, 
2006).   
 Interestingly, several lines of evidence indicate that TNF-α exerts its cellular 
effects not only by stimulating transcription of NF-κB-directed genes but also by 
activating PLA2 and inducing the AA cascade. AA metabolites, especially 
leukotrienes, seem to be involved in variety of intracellular TNF-α-induced events 
including NF-κB activation. In fact, some studies have demonstrated in TNF-α-
treated cells that PLA2 and LOX5 inhibitors interfere with transcription of genes 
dependent on NF-κB (van Puijenbroek et al., 1999;Anthonsen et al., 2001). This 
observation gives more insight into the potential mechanism underlying 
dexamethasone’s ability to fully reverse the TNF-α inhibitory effect on phagocytosis 
in our system. In addition, as discussed in chapter 1.5.2, PGs and particularly PGE2, 
inhibit Mφ phagocytosis and therefore the reduction of AA metabolism by 
dexamethasone could significantly contribute to its pro-phagocytic properties. Yet, in 
order to prove that in my study dexamethasone overrides TNF-α-induced inhibition 
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of phagocytosis by blocking AA cascade future work should be performed involving 
e.g., measurement of PLA2 activity, release of AA metabolites or NF-κB activation. 
Nevertheless, my findings provide further insight into the anti-inflammatory 
properties of glucocorticoids and may explain, at least in part, their efficacy in 
treatment of chronic inflammatory diseases (see chapter 1.5.1 for further 
information).  
 Next, I performed some experients in order to investigate if another class of 
anti-inflammatory drugs, NSAID (see chapter 1.5.2 for more details), would exert 
similar effects to dexamethasone. As demonstrated in Figure 5.8, in contrast to 
dexamethasone, none of the tested NSAID augmented Mφ phagocytosis of apoptotic 
cells. In fact, when used at very high concentrations (1000 µM, except indomethacin 
100 µM), they inhibited the MDMφ clearance of apoptotic neutrophils. In addition, 
MDMφ treatment with selective COX1 (SC-560) or COX2 (NS-398) inhibitors (250 
µM) also reduced MDMφ capacity for phagocytosis. Interestingly, when viability of 
cells was assessed (trypan blue), the results suggested that decrease in phagocytosis 
did not result from NSAID - induced cell toxicity (see Table 5.2). However, this 
assay does not distinguish between non-apoptotic and apoptotic cells and it is well-
established that NSAID can induce cell apoptosis by COX2 dependent and COX2-
independent mechanism (Jana, 2008). Thus, in order to give more insight into the 
exact mechanism underlying the above observation, apoptosis levels should be 
confirmed by additional methods e.g., flow cytometry or morphology. It is also 
possible that very high concentrations of NSAID exert some pro-inflammatory effects 
on cells. In fact, it has been reported that aspirin at 1000 µM may upregulate COX2 
activity (Mortaz et al., 2005). If this is the case, it is possible that subsequent 
production of PGs significantly contribute to the observed decreased phagocytosis 
(see chapter 1.5.2 for further information regarding the PGs effects on phagocytosis). 
On the other hand, NSAID have been shown to augment TNF-α release from LPS-
stimulated cells (Rouzer et al., 2004;Cho, 2007). The latter effect is associated with 
the ability of exogenous PGE2 and prostacyclin to suppress TNF-α release in LPS-
treated Mφ (Rouzer et al., 2004). It would be interesting, especially in a context of 
this study, to investigate, if PGs play important roles in TNF-α regulation in my 
system. PGE2 has been demonstrated to reduce phagocytosis per se (Rossi et al., 
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1998b) and therefore its effect may be insignificant in terms of augmentation of 
phagocytosis upon LPS treatment.  
 Aspirin, when compared to other NSAID, possesses quite unique anti-
inflammatory properties. First of all, aspirin has been shown to interfere with NF-κB 
activation via a quite specific inhibition of IKK2 (Mazur et al., 2007). Second, aspirin 
induces production of so-called aspirin-triggered lipoxins that have been shown to 
augment phagocytosis of apoptotic cells (as further discussed in chapter 1.5.2). 
Therefore, I sought to investigate if aspirin, similarly to dexamethasone, may reverse 
the inhibitory effects of TNF-α on phagocytosis. As demonstrated in Figure 5.9 
aspirin at 300 µM rescued phagocytosis inhibited by TNF-α. Yet, when used at a high 
concentration (1200 µM) this effect was minimal (possibly due to inhibitory effect on 
phagocytosis discussed in previous paragraphs). The exact mechanism underlying the 
reversal of TNF-α inhibition of phagocytosis by aspirin is still to be investigated 
however it quite likely involves inhibition of COX, NF-κB or production of aspirin-
triggered lipoxins.  
 Summing up, the above data demonstrate that MDMφ efferocytosis is 
dramatically regulated by their environment. After exposure to pro-inflammatory 
stimuli, at the onset of inflammation, the balance between cytokines shifts towards 
pro-inflammatory mediators (e.g., TNF-α) and this effect is associated with decreased 
uptake of apoptotic cells. However, during the resolution phase the balance of 
cytokines shifts towards anti-inflammatory mediators (e.g., IL-10) thereby 
augmenting efferocytosis and facilitating resolution of inflammation. As 
demonstrated in Figure 5.3, IL-10 is a very powerful inhibitor of pro-inflammatory 
cytokine production (Moore et al., 1990;Kontoyiannis et al., 2001;Denys et al., 2002) 
and consequently defects in either IL-10 secretion or function may represent a critical 
factor in development of inflammatory diseases (Ebert et al., 2009). It is also 
noteworthy that uptake of various phagocytic targets may alter cytokine production in 
Mφ and consequently influence their environment in an autocrine fashion. 
Phagocytosis of apoptotic cells actively inhibits, whereas phagocytosis of IgG-
opsonized cells induces production of pro-inflammatory cytokines such as TNF-α, 
IL-1β, IL-8 in both control or LPS treated Mφ (Fadok et al., 1998;Voll et al., 1997). 
Furthermore, it has been reported that apoptotic cells may have therapeutic potential 
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in LPS-induced septic shock by enhancing IL-10 production and reducing release of 
pro-inflammatory cytokines (Ren et al., 2008).  
 In addition, I was able to show that dexamethasone not only augments 
clearance of apoptotic cells but also rescue phagocytosis inhibited in the presence of 
LPS or TNF-α. This observation may explain, at least in part, the powerful anti-
inflammatory properties of steroids and their success in treatment of chronic 
inflammatory conditions. In contrast, NSAID do not increase phagocytosis per se. 
However, I did not evaluate their effects in cells challenged with pro-inflammatory 
stimuli (e.g., LPS) and upregulated levels of COX2. It is possible that in such 
circumstances NSAID, and especially aspirin (aspirin reversed TNF-α-induced 
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 Despite decades of research, little is known about the exact 
signals/mechanisms that trigger chronic inflammation and autoimmunity. Since 
numerous diseases have been demonstrated to have a chronic inflammatory 
component, it is necessary to better understand the underlying mechanisms. 
Currently, it is generally accepted that apoptosis of inflammatory cells and their 
subsequent non-inflammatory clearance by phagocytes are two key processes 
underlying the resolution of inflammation. They are controlled by many factors 
including cytokines, which allow cell communication and coordinate many 
physiological processes. TNF-α is a major pro-inflammatory cytokine, which is 
released in response to trauma and infection and plays an important role at the onset 
of inflammation. Yet, a few observations suggest that excessive or prolonged TNF-α 
release may be associated with development of chronic inflammation and 
autoimmunity (Michlewska et al., 2007). Chronically-inflamed sites are characterised 
by excess TNF-α and, importantly, TNF-α inhibitors, widely used in the clinical 
setting for treatment of RA, IBD or psoriasis, significantly delay disease progression. 
One can therefore speculate that the presence of TNF-α may affect processes 
implicated in resolution of inflammation (i.e., inflammatory cell apoptosis and their 
clearance by phagocytes) to influence the development of chronic inflammation and 


































FIGURE 6.1 Diagram representing the main hypothesis of this PhD thesis. An 
inflamed tissue is characterised by increased levels of TNF-α and defective processes 
implicated in resolution of inflammation. As demonstrated in this PhD thesis, TNF-α 
inhibits phagocytosis of apoptotic neutrophils; a key process involved in the resolving 
phase of inflammation. 
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 Previously published data demonstrated that TNF-α may exert variable effects 
on survival of inflammatory cells, such as neutrophils; inducing apoptosis at early 
time points (2-6 hours) and promoting survival after longer (12-24 hours) treatment 
(Ward et al., 1999). Furthermore, a few recent studies including this PhD thesis, 
showed that TNF-α, at least in vitro, inhibited clearance of apoptotic cells by mature 
Mφ (McPhillips et al., 2007;Borges et al., 2009;Michlewska et al., 2009). If this is 
the case in vivo, the excess of TNF-α may lead to accumulation of apoptotic material, 
secondary necrosis, consequential tissue damage, further release of TNF-α and 
exacerbation of inflammation. Thus, treatment with TNF-α inhibitors and 
consequential TNF-α depletion are likely to restore phagocytosis and resolve 
inflammation. However, TNF-α is critical to maintain immune functions and 
treatment with TNF-α inhibitors is associated with dampened immune responses and 
higher risk of severe infections, e.g., TB. This observation indicates that although 
TNF-α inhibition results in resolution of inflammation, this is not an optimal way of 
treatment. The precise timing of TNF-α release seems to be an important factor 
regulating onset and resolution of inflammation. Thus, there is a clinical need to 
better understand mechanisms underlying regulation of TNF-α release and its effects 
upon resolution of inflammation per se in order to develop new therapeutic strategies 
that would induce resolution of inflammation but at the same time allow maintenance 
of basic immune functions.  
 In this PhD thesis I have investigated the regulation of Mφ phagocytosis of 
apoptotic neutrophils by pro- and anti-inflammatory agents. In particular, I was 
interested in TNF-α effects and used exogenous TNF-α as well as a variety of agents 
to induce TNF-α production/release in differentiating monocytes/Mφ. In addition, I 
investigated the effects of anti-inflammatory agents (i.e., the anti-inflammatory 
cytokine IL-10, the synthetic steroid dexamethasone and NSAIDs) on Mφ 
phagocytosis of apoptotic neutrophils. Their ability to counteract the effects of pro-
inflammatory agents has also been examined.  
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6.2 SUMMARY  
 In order to investigate the role of TNF-α in the regulation of MDMφ 
phagocytosis of apoptotic neutrophils, MDMφ were treated with the bacterial derived 
cell activators (i.e., LPS, LTA and PGN) to induce MDMφ production of TNF-α. For 
comparison, MDMφ were also treated with exogenous TNF-α. As demonstrated in 
chapter 3, TNF-α treatment of mature MDMφ significantly inhibited the uptake of 
apoptotic neutrophils. This effect was observed at 6 hours after treatment (earlier time 
points were not examined in this thesis) and was dependent on TNF-α concentration 
and duration of treatment. These findings complement published studies suggesting 
that TNF-α inhibits phagocytosis by mature Mφ but does not exert such an effect on 
differentiating Mφ (Ren & Savill, 1995;McPhillips et al., 2007). In this PhD thesis, it 
has been showed for the first time that LPS treatment inhibits MDMφ phagocytosis of 
apoptotic neutrophils. Interestingly, even though LPS-induced TNF-α release 
occurred 6 hours after treatment, significant inhibition of phagocytosis was observed 
only after longer treatment (i.e., 96 hours). This observation complements data by 
McPhillips et al, who show that Mφ treated with LPS for 24 hours have unaffected 
ability to phagocytose apoptotic cells (McPhillips et al., 2007). In comparison to LPS, 
inhibitory effects of LTA and PGN were less pronounced and occurred at the 16 hour 
time point while increased concentrations of TNF-α were detectable at 6 hours 
following both treatments. When MDMφ were treated with PGN, initial decrease in 
phagocytosis occurred at the 16 hour time point, then disappeared at 32 and 48 hour 
time points and occurred again at 72 and 96 hour time points, partially reflecting the 
fluctuations in TNF-α concentration in culture medium. The above findings suggested 
that either the release of endogenous TNF-α is not solely responsible for inhibition of 
MDMφ phagocytosis or additional mechanisms interfered with the TNF-α-induced 
inhibition and maintained MDMφ ability to clear apoptotic cells in the presence of 
TNF-α (I investigated these hypotheses in more detail in chapters 4 and 5).  
 Another important finding presented in chapter 3 was that TNF-α and LPS 
had not blocked all phagocytic pathways in MDMφ and while both treatments 
significantly reduced clearance of apoptotic cells, phagocytosis of human IgG-
opsonised erythrocytes was not affected. Since various opsonins may bind to the 
surface of apoptotic cells, it is difficult to speculate if, in in vivo settings, TNF-α-
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induced inhibition of clearance of apoptotic cells results in secondary necrosis and 
exacerbation of inflammation. It is possible that in the presence of TNF-α apoptotic 
cells coated with opsonins are still cleared by alternative pathways and do not 
undergo secondary necrosis. Thus, as discussed in chapter 3, further in vivo studies 
should be performed to fully assess immunological consequences of TNF-α inhibitory 
effects on the phagocytosis of apoptotic neutrophils.  
 In experiments presented in chapter 4, I sought to investigate whether the LPS 
inhibitory effect upon phagocytosis was mediated by TNF-α (LPS treatment has been 
selected for these experiments due to a marked delay in mediating its inhibitory 
effect). Following 96 hours treatment, the strength of LPS-induced inhibition varied 
between donors and was positively correlated with the concentration of TNF-α in 
culture medium. Even though LPS-induced inhibition was significant in the majority 
of experiments, in a few samples I did not observe such an effect. Interestingly, this 
was associated with undetectable levels of TNF-α in culture medium prior to the 
phagocytosis assay.  
 In order to establish whether TNF-α production/release was critical for LPS to 
exert its inhibitory effect I tried to reduce TNF-α bioactivity/concentration in culture 
medium when MDMφ were treated with LPS. First of all, I used soluble TNF 
receptors: sTNF-R1/Fc and sTNF-R1. The sTNF-R1/Fc is composed of two subunits 
of TNF-R1 linked to the Fc portion of human IgG1 while sTNF-R1 is a monomeric 
receptor. Concomitant treatment of MDMφ with LPS (10 ng/ml) and sTNF-R1/Fc 
(500 ng/ml) significantly reversed the inhibitory effect of LPS upon phagocytosis 
suggesting a crucial role of TNF-α. This was further supported by a few important 
observations. Concomitant treatment of MDMφ with sTNF-R1/Fc and TNF-α 
blocked TNF-α-induced inhibition of phagocytosis. Furthermore, sTNF-R1/Fc was 
demonstrated not to induce Fc-mediated phagocytosis in our system. Theoretically, 
presence of the Fc-portion of human IgG1 within the sTNF-R1/Fc molecule could 
induce Fc-mediated phagocytosis and reverse the LPS-induced inhibition in this 
manner. This would, however, require binding of sTNF-R1/Fc to the cell surface 
(opsonisation). We demonstrated that the augmentation of phagocytosis by sTNF-
R1/Fc required its presence during the entire duration of LPS treatment. The addition 
of sTNF-R1/Fc into either neutrophil or MDMφ culture 30 minutes before the 
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phagocytosis assay or alternatively directly into the phagocytosis assay did not rescue 
phagocytosis. This suggested that sTNF-R1/Fc acts rather by neutralising TNF-α 
produced in response to LPS and not by inducing Fc-mediated phagocytosis 
(opsonisation is a quick process and 30 minutes would be enough to bind sTNF-
R1/Fc to a cell surface). I have also demonstrated that sTNF-R1/Fc, in contrast to 
ICs, did not bind to the surface of apoptotic neutrophils.  
 In contrast to sTNF-R1/Fc, treatment with sTNF-R1 did not significantly 
reverse the inhibitory effect of LPS upon phagocytosis (similar trend towards 
increased phagocytosis levels was observed). These findings are in agreement with 
published data (Scallon et al., 1995b;Mohler et al., 1993) demonstrating that dimeric 
TNF-Rs have much greater capacity for TNF-α binding when compared to 
monomeric TNF receptors (see section 4.4).  
 Since there is a growing interest in development of orally available TNF-α 
inhibitors, I have tried to reduce the concentration of sTNF-α in culture medium by 
blocking mTNF-α processing with TACE inhibitor TOPI-0. Although I could observe 
slightly increased phagocytosis when MDMφ were co-treated with LPS and TOPI-0, 
the reversal of LPS effect was not significant. As discussed in section 4.4, this 
observation may be potentially explained by the fact that TOPI-0 is not a selective 
TACE inhibitor and blocks activity of other cellular enzymes.  
 Having established that TNF-α release is necessary for LPS-induced 
inhibition of phagocytosis, we next sought to investigate mechanisms that delayed 
this process in our system. In experiments presented in chapter 5, I have partially 
explained why TNF-α release and inhibition of phagocytosis were not directly 
correlated phenomena (in our system TNF-α was released at 6 hours and inhibition 
occurred at 96 hours after LPS treatment). LPS is a general cell activator and induces 
the release of numerous cytokines, which, in turn, may potentially affect TNF-α 
release/effects. For instance, elevated IL-10 levels were detected in samples, where 
LPS treatment (96 hours) did not induce inhibition of phagocytosis and TNF-α 
concentration was minimal. Then, I measured concentrations of TNF-α and IL-10 at 
several time points following LPS, PGN and LTA treatments and observed that 
elevated IL-10 levels were associated with decreased TNF-α concentration. Thus, I 
hypothesised that presence of IL-10 interferes with TNF-α release/effects in our 
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system and delays the inhibitory effects of LPS. I supported this hypothesis with a 
few important findings. First of all, IL-10 per se increased MDMφ ability to 
phagocytose apoptotic neutrophils and, second, addition of exogenous IL-10 to LPS 
treated samples rescued phagocytosis. The latter effect was associated with the IL-10-
induced, concentration-dependent inhibition of TNF-α release. Interestingly, when 
IL-10 was added to TNF-α treated MDMφ, only slight augmentation of phagocytosis 
was observed. This indicated that, in my system, IL-10 delayed inhibitory effects of 
LPS mainly via inhibition of TNF-α release and not interference with the effects of 
TNF-α already present in the culture medium. Furthermore, when IL-10-mediated 
effects were blocked by addition of anti-IL-10-R1Ab, the LPS inhibitory effect on 
phagocytosis was much greater and occurred at 24 hours after treatment. Finally, the 
important role of IL-10 in maintenance of Mφ ability to phagocytose apoptotic cells 
was demonstrated in IL-10 deficient murine BMDMφ. IL-10 deficient BMDMφ, 
when compared to wt, were characterised by lower ability to phagocytose apoptotic 
neutrophils and this effect was independent of culture conditions (control samples, 
LPS or TNF-α treatments).  
 As discussed in chapter 5, dexamethasone in many ways resembles IL-10, i.e., 
augments MDMφ phagocytosis of apoptotic neutrophils (Giles et al., 2001;Liu et al., 
1999) and inhibits Mφ production of TNF-α (Barnes, 1998). In this PhD thesis, I 
demonstrated that dexamethasone rescued MDMφ phagocytosis upon treatment with 
either LPS or TNF-α but, interestingly, did not fully block the production of TNF-α 
by MDMφ treated with LPS. Since dexamethasone increased the uptake of both 
apoptotic neutrophils and IgG-opsonised erythrocytes, it is possible that 
dexamethasone-induced modulation of phagocytosis is more complex and involves 
several signalling pathways. Interestingly, some studies showed that dexamethasone 
induced Mφ production of IL-10 (Mozo et al., 2004;Xia et al., 2005). I did not find a 
significant increase in IL-10 concentration following MDMφ treatment with 
dexamethasone and LPS for 120 hours. Thus, it is possible that in my system 
dexamethasone effects on phagocytosis were not necessarily associated with 
increased IL-10 release. However, due to time limitation, IL-10 concentrations were 
not measured at earlier time points and I was unable to draw any final conclusion in 
this regard.  
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 In this PhD thesis, I investigated the effects of NSAID on MDMφ 
phagocytosis. In contrast to dexamethasone, NSAID did not augment MDMφ 
phagocytosis of apoptotic neutrophils and, interestingly, when used at greater 
concentrations (1000 µM) reduced MDMφ phagocytosis. Furthermore, aspirin was 
demonstrated to reverse the inhibitory effect of TNF-α on phagocytosis when used at 
lower concentration (300 µM). The latter finding is potentially associated with the 
unique ability of aspirin to generate aspirin-triggered lipoxins (Gilroy et al., 2004). 
Aspirin-triggered lipoxins, as discussed in section 1.5.2, augment MDMφ 
phagocytosis of apoptotic neutrophils. 
 In summary, it has been determined that prolonged pro-inflammatory 
challenge may affect resolution of inflammatory responses via inhibition of MDMφ 
efferocytosis. I have shown that TNF-α is a key mediator in this process and that IL-
10 exerts an important regulatory effect on TNF-α production and consequently on 
efferocytosis. Furthermore, I found several approaches to successfully decrease either 
TNF-α production or its inhibitory effect, and consequently reverse LPS-mediated 
inhibition of efferocytosis. The summary of the results is graphically presented in 
Figure 6.2. Data presented in this PhD thesis indicate the significance of TNF-α in 
development of chronic inflammation as well as cytokine regulation in the resolution 
of inflammation. Furthermore, presented findings provide important mechanistic 
information into the mode of action of steroids and anti-TNF-α agents and may help 
























FIGURE 6.2 Schematic representation of the effects of pro- (TNF-α) and anti-
inflammatory (IL-10, dexamethasone, TNF-α inhibitors) agents on clearance of 
apoptotic cells and resolution of inflammation. Pro-inflammatory situations e.g., 
trauma or infection (exposure to bacterial products such as LPS) result in release of 
TNF-α and potentially in reduced clearance of apoptotic neutrophils. An excessive or 
prolonged TNF-α release is associated with development of chronic inflammation. 
The latter can be prevented by inhibiting TNF-α expression with IL-10 or steroids 
(dexamethasone) or alternatively by blocking TNF-α bioactivity with TNF-α 
inhibitors (e.g., sTNF-R1/Fc).  
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6.3 CLINICAL IMPLICATION 
 Apoptosis of inflammatory cells and their subsequent clearance by Mφ are 
thought to be key mechanisms underlying resolution of inflammation. The sites of 
chronic inflammation are characterised by increased release of pro-inflammatory 
cytokines, e.g., TNF-α, but for a long time the exact TNF-α-induced processes 
delaying the resolving phase of inflammation have not been fully determined. 
Recently, a few studies have demonstrated that TNF-α inhibits clearance of apoptotic 
neutrophils by mature Mφ (McPhillips et al., 2007;Borges et al., 2009;Michlewska et 
al., 2009). Thus, potentially, overexpression of TNF-α at inflamed tissue may reduce 
phagocytosis of apoptotic cells resulting in secondary necrosis, release of cytotoxic 
cell contents with consequential damage into surrounding tissue, further TNF-α 
release and exacerbation of inflammation. This may explain, at least in part, the 
success of TNF-α inhibitors in delaying the progression of chronic inflammatory 
conditions such as RA, CD or psoriasis (see section 1.5.3). TNF-α inhibitors, by 
decreasing TNF-α bioactivity, restore clearance of apoptotic cells and prevent 
harmful consequences of secondary necrosis. Unfortunately, treatment with TNF-α 
inhibitors is associated with reduced immune responsiveness (as discussed in section 
1.2, physiological concentrations of TNF-α are crucial for the onset of inflammation). 
It is known that patients treated with TNF-α inhibitors are more prone to develop 
severe infections e.g., TB (Wallis, 2008). This adverse effect could be avoided by 
development of tissue/site-specific delivery systems that would deliver TNF-α 
inhibitors to chronically inflamed sites resulting in only local (not systemic) decrease 
in TNF-α bioactivity. For instance it has been shown that in mice with dextran 
sulphate sodium (DSS)-induced chronic colitis, administration of Lactococcus lactis 
engineered to secret monovalent and bivalent murine (m)TNF-neutralising 
nanobodies resulted in significantly dampened local colon inflammation and did not 
have a systemic effect (Vandenbroucke et al., 2010).  
 In contrast to TNF-α, the anti-inflammatory cytokine IL-10 has been reported 
to augment Mφ clearance of apoptotic cells (Xu et al., 2006;Ogden et al., 2005). In 
this PhD thesis, I was able not only to observe the pro-phagocytic effect of IL-10 but 
also to demonstrate that IL-10 delays the LPS-induced effect upon phagocytosis, 
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mainly by inhibiting TNF-α production. However, IL-10 has a very limited ability to 
reverse TNF-α-induced inhibition. Dexamethasone, similar to IL-10, rescued MDMφ 
phagocytosis upon LPS treatment and was shown to override the inhibitory effects of 
TNF-α. This may explain, at least in part, why synthetic steroids are such powerful 
anti-inflammatory therapeutics. Furthermore, by evaluating the effects of several pro- 
and anti-inflammatory agents I established that MDMφ phagocytosis of apoptotic 
neutrophils is actively regulated by a subtle balance between pro- (e.g., TNF-α) and 
anti-inflammatory (e.g., IL-10) cytokines. These findings are supported by others 
(Fernandez-Boyanapalli et al., 2009). Thus, as demonstrated in Figure 6.3, any factor 
that either impairs IL-10 release/signalling or induces an excessive and/or prolonged 
TNF-α release can potentially trigger exacerbation of inflammation. For instance, IL-
10 deficient mice were reported to develop spontaneous chronic IBD (Wei et al., 
2008).  
 Based on the above-mentioned findings, a concept of classically and 
alternatively activated Mφ has been recently introduced (Fernandez-Boyanapalli et 
al., 2009). Accordingly, pro-inflammatory mediators (e.g., TNF-α) are classical 
activators of Mφ, they can reduce Mφ efferocytosis and contribute to development 
chronic inflammation. On the contrary, anti-inflammatory mediators such as IL-10 
and glucocorticoids change Mφ inflammatory status into anti-inflammatory 
(alternative activation) (Michlewska et al., 2009;Borges et al., 2009) The latter effect 
is associated with enhanced clearance of apoptotic cells and resolution of 
inflammation. 
 It is possible that, in vivo, TNF-α inhibitors deplete TNF-α and rescue 
phagocytosis of apoptotic cells. Consequently, as discussed in chapter 1.3.2.4, 
phagocytes start producing anti-inflammatory mediators e.g., IL-10 with associated 
alteration of Mφ activation status from pro- into anti-inflammatory. The latter is 
associated with further release of the anti-inflammatory cytokine IL-10 and resolution 
of inflammation. Several studies support this hypothesis demonstrating that uptake of 
apoptotic cells changes the pattern of cytokines released by Mφ and stimulates IL-10 
release (Fadok et al., 1998;Voll et al., 1997). Thus, arguably an ideal therapeutic 
strategy for treatment of chronic inflammatory conditions should aim at shifting the 
cytokine balance towards anti-inflammatory IL-10 or IL-4 rather than reducing 
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bioactivity of TNF-α. As recently demonstrated, apoptotic cells could help to achieve 
this goal. Administration of apoptotic cells in mice can protect them from LPS-
induced septic shock by multiple mechanisms, including suppression of TNF-α and 
induction of IL-10 release by Mφ following phagocytosis of apoptotic cells (Ren et 
al., 2008). It is possible that also in humans administration of apoptotic cells could 
change the cytokine balance towards an anti-inflammatory scenario without affecting 
TNF-α bioactivity. Hypothetically, in such settings, cells would be able to produce 
sufficient concentrations of TNF-α in response to pro-inflammatory stimuli and 




































FIGURE 6.3 Schematic representation of fluctuations in a cytokine balance 
during subsequent phases of an inflammatory response. At the onset of 
inflammation the cytokine balance is shifted towards pro-inflammatory cytokines 
(e.g., TNF-α). A resolving phase of inflammation is, in turn, associated with 
production of anti-inflammatory mediators (e.g., IL-10) and upregulated apoptosis of 
inflammatory cells and their clearance by phagocytes. If production of anti-
inflammatory mediators is impaired or, alternatively, production of pro-inflammatory 
mediators is excessive, inflammation does not resolve and is associated with 
prolonged lifespan of inflammatory cells and reduced phagocytosis of apoptotic cells. 
The latter results in secondary necrosis and exacerbation of inflammation.  
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6.4 FUTURE DIRECTIONS 
 
 In this PhD thesis a few important observations have been made. Firstly, 
prolonged MDMφ treatment with LPS, LTA or PGN resulted in reduced clearance of 
apoptotic cells. These effects were associated with increased TNF-α release and, in 
the case of LPS treatment, we showed that TNF-α mediated LPS-induced inhibitory 
effects. Secondly, IL-10 significantly delayed the LPS inhibitory effect on 
phagocytosis, mainly by inhibition of TNF-α production. Similar findings were 
obtained for a synthetic steroid, dexamethasone (see section 6.3 for summary of the 
results). Interestingly, both IL-10 and glucocorticoids have been demonstrated to play 
an important role in maintenance of ‘endotoxin tolerance’ (Berg et al., 1995;Rearte et 
al., 2010). Data presented in this PhD thesis clearly indicate that the balance between 
pro- and anti-inflammatory mediators defines Mφ ability to phagocytose apoptotic 
cells. Yet, in order to fully understand these processes further work should be 
performed. TNF-α and IL-10 effects on Mφ clearance of apoptotic cells in vivo 
should be determined as well as elucidating the exact mechanisms underlying TNF-α-
induced inhibition or IL-10- and dexamethasone-induced augmentation of 
phagocytosis.  
 
6.4.1 THE EFFECTS OF TNF-α ON CLEARANCE OF 
APOPTOTIC INFLAMMATORY CELLS IN VIVO 
 Since all the experiments presented in this thesis were performed in vitro I 
think it would be prudent to investigate the effects of TNF-α on efferocytosis in vivo, 
in animal models of inflammation. TNF-α plays a crucial role in development of 
arthritis (see section 1.4.1) and, thus, a model of collagen-induced arthritis could be 
used in further investigations (Earp et al., 2008a;Earp et al., 2008b). It would be 
interesting to establish whether TNF-α indeed inhibits Mφ phagocytosis of 
inflammatory cells in vivo in such a model. I demonstrated that while TNF-α 
inhibited clearance of apoptotic cells it did not exert any significant effects on 
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clearance of opsonised particles. It is known that in in vivo settings apoptotic cells 
may undergo opsonisation and be cleared by other mechanisms. This would prevent 
secondary necrosis but not necessarily further TNF-α release. It is generally accepted 
that phagocytosis of opsonised particles, in contrast to phagocytosis of apoptotic 
cells, induces TNF-α release by Mφ (however, some exceptions have been reported 
and are discussed in section 1.3.2.4). Thus, it would be interesting to investigate 
whether excess of TNF-α at inflamed tissue results in accumulation of apoptotic 
material and secondary necrosis or, alternatively, in opsonisation of apoptotic cells 
and their clearance by distinct mechanisms. If the latter is true, it would be interesting 
to examine whether further release of TNF-α is induced resulting in exacerbation of 
inflammation.  
 
6.4.2 THE ROLE OF IL-10 IN PREVENTION OF 
CHRONIC INFLAMMATION (ALTERNATIVE 
ACTIVATION OF MΦ) 
 This PhD thesis complements data by others and demonstrates that IL-10 
increases MDMφ phagocytosis and, importantly, upon LPS treatment, inhibits the 
release of TNF-α and rescues phagocytosis. Therefore, one may speculate that 
reduced ability to produce IL-10 or defects in IL-10 signal transduction pathways 
could suffice to account for development of chronic inflammation. I have already 
demonstrated that MDMφ isolated from various donors responded to LPS with 
various degrees of inhibition of phagocytosis and these effects were associated with 
variable TNF-α and IL-10 release. Furthermore, in animal models, IL-10 deficiency 
have been shown to be associated with development of spontaneous IBD (Kuhn et 
al., 1993). Thus, it would be interesting to investigate if, in humans, development of 
chronic inflammatory conditions (e.g., RA, Crohn’s disease) is associated with 
defects in IL-10 production or signalling. Some reports have been already published 
and demonstrated that, in humans, both IL-10 deficiency and disrupted IL-10 
signalling were associated with greater risk of developing IBD, particularly ulcerative 
colitis or Crohn’s disease (Grundtner et al., 2009;Ebert et al., 2009). It would be 
interesting to examine whether IL-10 deficiency or impaired IL-10 signalling in vivo 
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is associated with elevated TNF-α levels, accumulation of apoptotic cells and 
development of chronic inflammatory conditions. This could be done with the use of 
animal models of inflammation (e.g., collagen-induced arthritis). Theoretically, 
animals elicit variable degrees of inflammation depending on the effectiveness of IL-
10-R signal transduction pathways or levels of IL-10 expression. One could then 
identify animals which are more prone to develop inflammation and investigate IL-10 
and TNF-α expression, IL-10 signal transduction and clearance of apoptotic immune 
cells. In addition, it would be interesting to study the effectiveness of IL-10-R signal 
transduction and IL-10 expression in Mφ from patients with chronic inflammatory 
conditions (e.g., RA). If any defects are identified one could investigate whether there 
is any association with increased plasma levels of TNF-α and accumulation of 
apoptotic material (reduced phagocytosis) in affected joints.  
 
6.4.3 THE MECHANISM UNDERLYING TNF-α-
INDUCED INHIBITION OF PHAGOCYTOSIS 
 As discussed in section 1.3.2.3 the capacity for phagocytosis ultimately 
depends on the activation status of Rho family GTPases i.e., Rac-1 and RhoA. Rac-1 
is obligatorily required for engulfment while RhoA inhibits this process. The study 
published by McPhillips and colleagues suggests that TNF-α treatment induces 
generation of oxidants, which, in turn, activate RhoA resulting in decreased 
phagocytosis (McPhillips et al., 2007). The mechanism underlying generation of 
oxidants likely involves activation of phospholipase cPLA2 and liberation of AA as 
exogenous AA exerted similar inhibitory effects to TNF-α and TNF-α-induced 
inhibition was reversed by blocking cPLA2 activity. TNF-α activates cPLA2 via both 
TNF-R1 and TNF-R2 signal transduction pathways and activation of ERK and c-Jun 
or, alternatively, by translocating cPLA2 to the plasma membrane and consequential 
calcium efflux (TNF-R2 induced pathway) (Jupp et al., 2003;Schievella et al., 1997)  
It would be of interest to establish whether, in this PhD thesis, TNF-α inhibited 
phagocytosis via activation of cPLA2 and generation of oxidants. This could be 
investigated by blocking cPLA2 activity with phospholipase inhibitors (e.g., 
pyrrolidine). Interestingly, a dexamethasone-induced protein, Anx-1, is an inhibitor 
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of cPLA2 (see section 5.4 for more details) and, in this PhD thesis, I have already 
demonstrated that dexamethasone reversed TNF-α-induced inhibition of 
phagocytosis. In addition, I could block RhoA activity with anti-oxidants such as N-
acetylcysteine (NAC) and investigate whether this would reverse TNF-α or LPS-
induced inhibition of phagocytosis. It has been recently reported that NAC enhances 
the resolution of LPS-induced pulmonary inflammation in mice through the inhibition 
of RhoA activity and the enhancement of apoptotic cell clearance (Moon et al., 
2010). Interestingly, in this study, LPS induced a significant increase in active RhoA 
and subsequential reduction in phagocytosis at 3 days post LPS treatment. These 
findings complement our data demonstrating that at least 72 hours LPS treatment is 
necessary for significant reduction of phagocytosis. The authors concluded that 
critical levels of oxidants are required for RhoA activation, which were only reached 
after at least 3 days of LPS treatment. It would be interesting to see whether, in our 
study, the delay of LPS-induced inhibitory effects was due to insufficient oxidants 
levels at earlier time points. 
 Furthermore, as described in section 1.3.2.2 expression of numerous cell 
surface receptors is critical for phagocytosis of apoptotic cells. Since TNF-α exerts its 
effects on cells by multiple mechanisms, it is possible that TNF-α changes expression 
of some cell surface receptors. Future work would therefore involve the use of 
fluorescently labelled antibodies and flow cytometric analysis of changes in 
expression of surface proteins in response to TNF-α.   
 
6.4.4 THE MECHANISM UNDERLYING IL-10- AND 
DEXAMETHASONE-INDUCED AUGMENTATION OF 
PHAGOCYTOSIS  
 In this PhD thesis, I have shown that both IL-10 and dexamethasone 
augmented MDMφ phagocytosis of apoptotic neutrophils and reversed the LPS-
induced inhibitory effect on phagocytosis. Thus, future work would include 
identification of the exact underlying mechanisms. As described in sections 1.3.2.3 
and 6.4.3 the ability of Mφ for uptake of apoptotic cells is regulated by the balance 
between active RhoA and Rac-1. McPhillips et al have shown that TNF-α inhibits 
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phagocytosis by activation of cPLA2, subsequent AA liberation associated with 
generation of oxidants and RhoA activation. It is possible that, in my study, 
dexamethasone counteracted the TNF-α inhibitory effect by inhibiting cPLA2 
activation. This hypothesis is further supported by my observation that 
dexamethasone fully reversed LPS-induced inhibition of phagocytosis without a 
complete inhibition of TNF-α release (see section 5.3.6 for more details). 
Theoretically, reduced activity of cPLA2 would result in an inhibition of AA release 
and consequently in decreased levels of active RhoA. It is possible that 
dexamethasone treatment also changes levels of active Rac1 or other small GTPase 
family members that have been demonstrated to increase phagocytosis (e.g., RhoG 
and Rab5 (Nakaya et al., 2006)). This could be investigated by western blotting for 
active forms of these proteins. I could also use pharmacological inhibitors to block 
activity of small GTPase family members involved in augmentation of phagocytosis 
(e.g., Rac-1). If Rac-1 activation is implicated, the pharmacological inhibition of Rac-
1 will interfere with dexamethasone-induced augmentation and reversal of LPS-
induced inhibition of phagocytosis.  
 Furthermore, data presented in this PhD thesis indicate that IL-10 reverses 
LPS-induced inhibitory effects on phagocytosis by inhibition of TNF-α production 
rather than by interference with TNF-α effects (see section 5.3.3 for more details). In 
the literature, data on mechanisms underlying IL-10-induced inhibition of TNF-α 
production are not conclusive. Initially, it has been thought that inhibition of NF-κB 
or MAPK is implicated but while some reports demonstrate that this is true others 
show otherwise (see section 1.2.2.2). In this PhD thesis, I obtained preliminary data 
demonstrating that IL-10 did not interfere with p38 activation upon LPS treatment 
(see Figures 5.10 and 5.11). It would be interesting to establish an exact mechanism 
underlying IL-10-induced inhibition of TNF-α production. This could be achieved by 
western blotting for phosphorylated forms of MAPK in MDMφ treated concomitantly 
with LPS and IL-10 or with the use of pharmacological inhibitors of MAPK. In 
addition, IL-10 may inhibit activation of transcription factors (e.g., NF-κB), which 
could be detected by western blotting. De novo synthesis of SOCS-3 (see section 
1.2.2.2 for more details) may also play an important role in inhibition of production 
of LPS-induced cytokines, including TNF-α.  If this is true, pharmacological 
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inhibition of SOCS-3 would block IL-10-induced reversal of the inhibitory effects of 
LPS on phagocytosis.  
 Finally, it is possible that MDMφ treatment with IL-10 or dexamethasone 
changes expression of cell surface phagocytic receptors (Mφ receptors for 
phagocytosis are discussed in chapter 1.3.2.2). This is relatively easy to investigate 
with the use of commercially available antibodies labelled with a fluorescent markers 
and flow cytometric analysis. It would be of interest to examine if TNF-α and IL-
10/dexamethasone exert opposing effects on expression of the same receptors. This 
would potentially allow identification of signalling pathways/important mediators 
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